<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methotrexate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methotrexate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Methotrexate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10856" href="/d/html/10856.html" rel="external">see "Methotrexate: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12595" href="/d/html/12595.html" rel="external">see "Methotrexate: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709040"><span class="drugH1">ALERT: US Boxed Warning</span>
<p style="text-indent:0em;">
<b>Methotrexate Oral:</b></p>
<div class="collapsible">
<span class="collapsible-title">Adverse reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for infections and adverse reactions of the bone marrow, GI tract, liver, lungs, skin, and kidneys. Withhold or discontinue methotrexate tablets as appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate can cause the following severe or fatal adverse reactions. Monitor closely and modify dose or discontinue methotrexate as appropriate. Bone marrow suppression, serious infections, renal toxicity and increased toxicity with renal impairment, GI toxicity, hepatic toxicity, pulmonary toxicity, hypersensitivity, and dermatologic reactions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pregnancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, methotrexate is contraindicated in pregnancy. For neoplastic diseases, advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception during and after treatment.</p></div>
</div>
<p style="text-indent:0em;">
<b>Methotrexate Injection:</b></p>
<div class="collapsible">
<span class="collapsible-title">Intrathecal and high-dose therapy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">For intrathecal and high-dose therapy, use preservative-free formulation of methotrexate and diluents. Do NOT use formulations or diluents containing preservatives for intrathecal and high-dose therapy because they contain benzyl alcohol. Formulations with benzyl alcohol can cause severe central nervous toxicity or metabolic acidosis. Use only preservative-free methotrexate injection for treatment of neonates or low-birth-weight infants and for intrathecal use. Do not use benzyl alcohol–containing formulations for high-dose regimens unless immediate treatment is required and preservative-free formulations are not available.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Appropriate use:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious adverse reactions, including deaths, have been reported with methotrexate in the treatment of malignancy, psoriasis, and rheumatoid arthritis. Closely monitor for adverse reactions of the bone marrow, GI tract, liver, lungs, skin, and kidneys. Patients should be informed by their physician of the risks involved and be under a physician's care throughout therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">The use of methotrexate high-dose regimens recommended for osteosarcoma requires meticulous care. High-dose regimens of methotrexate injection for other neoplastic diseases are investigational, and a therapeutic advantage has not been established.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pregnancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate can cause embryo-fetal toxicity, including fetal death and/or congenital anomalies. Use in rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis, and psoriasis is contraindicated in pregnancy. Therefore, it is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks. Verify the pregnancy status of females of reproductive potential prior to initiating therapy. Advise females and males of reproductive potential to use effective contraception during and after treatment with methotrexate.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Unexpectedly severe (sometimes fatal) bone marrow suppression and aplastic anemia have been reported with concomitant administration of methotrexate (usually in high dosage) along with some nonsteroidal anti-inflammatory drugs (NSAIDs).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Renal impairment:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate elimination is reduced in patients with impaired renal function, ascites, or pleural effusions. Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of methotrexate administration.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate causes hepatotoxicity, fibrosis, and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. Liver biopsy after sustained use often shows histologic changes, and fibrosis and cirrhosis have been reported; these latter lesions may not be preceded by symptoms or abnormal liver function tests in the psoriasis population. For this reason, periodic liver biopsies are usually recommended for psoriatic patients who are under long-term treatment. Persistent abnormalities in liver function tests may precede appearance of fibrosis or cirrhosis in the rheumatoid arthritis population.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pneumonitis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate-induced lung disease, including acute or chronic interstitial pneumonitis, is a potentially dangerous lesion, which may occur acutely at any time during therapy and has been reported at low doses. It is not always fully reversible and fatalities have been reported. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Unexpectedly severe (sometimes fatal) GI toxicity has been reported with concomitant administration of methotrexate (usually in high dosage) along with some NSAIDs. Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise hemorrhagic enteritis and death from intestinal perforation may occur.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Secondary malignancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tumor lysis syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Like other cytotoxic drugs, methotrexate may induce tumor lysis syndrome in patients with rapidly growing tumors. Appropriate supportive and pharmacologic measures may prevent or alleviate this complication.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe, occasionally fatal skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, IM, IV, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Opportunistic infections:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Potentially fatal opportunistic infections, especially <i>Pneumocystis jirovecii</i> pneumonia, may occur with methotrexate therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other serious reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Other serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for infections and adverse reactions of the bone marrow, kidneys, liver, nervous system, GI tract, lungs, and skin. Withhold or discontinue methotrexate injection as appropriate.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Radiotherapy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Experienced physician (injection):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate should be used only by health care providers whose knowledge and experience include the use of antimetabolite therapy.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F194555"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Jylamvo;</li>
<li>Otrexup;</li>
<li>Rasuvo;</li>
<li>RediTrex [DSC];</li>
<li>Trexall;</li>
<li>Xatmep</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867512"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Methotrexate;</li>
<li>AURO-Methotrexate;</li>
<li>JAMP-Methotrexate [DSC];</li>
<li>Metoject;</li>
<li>PMS-Methotrexate</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F194602"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antimetabolite (Antifolate);</li>
<li>
                        Antirheumatic, Disease Modifying;</li>
<li>
                        Immunosuppressant Agent</li></ul></div>
<div class="block doa drugH1Div" id="F194560"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Fatal errors have occurred when methotrexate was administered as a <b>daily</b> dose instead of a <b>weekly</b> dose. Verify the indication before administration; oral methotrexate is typically only administered <b>daily</b> for an oncology-related indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>). Only preservative-free formulations should be used for intrathecal administration and for high-dose methotrexate regimens. Methotrexate doses between 100 to 500 mg/m<sup>2</sup>
<b>may</b>
<b>require</b> leucovorin calcium rescue. Doses &gt;500 mg/m<sup>2</sup>
<b>require</b> leucovorin calcium rescue (refer to "Dosing: Adjustment for Toxicity" for leucovorin calcium dosing).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: For nononcology uses,</b> during <b>chronic</b> therapy, treat with folic acid to reduce the risk of adverse effects; leucovorin may be considered in patients who do not respond to folic acid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kremer.1','lexi-content-ref-31276602','lexi-content-ref-30341597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kremer.1','lexi-content-ref-31276602','lexi-content-ref-30341597'])">Ref</a></span>). In patients with inadequate response or intolerance to oral methotrexate therapy at doses ≥15 mg/<b>week</b>, may consider switching to parenteral administration (using a 1:1 dose conversion) or dividing the weekly oral dose (eg, in 2 to 3 divided doses administered every 12 hours over 12 to 24 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10746262','lexi-content-ref-Kremer.1','lexi-content-ref-31276602','lexi-content-ref-17519278','lexi-content-ref-19033290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10746262','lexi-content-ref-Kremer.1','lexi-content-ref-31276602','lexi-content-ref-17519278','lexi-content-ref-19033290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>
<i>Antiemetic prophylaxis:</i> Methotrexate IV doses ≥250 mg/m<sup>2</sup> are associated with moderate emetic potential; antiemetics may be recommended to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oncology uses</b>
<b>:</b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b5fd58c-2ade-43ce-a3f5-be85a60e433f">Acute lymphoblastic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute lymphoblastic leukemia: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Meningeal leukemia prophylaxis or treatment:</b>
<b>Intrathecal:</b> 12 to 15 mg (maximum 15 mg/dose) every 2 to 7 days; continue for 1 dose beyond cerebrospinal fluid (CSF) cell count normalization (manufacturer's labeling). <b>Note:</b> Optimal intrathecal chemotherapy dosing should be based on age rather than on BSA; CSF volume correlates with age and not to BSA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6366138','lexi-content-ref-11248578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6366138','lexi-content-ref-11248578'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>CALGB 8811 regimen (as a component of combination chemotherapy): </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Early intensification:</i>
<b>Intrathecal:</b> 15 mg on day 1 of early intensification phase, repeat in 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7718875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7718875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>CNS prophylaxis/interim maintenance phase:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Intrathecal:</b> 15 mg on days 1, 8, 15, 22, and 29 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7718875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7718875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 20 mg/m<sup>2</sup> on days 36, 43, 50, 57, and 64 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7718875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7718875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Prolonged maintenance:</i>
<b>Oral:</b> 20 mg/m<sup>2</sup> on days 1, 8, 15, and 22 every 4 weeks for 24 months from diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7718875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7718875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Dose-intensive regimen (as a component of combination chemotherapy):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 200 mg/m<sup>2</sup> over 2 hours, followed by 800 mg/m<sup>2</sup> over 24 hours beginning on day 1, (followed by leucovorin rescue) of even numbered cycles (in combination with cytarabine; alternates with Hyper-CVAD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>CNS prophylaxis:</i>
<b>Intrathecal:</b> 12 mg on day 2 of each cycle; duration depends on risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance:</i>
<b>IV:</b> 10 mg/m<sup>2</sup>/day for 5 days every month for 2 years (in combination with prednisone, vincristine, and mercaptopurine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Protocol 8787 regimen (as part of a multiphase, multiagent regimen): Patients &lt;60 years of age:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>CNS prophylaxis:</i>
<b>Intrathecal:</b> 12 mg at the start of induction, then 12 mg with first postremission chemotherapy, then 12 mg once weekly for 4 more doses, for a total of 6 doses (patients with CNS disease at diagnosis required a total of 10 doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12011123']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12011123'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Consolidation phases (1C, 2C, and 3C): </i>
<b>IV:</b> 220 mg/m<sup>2</sup> bolus, followed by 60 mg/m<sup>2</sup>/hour for 36 hours beginning on days 1 and 15 (followed by leucovorin rescue) of each 28-day consolidation cycle (in combination with mercaptopurine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12011123']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12011123'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance:</i>
<b>Oral:</b> 20 mg/m<sup>2</sup> on days 1, 8, 15, and 22 every 4 weeks (in combination with mercaptopurine) until in complete remission for 30 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12011123']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12011123'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a09fe642-d4d8-4360-a4a7-d0828247d633">Acute promyelocytic leukemia, maintenance phase</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute promyelocytic leukemia, maintenance phase (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 15 mg/m<sup>2</sup> once weekly for 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17975017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17975017'])">Ref</a></span>) or 20 mg/m<sup>2</sup> once weekly for 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20705755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20705755'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 15 mg/m<sup>2</sup> once weekly for 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14576047']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14576047'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3810c766-bd22-4b38-a74f-83d570ec742e">Bladder cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Bladder cancer (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Locally advanced or metastatic disease:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Dose-dense MVAC regimen: <b>IV:</b> 30 mg/m<sup>2</sup> on day 1 every 14 days (in combination with vinblastine, doxorubicin, cisplatin, and growth factor support) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11352955','lexi-content-ref-16330205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11352955','lexi-content-ref-16330205'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">MVAC regimen: <b>IV: </b>30 mg/m<sup>2</sup> on days 1, 15, and 22 every 28 days (in combination with vinblastine, doxorubicin, and cisplatin) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11001674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11001674'])">Ref</a></span>) <b>or</b> 30 mg/m<sup>2</sup> on days 1, 15, and 22 every 28 days (in combination with vinblastine, doxorubicin, and cisplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11352955','lexi-content-ref-16330205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11352955','lexi-content-ref-16330205'])">Ref</a></span>) <b>or</b> 30 mg/m<sup>2</sup> on days 1, 15, and 22 every 28 days (in combination with vinblastine, doxorubicin, cisplatin, and filgrastim) for up to 6 cycles or until loss of clinical benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14665607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14665607'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Neoadjuvant treatment:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Patients with non-organ confined disease at cystectomy who did not receive cisplatin-based neoadjuvant chemotherapy should be offered an adjuvant cisplatin-based chemotherapy regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28456635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28456635'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Dose-dense MVAC regimen: <b>IV: </b>30 mg/m<sup>2</sup> on day 1 every 14 days (in combination with vinblastine, doxorubicin, cisplatin, and pegfilgrastim) for 3 or 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24821883','lexi-content-ref-24821881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24821883','lexi-content-ref-24821881'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">MVAC regimen: <b>IV: </b>30 mg/m<sup>2</sup> on days 1, 15, and 22 every 28 days (in combination with vinblastine, doxorubicin, and cisplatin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12944571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12944571'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CMV regimen: <b>IV: </b>30 mg/m<sup>2</sup> on days 1 and 8 every 21 days (in combination with cisplatin, vinblastine, and leucovorin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21502557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21502557'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f629398a-17b2-4a1a-8177-10deeef034f4">Breast cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Breast cancer: </b>CMF regimen: <b>IV: </b>40 mg/m<sup>2</sup> days 1 and 8 every 4 weeks (in combination with cyclophosphamide and fluorouracil) for 6 to 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7877646','lexi-content-ref-9704715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7877646','lexi-content-ref-9704715'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd37b45c-f0bf-42b1-93a9-91edf9f9dd3e">Gestational trophoblastic neoplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Gestational trophoblastic neoplasia:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Gestational trophoblastic neoplasia, low-risk disease (off-label dosing):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>8-day regimen: </i>
<b>IM:</b> 1 mg/kg every 48 hours (on days 1, 3, 5, and 7) for 4 doses (with leucovorin 30 hours after each methotrexate dose), repeat cycle every 14 days until hCG level is normal, followed by 2 to 3 more cycles as consolidation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33384141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33384141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>5-day regimen: </i>
<b>IV/IM:</b> 0.4 mg/kg (maximum dose: 25 mg) once daily for 5 days, repeat every 14 days until hCG level is normal, followed by 2 to 3 more cycles as consolidation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33384141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33384141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Gestational trophoblastic neoplasia, high-risk metastatic disease (off-label dosing):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>EMA-CO regimen: </i>
<b>IV:</b> 100 mg/m<sup>2</sup> IV push followed by 200 mg/m<sup>2</sup> over 12 hours on day 1 (with leucovorin 24 hours after the start of methotrexate; in combination with dactinomycin, etoposide, vincristine, and cyclophosphamide) every 14 days and continuing for at least 2 cycles after hCG level is normal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14675675','lexi-content-ref-17086804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14675675','lexi-content-ref-17086804'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>EMA-EP regimen: </i></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Patients without brain metastases:</i>
<b>IV: </b>100 mg/m<sup>2</sup> IV push followed by 200 mg/m<sup>2</sup> over 12 hours on day 1 every 2 weeks (in combination with etoposide, leucovorin, dactinomycin, and cisplatin), continue for 2 cycles after hCG level is normal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15086738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15086738'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Patients with brain metastases:</i>
<b>IV: </b>100 mg/m<sup>2</sup> IV push followed by 1,000 mg/m<sup>2</sup> over 12 hours on day 1 every 2 weeks (in combination with etoposide, leucovorin, dactinomycin, and cisplatin), continue for 4 cycles after hCG level is normal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15086738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15086738'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>EP-EMA regimen: </i>EMA: <b>IV:</b> 300 mg/m<sup>2</sup> over 12 hours on day 1 (in combination with etoposide, leucovorin, and dactinomycin); alternating weekly with EP (etoposide and cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10673528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10673528'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a08144cd-2dce-4e00-8d82-7305842b16b4">Graft-versus-host disease, acute, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Graft-versus-host disease, acute, prophylaxis (off-label use):</b>
<b>IV:</b> 15 mg/m<sup>2</sup> on day 1 and 10 mg/m<sup>2</sup> on days 3 and 6 after allogeneic transplant (in combination with cyclosporine and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8413388','lexi-content-ref-10871150','lexi-content-ref-10534058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8413388','lexi-content-ref-10871150','lexi-content-ref-10534058'])">Ref</a></span>) <b>or</b> 15 mg/m<sup>2 </sup>on day 1 and 10 mg/m<sup>2 </sup>on days 3, 6, and 11 after allogeneic transplant (in combination with cyclosporine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10871150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10871150'])">Ref</a></span>) <b>or</b> 15 mg/m<sup>2 </sup>on day 1 and 10 mg/m<sup>2 </sup>on days 3, 6, and 11 after allogeneic transplant (in combination with cyclosporine, followed by leucovorin); may omit day 11 methotrexate for ≥ grade 2 toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23892326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23892326'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01cd0f58-ce35-4245-b8e0-406d23a85003">Head and neck cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Head and neck cancer (squamous cell carcinoma):</b>
<b>IV:</b> 40 mg/m<sup>2</sup> once weekly until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1634913','lexi-content-ref-15341981','lexi-content-ref-19289630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1634913','lexi-content-ref-15341981','lexi-content-ref-19289630'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="368ac808-1d7d-444a-a321-3265d3d03a27">Large granular lymphocyte leukemia, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Large granular lymphocyte leukemia, symptomatic (off-label use): Oral: </b>Initial: 5 to 7.5 mg once weekly (with or without prednisone), escalate up to 15 to 20 mg once weekly or 10 mg/m<sup>2</sup>/week over 1 to 3 months; methotrexate was administered in split doses in the morning and evening on <b>one </b>day per week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7919331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7919331'])">Ref</a></span>) <b>or </b>10 mg/m<sup>2</sup>/week (administered in divided doses in the morning and evening on <b>one </b>day per week), in combination with prednisone, followed by a prednisone taper after 30 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25306898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25306898'])">Ref</a></span>) <b>or</b> 10 mg/m<sup>2</sup>/week (administered in divided doses in the morning and evening on <b>one </b>day per week), with or without prednisone; discontinue treatment if no response after 4 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21190991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21190991'])">Ref</a></span>) <b>or</b> 7.5 mg/m<sup>2</sup> once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20378561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20378561'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0732fee7-ebaa-4201-b793-d6925b064912">Mycosis fungoides</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Mycosis fungoides (cutaneous T-cell lymphoma):</b>
<b>Oral or IM:</b> 25 to 75 mg orally once weekly (as a single agent) or 10 mg/m<sup>2</sup> orally twice weekly (as part of a combination regimen) <b>or</b> 5 to 50 mg IM once weekly (for early stage) or 15 to 37.5 mg IM twice weekly (if poor response to weekly therapy) (manufacturer's labeling) <b>or</b> 25 mg orally once weekly, may increase to 50 mg orally once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14576667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14576667'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ac1551d4-0bff-4d8a-8de4-b0eed5c04298">Non-Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Non-Hodgkin lymphoma:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Burkitt lymphoma:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Modified CODOX-M/IVAC regimen ± rituximab </i>
<i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21339382','lexi-content-ref-15160953','lexi-content-ref-18612102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21339382','lexi-content-ref-15160953','lexi-content-ref-18612102'])">Ref</a></span>):</i> Cycles 1 and 3 of CODOX-M (CODOX-M alternates with IVAC).</p>
<p style="text-indent:-2em;margin-left:10em;">Adults ≤65 years of age: <b>IV:</b> 300 mg/m<sup>2</sup> over 1 hour on day 10 followed by 2,700 mg/m<sup>2</sup> over 23 hours (with leucovorin rescue).</p>
<p style="text-indent:-2em;margin-left:10em;">Adults &gt;65 years of age:<b> IV:</b> 100 mg/m<sup>2</sup> over 1 hour on day 10 followed by 900 mg/m<sup>2</sup> over 23 hours (with leucovorin rescue).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>High-dose methotrexate/cytarabine alternating with Hyper-CVAD:</i>
<b>IV: </b>1,000 mg/m<sup>2</sup> over 24 hours on day 1 during even courses (2, 4, 6, and 8) of 21-day treatment cycles (with leucovorin rescue) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16502413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16502413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>9251 regimen:</i>
<b>IV:</b> 150 mg/m<sup>2</sup> over 30 minutes followed by 1,350 mg/m<sup>2</sup> over 23.5 hours (with leucovorin rescue) on day 1 of cycles 2 through 7 (in combination with cyclophosphamide, prednisone, ifosfamide, mesna, vincristine, cytarabine, etoposide, dexamethasone, doxorubicin, and CNS prophylaxis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11600602','lexi-content-ref-15042678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11600602','lexi-content-ref-15042678'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Mantle cell lymphoma: High-dose methotrexate/cytarabine alternating with Hyper-CVAD (± rituximab):</b>
<b>IV:</b> 200 mg/m<sup>2</sup> bolus on day 1 or day 2 followed by 800 mg/m<sup>2</sup> over 24 hours during even courses (2, 4, 6, and 8) of 21-day treatment cycles (with leucovorin rescue) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9850025','lexi-content-ref-16145068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9850025','lexi-content-ref-16145068'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49e41d16-77ea-49f7-a32a-865bf8bfa071">Nonleukemic meningeal cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Nonleukemic meningeal cancer (off-label use):</b>
<b>Intrathecal:</b> 12 mg/dose twice weekly for 4 weeks, then weekly for 4 doses, then monthly for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9552066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9552066'])">Ref</a></span>) <b>or</b> 10 mg twice weekly for 4 weeks, then weekly for 1 month, then every 2 weeks for 2 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10589750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10589750'])">Ref</a></span>) <b>or</b> 10 to 15 mg twice weekly for 4 weeks, then once weekly for 4 weeks, then a maintenance regimen of once a month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20689429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20689429'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="892a32f8-154f-41d0-a59a-cc8169aa39d2">Osteosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Osteosarcoma:</b> Adults ≤30 years of age: MAP regimen: <b>IV:</b> 12 <b>g</b>/m<sup>2</sup> (maximum: 20 <b>g</b>/dose) over 4 hours (followed by leucovorin rescue) for 4 doses during induction (before surgery) at weeks 4, 5, 9, and 10, and for 8 doses during maintenance (after surgery) at weeks 15, 16, 20, 21, 24, 25, 28, and 29 (in combination with doxorubicin and cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26033801','lexi-content-ref-25421877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26033801','lexi-content-ref-25421877'])">Ref</a></span>); other combinations, intervals, age ranges, and doses (8 to 14 <b>g</b>/m<sup>2</sup>/dose) have been described (with leucovorin rescue), refer to specific reference for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11118462','lexi-content-ref-12853357','lexi-content-ref-17267204','lexi-content-ref-1370176','lexi-content-ref-15774791','lexi-content-ref-3466693','lexi-content-ref-2448428']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11118462','lexi-content-ref-12853357','lexi-content-ref-17267204','lexi-content-ref-1370176','lexi-content-ref-15774791','lexi-content-ref-3466693','lexi-content-ref-2448428'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fe2f15f6-7823-4d0e-8183-6652b48c33a5">Primary CNS lymphoma, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Primary CNS lymphoma, newly diagnosed (off-label use):</b>
<b>IV:</b> 8 <b>g</b>/m<sup>2</sup> over 4 hours (followed by leucovorin rescue) every 14 days until complete response or a maximum of 8 cycles; if complete response, follow with 2 consolidation cycles at the same dose every 14 days (with leucovorin rescue), followed by 11 maintenance cycles of 8 <b>g</b>/m<sup>2</sup> every 28 days (with leucovorin rescue) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12637469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12637469'])">Ref</a></span>) <b>or</b>
<i>R-MPV regimen:</i> 3.5 <b>g</b>/m<sup>2</sup> over 2 hours on day 2 every 2 weeks (in combination with rituximab, vincristine, procarbazine, and leucovorin [with intra-Ommaya methotrexate 12 <b>mg</b> between days 5 and 12 of each cycle if positive CSF cytology]) for 5 to 7 induction cycles followed by reduced-dose whole brain radiotherapy and then cytarabine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24101038','lexi-content-ref-17947720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24101038','lexi-content-ref-17947720'])">Ref</a></span>) or autologous stem cell transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25568347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25568347'])">Ref</a></span>) <b>or</b>
<i>R-MP regimen (patients ≥65 years of age):</i> 3 <b>g</b>/m<sup>2</sup> over 4 hours on days 2, 16, and 30 of a 42-day cycle (in combination with rituximab, procarbazine, and leucovorin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27843136']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27843136'])">Ref</a></span>) <b>or</b>
<i>MT-R regimen:</i> 8 <b>g</b>/m<sup>2</sup> once every 2 weeks (adjusted for creatinine clearance [refer to protocol for details] and in combination with leucovorin, temozolomide, and rituximab) for 7 doses, then followed by high-dose consolidation chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23569323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23569323'])">Ref</a></span>) <b>or </b>3.5 <b>g</b>/m<sup>2</sup> on weeks 1, 3, 5, 7, and 9 (in combination with leucovorin, temozolomide, and rituximab), followed by whole-brain radiotherapy and then post-radiation temozolomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27022122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27022122'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c2417d1-7897-48cc-9da1-26594fc09932">Primary cutaneous anaplastic large cell lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Primary cutaneous anaplastic large cell lymphoma (off-label use): Oral: </b>15 to 25 mg once weekly (range: 10 to 60 mg once weekly); based on response, may increase dosing interval up to once every 2 weeks after the weekly dose has been optimized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8609262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8609262'])">Ref</a></span>) <b>or</b> 5 to 50 mg once weekly (median dose: 20 to 25 mg once weekly) for up to 48 weeks or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28600132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28600132'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="982f4303-339c-4c1a-99c3-5e173bacf459">Soft tissue sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Soft tissue sarcoma (desmoid tumors, aggressive fibromatosis), advanced (off-label use):</b>
<b>IV:</b> 30 mg/m<sup>2</sup> every 7 to 10 days (dose usually rounded to 50 mg) in combination with vinblastine for 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11571741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11571741'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nononcology uses:</b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e3c43cc3-856a-4859-aa7b-f28ffd8da56c">Atopic dermatitis or eczema, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Atopic dermatitis or eczema, moderate to severe (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, SUBQ, IM:</b> Initial: 10 to 15 mg once <b>weekly </b>(in combination with folic acid). Adjust dose by 2.5 to 5 mg/<b>week </b>every 2 to 4 weeks if needed based on response (usual dosage range: 7.5 to 25 mg/<b>week</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24813298','lexi-content-ref-28967549','lexi-content-ref-21514637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24813298','lexi-content-ref-28967549','lexi-content-ref-21514637'])">Ref</a></span>). Consider discontinuation if no improvement after 12 to 16 weeks on dosages ≥15 mg/<b>week </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24813298']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24813298'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="144bfda0-cd07-4b30-a02a-f08025a0fc36">Bullous pemphigoid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Bullous pemphigoid (alternative agent) (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IM, SUBQ: </b>Initial: 5 mg once <b>weekly </b>(in combination with folic acid); often also given in combination with glucocorticoids. Increase dose as tolerated by 2.5 mg/<b>week</b> approximately every 4 weeks if needed (usual dosage range: 5 to 20 mg/<b>week</b>). Once disease control is achieved, gradually taper therapy (eg, every 2 to 4 weeks) to minimum effective dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10321603','lexi-content-ref-18490587','lexi-content-ref-Murrell.1','lexi-content-ref-8089289']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10321603','lexi-content-ref-18490587','lexi-content-ref-Murrell.1','lexi-content-ref-8089289'])">Ref</a></span>). Consider discontinuation if no improvement after 4 weeks on dosages ≥15 mg/<b>week</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Murrell.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Murrell.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59567581-c67d-4a97-908a-59b5a164c324">Crohn disease, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Crohn disease, moderate to severe (alternative agent) (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For use as part of an appropriate combination regimen for induction of remission and as an alternative monotherapy for maintenance of remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508','lexi-content-ref-34051983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508','lexi-content-ref-34051983'])">Ref</a></span>). Patient should be under the care of a clinician experienced with using methotrexate for this condition.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, SUBQ, Oral: </b>Initial: 15 to 25 mg administered IM or SUBQ once <b>weekly </b>(in combination with folic acid); an initial dose of 12.5 to 15 mg/<b>week</b> administered orally or parenterally may be used when adding to biologic therapy. For lower initial doses, may gradually increase dose (eg, by 5 mg/<b>week</b> every month) if needed (maximum: 25 mg/<b>week</b>). If remission is sustained after 4 months, may reduce dose to 15 mg/<b>week</b> administered orally or parenterally (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508','lexi-content-ref-34051983','lexi-content-ref-Hashash.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508','lexi-content-ref-34051983','lexi-content-ref-Hashash.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="047a4296-aea5-4cc5-9411-b3f5e9e00170">Dermatomyositis, cutaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Dermatomyositis, cutaneous (alternative agent) (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>In patients with mild disease, may be used as combination therapy when response to initial systemic therapy (eg, with hydroxychloroquine) is inadequate, <b>or</b> as an alternative initial systemic therapy in patients who cannot take preferred agents. In patients with severe disease, may be used as initial systemic therapy with or without hydroxychloroquine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vleugels.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vleugels.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, SUBQ, IM:</b> Initial: 5 to 15 mg once <b>weekly </b>(in combination with folic acid). May increase dose by 2.5 mg/<b>week</b> every 1 to 2 weeks up to a goal of 25 mg/<b>week</b>, <b>or</b> directly to 25 mg/<b>week</b> after 2 weeks on the initial dose, if needed based on response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27098592','lexi-content-ref-Vleugels.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27098592','lexi-content-ref-Vleugels.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9838f87f-41c7-4239-92f6-22c6626f72b4">Dermatomyositis/polymyositis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Dermatomyositis/Polymyositis (alternative agent) (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For use as an adjunct to glucocorticoids, <b>or</b> as an alternative initial therapy in patients who cannot receive glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30341597','lexi-content-ref-Miller.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30341597','lexi-content-ref-Miller.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, SUBQ, IM: </b>Initial: 7.5 to 15 mg once <b>weekly </b>(in combination with folic acid); adjust dose by 2.5 mg/<b>week</b> every 2 to 4 weeks if needed based on response (usual dose: 15 to 25 mg once <b>weekly</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30341597','lexi-content-ref-27098592','lexi-content-ref-Miller.2019','lexi-content-ref-19019306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30341597','lexi-content-ref-27098592','lexi-content-ref-Miller.2019','lexi-content-ref-19019306'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb95828d-77d8-4ec8-a68d-9f96a081c510">Discoid lupus erythematosus and subacute cutaneous lupus erythematosus, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Discoid lupus erythematosus and subacute cutaneous lupus erythematosus, refractory (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ (preferred), IM, Oral:</b> 10 to 25 mg once <b>weekly</b> (in combination with folic acid) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27859683','lexi-content-ref-20800319','lexi-content-ref-16029342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27859683','lexi-content-ref-20800319','lexi-content-ref-16029342'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18e6e26c-d8fa-42b9-8a6b-e440bcbad715">Eosinophilic granulomatosis with polyangiitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May be used as an alternative induction therapy (in combination with glucocorticoids) in patients with mild disease, <b>or</b> as maintenance therapy; efficacy data are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235894','lexi-content-ref-King.1','lexi-content-ref-15675136']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235894','lexi-content-ref-King.1','lexi-content-ref-15675136'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, SUBQ:</b> Initial: 15 mg once <b>weekly </b>(in combination with folic acid), then increase dose by 5 mg/<b>week </b>every 2 to 8 weeks up to 25 mg/<b>week </b>if tolerated. If remission is sustained after 12 to 18 months, may gradually taper dosage until discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-King.1','lexi-content-ref-15675136']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-King.1','lexi-content-ref-15675136'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0010c8c6-f067-4d53-ab4d-1d64ac0e1e39">Giant cell arteritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Giant cell arteritis (alternative agent) (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use as an alternative to tocilizumab in patients who require glucocorticoid-sparing therapy; clinical experience suggests limited efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31270110','lexi-content-ref-34235884','lexi-content-ref-Salvarani.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31270110','lexi-content-ref-34235884','lexi-content-ref-Salvarani.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, SUBQ: </b>Initial: 10 to 15 mg once <b>weekly</b> (in combination with folic acid) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31270110','lexi-content-ref-11177313','lexi-content-ref-17665429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31270110','lexi-content-ref-11177313','lexi-content-ref-17665429'])">Ref</a></span>). Adjust dose by 2.5 to 5 mg/<b>week </b>if needed based on response (usual dosage range: 7.5 to 15 mg/<b>week</b>; some experts use doses up to 25 mg/<b>week</b>); may discontinue therapy after 24 months if disease remission is achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11177313','lexi-content-ref-28134073','lexi-content-ref-17665429','lexi-content-ref-Salvarani.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11177313','lexi-content-ref-28134073','lexi-content-ref-17665429','lexi-content-ref-Salvarani.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eb007dc6-895a-4a2a-b099-9ecdac79ad9e">Granulomatosis with polyangiitis and microscopic polyangiitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Granulomatosis with polyangiitis and microscopic polyangiitis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use as maintenance therapy (regardless of initial disease severity) to extend remission and prevent relapse; may also be used as induction therapy (in combination with glucocorticoids) <b>only </b>for patients with <b>non–organ-</b> and<b> non–life-threatening</b> disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235894','lexi-content-ref-27338776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235894','lexi-content-ref-27338776'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, SUBQ, IM:</b> Initial: 15 to 20 mg once <b>weekly </b>(in combination with folic acid), then increase dose by 2.5 to 5 mg/<b>week </b>every 2 to 8 weeks based on response up to 25 mg/<b>week</b>. If remission is sustained after 1 to 2 years, may gradually taper dosage (eg, reduce by 2.5 mg/<b>week </b>each month) until discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27338776','lexi-content-ref-12727579','lexi-content-ref-Merkel.2','lexi-content-ref-19109574','lexi-content-ref-12161090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27338776','lexi-content-ref-12727579','lexi-content-ref-Merkel.2','lexi-content-ref-19109574','lexi-content-ref-12161090'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="93dcbe85-1921-4211-a7d5-0bfc9b0b030d">Lichen sclerosus, extragenital, extensive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Lichen sclerosus, extragenital, extensive (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use in patients with persistent, active disease despite topical corticosteroids; may use with systemic glucocorticoids for rapidly progressing disease. Efficacy data are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29313888','lexi-content-ref-Jacobe.2','lexi-content-ref-19917961']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29313888','lexi-content-ref-Jacobe.2','lexi-content-ref-19917961'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, SUBQ, IM</b>
<b>:</b> Initial: 10 to 15 mg once <b>weekly </b>(in combination with folic acid); may increase to 17.5 to 25 mg once <b>weekly</b> after 4 to 12 weeks if needed based on response. If remission is sustained after 6 to 9 months, may gradually taper dosage (eg, reduce by 2.5 mg/<b>week</b> every 2 to 4 weeks) until lowest effective dose or discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jacobe.2','lexi-content-ref-19917961','lexi-content-ref-9704833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jacobe.2','lexi-content-ref-19917961','lexi-content-ref-9704833'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea3d0758-f7db-404e-9781-7274b3544595">Morphea or localized scleroderma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Morphea or localized scleroderma (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use in patients with severe skin and/or musculoskeletal involvement, either as monotherapy or in combination with glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28792092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28792092'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ, Oral:</b> 12.5 to 25 mg once <b>weekly </b>(in combination with folic acid). May gradually taper therapy after 6 to 12 months of disease inactivity (usual total duration: 1 to 2 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28792092','lexi-content-ref-Jacobe.1','lexi-content-ref-19210503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28792092','lexi-content-ref-Jacobe.1','lexi-content-ref-19210503'])">Ref</a></span>). <b>Note:</b> May consider a second (or third) course of methotrexate in patients who experience disease relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19210503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19210503'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c3590ee-986e-4df6-ba23-d923efa209b2">Psoriasis, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Psoriasis, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patient should be under the care of a clinician experienced with using methotrexate for this condition.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IM, SUBQ:</b> Initial: 10 to 15 mg once <b>weekly </b>(in combination with folic acid). Adjust dose gradually (eg, every 4 to 8 weeks) if needed based on response (usual dosage range: 7.5 to 25 mg/<b>week</b>); do not exceed 30 mg/<b>week</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32119894','lexi-content-ref-Feldman.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32119894','lexi-content-ref-Feldman.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Rheumatoid arthritis:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patient should be under the care of a clinician experienced with using methotrexate for this condition.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, SUBQ, IM:</b> Initial: 7.5 to 15 mg once <b>weekly </b>(in combination with folic acid). Increase dose by 2.5 to 5 mg/<b>week</b> every 4 to 12 weeks if needed based on response (maximum: 25 mg/<b>week</b>); current guidelines suggest titrating to a target dose of ≥15 mg/<b>week</b> within 4 to 6 weeks of initiation. Once disease remission is achieved, may gradually reduce dose (eg, by 2.5 mg/<b>week</b> every 1 to 2 months) to 15 mg/<b>week</b> to limit adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34101387','lexi-content-ref-18163521','lexi-content-ref-Cohen.1','lexi-content-ref-28264816','lexi-content-ref-Kremer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34101387','lexi-content-ref-18163521','lexi-content-ref-Cohen.1','lexi-content-ref-28264816','lexi-content-ref-Kremer.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b16c4b4-384f-431d-a101-c5fbadff381a">Sarcoidosis, pulmonary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Sarcoidosis, pulmonary (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use as an adjunctive agent in patients whose disease progresses despite glucocorticoids or in those who require glucocorticoid-sparing therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33268456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33268456'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, SUBQ, IM: </b>Initial: 5 to 7.5 mg once <b>weekly</b> (in combination with folic acid). Increase dose gradually (eg, by 2.5 mg/<b>week </b>every 2 weeks) if needed up to 20 mg/<b>week</b>; usual dosage range: 10 to 15 mg/<b>week</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10746262','lexi-content-ref-33268456','lexi-content-ref-34140301','lexi-content-ref-22495110','lexi-content-ref-King.2','lexi-content-ref-34143362','lexi-content-ref-23880702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10746262','lexi-content-ref-33268456','lexi-content-ref-34140301','lexi-content-ref-22495110','lexi-content-ref-King.2','lexi-content-ref-34143362','lexi-content-ref-23880702'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f4fef82e-1c66-4733-989c-c78ab4926a7e">Scleritis, idiopathic, noninfectious</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Scleritis, idiopathic, noninfectious (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use in patients with persistent or progressive disease or who require glucocorticoid-sparing therapy; in patients with necrotizing scleritis, alternative agents should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dana.1','lexi-content-ref-30852832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dana.1','lexi-content-ref-30852832'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ, Oral:</b> Initial: 7.5 to 15 mg once <b>weekly </b>(in combination with glucocorticoids and folic acid). Increase dose by 5 mg/<b>week </b>every week if needed based on response (maximum: 25 mg/<b>week</b>); may gradually taper and discontinue therapy if disease remission is maintained for 6 to 12 months after glucocorticoids are stopped (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dana.1','lexi-content-ref-14533032','lexi-content-ref-30852832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dana.1','lexi-content-ref-14533032','lexi-content-ref-30852832'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9705e60d-13b5-4a91-8e4c-b52a6c5adeaa">Still disease, adult-onset, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Still disease, adult-onset, moderate to severe (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use as an adjunct to glucocorticoids in patients with moderate to severe, arthritis-predominant disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mandl.1','lexi-content-ref-16365690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mandl.1','lexi-content-ref-16365690'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, SUBQ:</b> Initial: 10 to 15 mg once <b>weekly </b>(in combination with folic acid); increase dose by 2.5 mg/<b>week </b>every week if needed after the first 4 weeks based on response (maximum: 25 mg/<b>week</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20506370','lexi-content-ref-Mandl.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20506370','lexi-content-ref-Mandl.1'])">Ref</a></span>). Once disease control is achieved for ≥3 months, gradually taper therapy (eg, by 2.5 to 5 mg/<b>week</b> every 2 to 3 months) to minimum effective dose; may discontinue therapy based on response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mandl.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mandl.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bbd4868-9b68-4f56-a652-b28778790f81">Systemic lupus erythematosus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Systemic lupus erythematosus (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use in patients with arthritis-predominant disease who require glucocorticoid-sparing therapy, <b>or</b> in patients with persistent arthritis symptoms despite first-line therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30926722','lexi-content-ref-33280011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30926722','lexi-content-ref-33280011'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, SUBQ:</b> Initial: 5 to 15 mg once <b>weekly </b>(in combination with folic acid). Increase dose gradually (eg, by 2.5 mg/<b>week </b>every 4 weeks) if needed based on response (maximum: 20 to 25 mg/<b>week</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19035431','lexi-content-ref-33280011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19035431','lexi-content-ref-33280011'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="097035e9-a2bc-49ee-970b-7179920949e1">Systemic sclerosis or scleroderma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Systemic sclerosis or scleroderma (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use in patients with diffuse skin involvement, <b>or</b> in patients with overlapping skin and musculoskeletal involvement; methotrexate should <b>not</b> be used in patients with pulmonary involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28792092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28792092'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, SUBQ:</b> Initial: 10 mg once <b>weekly </b>(in combination with folic acid); adjust dose by 2.5 mg/<b>week </b>every 4 weeks up to target dose of 15 to 25 mg/<b>week </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Denton.1','lexi-content-ref-11407694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Denton.1','lexi-content-ref-11407694'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3366b908-8b85-4957-b3ac-11825415246c">Takayasu arteritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Takayasu arteritis (off-label use): Oral, SUBQ:</b> Initial: 15 mg once <b>weekly </b>in combination with a glucocorticoid and folic acid. Increase dose by 2.5 to 5 mg/<b>week </b>every 1 to 2 weeks if needed based on response (maximum: 25 mg/<b>week</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7908520','lexi-content-ref-Merkel.1','lexi-content-ref-34235884','lexi-content-ref-21044455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7908520','lexi-content-ref-Merkel.1','lexi-content-ref-34235884','lexi-content-ref-21044455'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d785773-56ee-4687-8d04-95ad33a30c51">Termination of intrauterine pregnancy, first trimester</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Termination of intrauterine pregnancy, first trimester (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use <b>only </b>as an alternative to mifepristone/misoprostol combination or misoprostol-only regimens in patients at ≤49 days of gestation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32804884','lexi-content-ref-8773418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32804884','lexi-content-ref-8773418'])">Ref</a></span>). Do <b>not </b>administer folic acid (including folic acid-containing vitamins) during methotrexate therapy for this indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8773418','lexi-content-ref-27208607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8773418','lexi-content-ref-27208607'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 50 mg/m<sup>2</sup> once, followed by vaginal misoprostol 3 to 7 days later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8773418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8773418'])">Ref</a></span>); maximum dose has not been established; some experts do not exceed a methotrexate dose of 100 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bartz.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bartz.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c89560b3-38b8-4ff8-85f5-a7472ee7f941">Tubal ectopic pregnancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Tubal ectopic pregnancy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May be used as an alternative to surgery for selected patients who meet <b>all </b>the following criteria: <b>no </b>fetal cardiac activity, hemodynamic stability, serum beta-hCG ≤5,000 milli-international units/mL, and ability to comply with posttreatment follow-up. May be given as single-dose or multiple-dose protocol; some experts prefer the single-dose regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470343','lexi-content-ref-Tulandi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470343','lexi-content-ref-Tulandi.1'])">Ref</a></span>). Regimens are named for the minimum number of planned doses; actual number of doses given may be greater.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Single-dose regimen:</i>
<b> Note:</b> Do <b>not </b>administer folic acid during methotrexate therapy during this regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470343'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IM:</b> 50 mg/m<sup>2</sup> on day 1; maximum dose has not been established; some experts do not exceed 100 mg. Measure serum hCG level on days 1, 4 and 7; if the hCG decrease from day 4 to 7 is &lt;15%, administer a second 50 mg/m<sup>2</sup> dose on day 7 and measure serum hCG level again on day 14; if the hCG decrease from day 7 to 14 is &lt;15%, administer a third 50 mg/m<sup>2</sup> dose (maximum dose has not been established; some experts do not exceed 100 mg/dose for each dose). Consider surgical management if hCG does not adequately decrease after 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470343','lexi-content-ref-27813249','lexi-content-ref-8317518','lexi-content-ref-Tulandi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470343','lexi-content-ref-27813249','lexi-content-ref-8317518','lexi-content-ref-Tulandi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Two-dose regimen:</i>
<b>Note:</b> Do <b>not </b>administer folic acid during methotrexate therapy during this regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470343'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IM:</b> 50 mg/m<sup>2</sup> on days 1 and 4; maximum dose has not been established; some experts do not exceed 100 mg/dose for each dose. Measure serum hCG level on days 1, 4, and 7; if the hCG decrease from day 4 to 7 is &lt;15%, administer a third 50 mg/m<sup>2</sup> dose and measure serum hCG level again on day 11; if hCG decrease from day 7 to 11 is &lt;15%, administer a fourth 50 mg/m<sup>2</sup> dose and measure serum hCG level on day 14 (some experts do not exceed 100 mg/dose for each dose). Consider surgical management if hCG does not adequately decrease after 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470343','lexi-content-ref-17097649','lexi-content-ref-Tulandi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470343','lexi-content-ref-17097649','lexi-content-ref-Tulandi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Multidose regimen (in combination with leucovorin):</i>
<b>IM:</b> 1 mg/kg on day 1; maximum dose has not been established; some experts do not exceed 100 mg. Measure hCG level on days 1, 3, 5, 7, and 14. Administer subsequent 1 mg/kg doses on days 3, 5, 7, and 14 only if there is a &lt;15% decline in hCG from previous measurement; maximum dose has not been established; some experts do not exceed 100 mg/dose for each dose. Administer leucovorin on days 2, 4, 6, 8, and 15 only if methotrexate was given on the previous day. Consider surgical management if hCG does not adequately decrease after 5 doses (total treatment may be between 1 and 5 doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470343','lexi-content-ref-2444463','lexi-content-ref-2784113','lexi-content-ref-Tulandi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470343','lexi-content-ref-2444463','lexi-content-ref-2784113','lexi-content-ref-Tulandi.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990820"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling. Limited data are available describing methotrexate dosage adjustment in kidney impairment. The following general and regimen-specific dosage adjustments have been recommended:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>General dosage adjustment recommendations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">Kintzel 1995:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;60 mL/minute: No dose adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 46 to 60 mL/minute: Administer 65% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 31 to 45 mL/minute: Administer 50% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">Aronoff 2007:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;50 mL/minute: No dose adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 50 mL/minute: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b></p>
<p style="text-indent:-2em;margin-left:6em;">Cases of methotrexate toxicity (including death) have been reported in hemodialysis patients receiving methotrexate, even at low methotrexate doses. Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21833520','lexi-content-ref-11865117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21833520','lexi-content-ref-11865117'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Case reports describing methotrexate administration in patients with cancer with close monitoring of methotrexate concentrations, leucovorin rescue, and frequent and/or extended dialysis using high-flux membranes to facilitate methotrexate removal have been published (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10607779','lexi-content-ref-19339090','lexi-content-ref-22432089','lexi-content-ref-8957036','lexi-content-ref-30362229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10607779','lexi-content-ref-19339090','lexi-content-ref-22432089','lexi-content-ref-8957036','lexi-content-ref-30362229'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Cases of methotrexate toxicity (including death) have been reported in peritoneal dialysis patients receiving methotrexate, even at low doses. Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21833520','lexi-content-ref-11865117','lexi-content-ref-16969149']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21833520','lexi-content-ref-11865117','lexi-content-ref-16969149'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> Administer 50% of methotrexate dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Regimen-specific dosage adjustments:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">Acute lymphoblastic lymphoma, dose-intensive (Hyper-CVAD) regimen (usual methotrexate dose: 200 mg/m<sup>2</sup> over 2 hours, followed by 800 mg/m<sup>2</sup> over 24 hours with leucovorin rescue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653870'])">Ref</a></span>)): <b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">SCr &lt;1.5 mg/dL: No methotrexate dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">SCr 1.5 to 2 mg/dL: Administer 75% of methotrexate dose.</p>
<p style="text-indent:-2em;margin-left:6em;">SCr &gt;2 mg/dL: Administer 50% of methotrexate dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Breast cancer, CMF regimen (usual methotrexate dose: 40 mg/m<sup>2</sup> days 1 and 8 every 4 weeks [in combination with cyclophosphamide and fluorouracil]); CrCl is calculated using the Cockcroft-Gault equation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26755510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26755510'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Females ≥65 years of age:<b> IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &gt;80 mL/minute: No methotrexate dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 51 to 80 mL/minute: Reduce methotrexate dose to 30 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 30 to 50 mL/minute: Reduce methotrexate dose to 20 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;30 mL/minute: Avoid methotrexate use.</p>
<p style="text-indent:-2em;margin-left:4em;">Primary CNS lymphoma, high dose methotrexate (usual methotrexate dose: 8 <b>g</b>/m<sup>2</sup> over 4 hours with leucovorin rescue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16972068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16972068'])">Ref</a></span>)); CrCl is measured or can be calculated using the Cockcroft-Gault equation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16972068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16972068'])">Ref</a></span>): <b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥100 mL/minute: No methotrexate dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 50 to 99 mL/minute: Calculate dose using percentage reduction of CrCl below 100 mL/minute. Example: If CrCl is 80 mL/minute, adjust dose to 0.8 × 8 <b>g</b>/m<sup>2</sup> = 6.4 <b>g</b>/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;50 mL/minute: Avoid methotrexate use.</p></div>
<div class="block doha drugH1Div" id="F50988031"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment prior to treatment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution and consider a reduced dose in patients with impaired hepatic function or preexisting hepatic damage. The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16473644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16473644'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Bilirubin 3.1 to 5 mg/dL <b>or</b> transaminases &gt;3 times ULN: Administer 75% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Bilirubin &gt;5 mg/dL: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity during treatment: Withhold, consider a reduced dose, or discontinue methotrexate as appropriate.</p></div>
<div class="block doo drugH1Div" id="F20342088"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2</sup></i>
<i>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>). <b>Note:</b> Some protocols may have maximum recommended doses.</p></div>
<div class="block dot drugH1Div" id="F15255058"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Methotrexate toxicities:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonhematologic toxicity:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Anaphylaxis or other severe hypersensitivity reactions: Discontinue methotrexate (immediately) and manage as appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic toxicity: Withhold or discontinue methotrexate as appropriate. For severe toxicity (toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis, skin necrosis, and erythema multiforme), discontinue methotrexate.</p>
<p style="text-indent:-2em;margin-left:6em;">GI toxicity (severe): Withhold or discontinue methotrexate as appropriate. For diarrhea, stomatitis, or vomiting, which may lead to dehydration, withhold methotrexate until recovery.</p>
<p style="text-indent:-2em;margin-left:6em;">Infection (serious): Withhold, modify dose, or discontinue methotrexate and manage infection as appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">Neurotoxicity: Withhold or discontinue methotrexate as appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">Pulmonary toxicity: Withhold or discontinue methotrexate as appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">Secondary malignancy/lymphoproliferative disease: Discontinue methotrexate.</p>
<p style="text-indent:-2em;margin-left:6em;">Withhold or discontinue (oral products) as appropriate for severe GI toxicity, hepatotoxicity, pulmonary toxicity, severe dermatological reaction, severe renal toxicity, serious infection, or neurotoxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">Discontinue (oral products) for anaphylaxis or other severe hypersensitivity reactions or for secondary malignancy (eg, lymphoproliferative disease).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematologic toxicity:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Oncologic uses:</p>
<p style="text-indent:-2em;margin-left:8em;">Myelosuppression: Withhold, reduce dose, or discontinue methotrexate as appropriate.</p>
<p style="text-indent:-2em;margin-left:8em;">Profound granulocytopenia and fever: Evaluate immediately; consider broad-spectrum parenteral antimicrobial coverage</p>
<p style="text-indent:-2em;margin-left:6em;">Psoriasis, rheumatoid arthritis: Significant blood count decrease: Discontinue immediately</p>
<p style="text-indent:-2em;margin-left:6em;">Myelosuppression (oral products): Withhold, modify dose, or discontinue as indicated.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Leucovorin calcium dosing </b>(from methotrexate injection prescribing information; other leucovorin dosing/schedules may be specific to chemotherapy protocols):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Normal methotrexate elimination (serum methotrexate level ~10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and &lt;0.2 micromolar at 72 hours):</i> Leucovorin calcium 15 mg (oral, IM, or IV) every 6 hours for 60 hours (10 doses) beginning 24 hours after the start of methotrexate infusion</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Delayed late methotrexate elimination (serum methotrexate level remaining &gt;0.2 micromolar at 72 hours and &gt;0.05 micromolar at 96 hours after administration):</i> Continue leucovorin calcium 15 mg (oral, IM or IV) every 6 hours until methotrexate level is &lt;0.05 micromolar</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Delayed early methotrexate elimination and/or acute renal injury (serum methotrexate level ≥50 micromolar at 24 hours, or ≥5 micromolar at 48 hours, or a doubling of serum creatinine level at 24 hours after methotrexate administration):</i> Leucovorin calcium 150 mg IV every 3 hours until methotrexate level is &lt;1 micromolar, then 15 mg IV every 3 hours until methotrexate level &lt;0.05 micromolar</p>
<p style="text-indent:-2em;margin-left:2em;">Leucovorin nomogram dosing for high-dose methotrexate overexposure (<b>generalized leucovorin dosing</b> derived from reference nomogram figures, refer to each reference (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-342086','lexi-content-ref-Bleyer.1','lexi-content-ref-16794248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-342086','lexi-content-ref-Bleyer.1','lexi-content-ref-16794248'])">Ref</a></span>) or institution-specific nomogram for details):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>At 24 hours:</b></p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ≥100 micromolar at ~24 hours, leucovorin is initially dosed at 1,000 mg/m<sup>2</sup> IV every 6 hours</p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ≥10 to &lt;100 micromolar at 24 hours, leucovorin is initially dosed at 100 mg/m<sup>2</sup> IV every 3 or 6 hours</p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ~1 to 10 micromolar at 24 hours, leucovorin is initially dosed at 10 mg/m<sup>2</sup> IV or orally every 3 or 6 hours</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>At 48 hours:</b></p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ≥100 micromolar at 48 hours, leucovorin is dosed at 1,000 mg/m<sup>2</sup> IV every 6 hours</p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ≥10 to &lt;100 micromolar at 48 hours, leucovorin is dosed at 100 mg/m<sup>2</sup> IV every 3 hours</p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ~1 to 10 micromolar at 48 hours, leucovorin is dosed at 100 mg/m<sup>2</sup> IV every 6 hours <b>or</b> 10 mg/m<sup>2</sup> IV or orally to 100 mg/m<sup>2</sup> IV every 3 hours</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>At 72 hours:</b></p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ≥10 micromolar at 72 hours, leucovorin is dosed at 100 to 1,000 mg/m<sup>2</sup> IV every 3 to 6 hours</p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ~1 to 10 micromolar at 72 hours, leucovorin is dosed at 10 mg/m<sup>2</sup> IV or orally to 100 mg/m<sup>2</sup> IV every 3 hours</p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ~0.1 to 1 micromolar at 72 hours, leucovorin is dosed at 10 mg/m<sup>2</sup> IV or orally every 3 to 6 hours</p>
<p style="text-indent:-2em;margin-left:4em;">If serum creatinine is increased more than 50% above baseline, increase the standard leucovorin dose to 100 mg/m<sup>2</sup> IV every 3 hours, then adjust according to methotrexate levels above.</p>
<p style="text-indent:-2em;margin-left:4em;">Follow methotrexate levels daily, leucovorin may be discontinued when methotrexate level is &lt;0.1 micromolar</p></div>
<div class="block doe drugH1Div" id="F194561"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; adjust for renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer:</b> Patients &gt;60 years of age: CMF regimen:<b> IV:</b> 30 mg/m<sup>2</sup> on days 1 and 8 every 4 weeks (in combination with cyclophosphamide and fluorouracil) for up to 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7877646']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7877646'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningeal leukemia:</b>
<b>Intrathecal:</b> Consider a dose reduction (CSF volume and turnover may decrease with age).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphoma:</b> CODOX-M/IVAC regimen: Cycles 1 and 3 of CODOX-M: <b>IV:</b> 100 mg/m<sup>2</sup> over 1 hour on day 10 followed by 900 mg/m<sup>2</sup> over 23 hours (with leucovorin rescue); CODOX-M cycles alternate with IVAC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18612102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18612102'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary CNS lymphoma, newly diagnosed (off-label use):</b> Patients ≥65 years of age: R-MP regimen:<b> IV:</b> 3 <b>g</b>/m<sup>2</sup> over 4 hours on days 2, 16, and 30 of a 42-day cycle (in combination with rituximab, procarbazine, and leucovorin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27843136']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27843136'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis/psoriasis:</b>
<b>Oral:</b> Initial: 5 to 7.5 mg/week.</p></div>
<div class="block dop drugH1Div" id="F194583"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12595" href="/d/html/12595.html" rel="external">see "Methotrexate: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Only preservative-free formulations should be used for intrathecal administration and for high-dose methotrexate regimens. Methotrexate doses between 100 to 500 mg/m<sup>2</sup> may require leucovorin calcium rescue. Methotrexate doses &gt;500 mg/m<sup>2</sup> require leucovorin calcium rescue.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing may be presented as mg/m<sup>2</sup> or mg/<b>kg</b>; verify dosage unit for calculations; maximum doses may be presented in mg or <b>g</b>; extra precautions should be taken. Frequency of dosing is indication specific (generally weekly or specific days within a protocol); patient harm (including fatality) may occur if administered incorrectly (eg, if a weekly dose is given daily); extra precautions should be taken to verify appropriate frequency. <b>For oncology uses, </b>regimens with corresponding dosing and frequency are highly variable and subject to frequent changes; typical dose ranges presented; specific protocols should be consulted.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>
<i>Antiemetic prophylaxis:</i> Doses ≥12 <b>g</b>/m<sup>2</sup> IV are associated with a high emetic potential, while a 5 <b>g</b>/m<sup>2</sup> IV dose is associated with a moderate emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637','lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637','lexi-content-ref-30729654'])">Ref</a></span>); antiemetics may be recommended to prevent nausea and vomiting.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2647719a-6466-4817-b8e3-9f6b3c1e3136">Acute lymphoblastic leukemia of infancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia (ALL) of infancy: </b>Limited data available: <b>Note: </b>Intrathecal therapy is also administered (refer to specific reference for intrathecal dosing used within protocol); other combination chemotherapy variable based on protocol and phase of treatment; refer to specific protocol:</p>
<p style="text-indent:-2em;margin-left:4em;">Intensification and Consolidation: Infant (&lt;1 year of age) at diagnosis: IV: 4,000 to 5,000 mg/m<sup>2</sup> over 24 hours every 7 days for 2 doses; specific days depend on protocol phase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25399948','lexi-content-ref-17658395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25399948','lexi-content-ref-17658395'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e377156d-8f9e-4a56-82c0-10bb27765b84">Acute lymphoblastic leukemia/lymphoma, immature B-cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia (ALL)/lymphoma (LBL), immature <span style="text-decoration: underline">B-cell</span></b>
<b>: </b>Limited data available; multiple regimens reported:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Intrathecal therapy is also administered (refer to specific reference for intrathecal dosing used within protocol); methotrexate should be used as part of a combination regimen; refer to specific protocols:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Interim maintenance:</i></p>
<p style="text-indent:-2em;margin-left:8em;">High-dose methotrexate: Children and Adolescents: IV: 500 mg/m<sup>2</sup> over 30 minutes followed by 4,500 mg/m<sup>2</sup> over 23.5 hours to complete a total dose of 5,000 mg/m<sup>2</sup> over 24 hours on days 1, 15, 29, and 43 (with leucovorin rescue) in combination with vincristine, mercaptopurine, and intrathecal methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27114587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27114587'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Escalating-dose methotrexate (Capizzi [C-MTX]): Children and Adolescents: IV: Initial dose: 100 mg/m<sup>2</sup> then escalate dose by 50 mg/m<sup>2</sup> every 10 days for 5 doses total in combination with vincristine, pegaspargase, and intrathecal methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27114587','lexi-content-ref-18039957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27114587','lexi-content-ref-18039957'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i> Maintenance:</i> Children and Adolescents: Oral: 20 mg/m<sup>2</sup> once <b>weekly</b> in combination with vincristine, prednisone, mercaptopurine, and intrathecal methotrexate. On weeks intrathecal methotrexate is administered, consider holding the oral methotrexate for that week; refer to specific protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27114587','lexi-content-ref-18039957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27114587','lexi-content-ref-18039957'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CNS prophylaxis intrathecal therapy:</i> Infants, Children, and Adolescents: Intrathecal: Age-based dosing: Days of administration vary based on risk status and protocol; refer to institutional protocols or reference for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27114587','lexi-content-ref-17455314','lexi-content-ref-16609069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27114587','lexi-content-ref-17455314','lexi-content-ref-16609069'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;1 year: 6 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">1 to &lt;2 years: 8 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">2 to &lt;3 years: 10 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">3 to ≤8 years: 12 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;8 years: 15 mg.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="760da03b-5fb2-418e-a724-8d1b2564e814">Acute lymphoblastic leukemia/lymphoma, immature T-cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia (ALL)/lymphoma (LBL), immature <span style="text-decoration: underline">T-cell</span>: </b> Limited data available; multiple regimens reported:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Intrathecal therapy is also administered (refer to specific reference for intrathecal dosing used within protocol); methotrexate should be used as part of a combination regimen; refer to specific protocols:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Interim maintenance:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Escalating-dose methotrexate (Capizzi [C-MTX]): Children and Adolescents: IV: Initial dose: 100 mg/m<sup>2</sup> then escalate dose by 50 mg/m<sup>2</sup> every 10 days for 5 doses total in combination with vincristine and pegaspargase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813610','lexi-content-ref-30138085']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813610','lexi-content-ref-30138085'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS prophylaxis intrathecal therapy</i>: Children and Adolescents: Intrathecal: Age-adjusted dosing: Days of administration vary based on risk status and protocol; refer to protocol for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813610','lexi-content-ref-30138085']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813610','lexi-content-ref-30138085'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">1 to &lt;2 years: 8 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">2 to &lt;3 years: 10 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">3 to &lt;9 years: 12 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">≥9 years: 15 mg.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3af7be48-9503-48e3-b4fb-fbcfba6a47a9">CNS tumors, malignant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS tumors, malignant (medulloblastoma, PNET, ependymoma, brainstem glioma): </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;10 years: IV: 400 mg/<b>kg</b> on day 4 with leucovorin rescue until level less than 0.1 micromolar (µM); administer methotrexate every 21 days for 5 cycles (in combination with cisplatin, vincristine, etoposide, and cyclophosphamide; then followed by an autotransplant) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15611503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15611503'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="698502f2-8371-4f7b-b52e-f26b1c2278b7">Crohn disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease: </b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">BSA-directed dosing: 15 mg/m<sup>2</sup> once weekly; maximum dose: 25 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9602195','lexi-content-ref-22516861','lexi-content-ref-20081543','lexi-content-ref-18042110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9602195','lexi-content-ref-22516861','lexi-content-ref-20081543','lexi-content-ref-18042110'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-9602195','lexi-content-ref-18042110','lexi-content-ref-19412004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-9602195','lexi-content-ref-18042110','lexi-content-ref-19412004'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">20 to 29 kg: 10 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">30 to 39 kg: 15 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">40 to 49 kg: 20 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">≥50 kg: 25 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral, SUBQ: <b>Note:</b> Should be used in patients intolerant or unresponsive to purine analog therapy (eg, azathioprine, mercaptopurine); use in combination with folic acid supplementation.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ddc801b-4d44-4c9c-bd35-43d95c52ace1">Dermatomyositis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatomyositis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IM or SUBQ (preferred): Initial: 15 to 20 mg/m<sup>2</sup>
<b>or</b> 1 mg/<b>kg</b> (whichever is less) once weekly; maximum dose: 40 mg/dose; used in combination with corticosteroids and with either folic acid or folinic acid supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20191521','lexi-content-ref-16255046','lexi-content-ref-26645190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20191521','lexi-content-ref-16255046','lexi-content-ref-26645190'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral (not preferred): Initial: 15 mg/m<sup>2</sup>
<b>or</b> 1 mg/<b>kg</b> (whichever is less) once weekly; maximum dose: 40 mg/dose; used in combination with corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20191521','lexi-content-ref-16255046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20191521','lexi-content-ref-16255046'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a08144cd-2dce-4e00-8d82-7305842b16b4">Graft-versus-host disease, acute, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease (aGVHD), acute, prophylaxis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Multiple regimens reported and may vary by dose and frequency of dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">Standard dose: Children and Adolescents: IV: 15 mg/m<sup>2</sup>/dose on day 1 and 10 mg/m<sup>2</sup>/dose on days 3 and 6 after allogeneic transplant (in combination with cyclosporine and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8413388','lexi-content-ref-10871150','lexi-content-ref-10534058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8413388','lexi-content-ref-10871150','lexi-content-ref-10534058'])">Ref</a></span>) <b>or</b> 15 mg/m<sup>2</sup>/dose on day 1 and 10 mg/m<sup>2</sup>/dose on days 3, 6, and 11 after allogeneic transplant (in combination with cyclosporine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10871150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10871150'])">Ref</a></span>). Leucovorin rescue may be administered according to protocol.</p>
<p style="text-indent:-2em;margin-left:4em;">Mini-dose: Children and Adolescents: IV: 5 mg/m<sup>2</sup>/dose; frequency of dosing reported is variable; following haploidentical stem cell transplant, doses were administered on days 5, 7, 10, and 15 in combination with posttransplant cyclophosphamide and cyclosporine and leucovorin rescue administered 24 hours after methotrexate dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32224144']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32224144'])">Ref</a></span>); following cord blood transplant, doses were administered on days 1, 3, and 6 in combination with tacrolimus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Shiratori.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Shiratori.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7adb1123-e6d3-4193-a4da-4e4eab6e5b54">Juvenile idiopathic arthritis, polyarticular</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis (JIA), polyarticular: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Therapy should be individualized based on disease severity and activity; when initiating therapy, a trial of at least 3 months is considered adequate; however, if there is no response or only minimal response after 6 to 8 weeks, changing therapy or adding additional therapy may be appropriate. Due to variable bioavailability of oral administration and GI side effects, some experts suggest subcutaneous administration over oral, especially when doses are &gt;10 mg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31021516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31021516'])">Ref</a></span>). When switching between dosage forms and routes of administration, dosage adjustment may be needed.</p>
<p style="text-indent:-2em;margin-left:4em;">BSA-directed dosing: Children and Adolescents: Oral, IM, SUBQ: Initial: 10 to 15 mg/m<sup>2</sup> once weekly; adjust gradually up to 20 to 30 mg/m<sup>2</sup> once weekly; maximum dose: 25 mg/dose. To reduce GI side effects and improve bioavailability and efficacy, consider parenteral administration (IM, SUBQ) of doses &gt;10 mg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31021516','lexi-content-ref-24339215','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31021516','lexi-content-ref-24339215','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing: Children and Adolescents: Oral, SUBQ: Initial: 0.5 mg/<b>kg</b> once weekly; maximum initial dose: 15 mg/dose; if symptoms worsen or are unchanged after 4 weeks, may increase to SUBQ: 1 mg/<b>kg</b>; maximum dose: 25 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24339215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24339215'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ec06004-9e99-4ea0-a9b5-ef91bff8b7dc">Meningeal leukemia, prophylaxis or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningeal leukemia, prophylaxis or treatment: Note: </b>Frequency and duration of treatment based on protocol; treatment dosing may be a frequency of every 2 to 7 days (based on protocol); for treatment, often used in combination with cytarabine and hydrocortisone (triple intrathecal therapy); refer to institutional protocols or references for details. Optimal intrathecal chemotherapy dosing should be based on age rather than on BSA; CSF volume correlates with age and not to BSA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6366138','lexi-content-ref-11248578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6366138','lexi-content-ref-11248578'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Intrathecal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6366138','lexi-content-ref-27114587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6366138','lexi-content-ref-27114587'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;1 year: 6 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">1 to &lt;2 years: 8 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">2 to &lt;3 years: 10 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">3 to &lt;9 years: 12 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">≥9 years: 15 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef0dfdb9-b4d0-45f7-b059-6fb32f2f1247">Non-Hodgkin lymphoma, mature B-cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphoma, mature <span style="text-decoration: underline">B-cell</span>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermediate risk</i>: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22940833','lexi-content-ref-25066629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22940833','lexi-content-ref-25066629'])">Ref</a></span>): <b>Note:</b> Some regimens may include periodic intrathecal methotrexate doses; refer to institution-specific protocols or references cited; only intravenous dosing provided.</p>
<p style="text-indent:-2em;margin-left:6em;">Induction 1 and 2 (COPADM regimen) and Consolidation 1 and 2 (CYM regimen): Children and Adolescents: IV: 3,000 mg/m<sup>2</sup> over 3 hours with leucovorin rescue; combination chemotherapy varied with protocol phase.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>High risk:</i> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17138821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17138821'])">Ref</a></span>): <b>Note:</b> Some regimens may include periodic intrathecal methotrexate doses; refer to institution-specific protocols or references cited; only intravenous dosing provided.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months, Children, and Adolescents: IV: 8,000 mg/m<sup>2</sup> over 4 hours once followed by leucovorin rescue; specific day of therapy and combination chemotherapy depend on protocol phase and clinical factors (eg, CNS positive).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a8c3fca-abf8-4c1f-bae0-4af9b5c00048">Non-Hodgkin lymphoma, mature T-cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphoma, mature <span style="text-decoration: underline">T-cell</span> (anaplastic large cell lymphoma [ALCL]):</b> Limited data available: <b>Note:</b> Both intravenous and intrathecal methotrexate dosing were part of protocol; use extra precaution ensuring route and dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 3,000 mg/m<sup>2</sup> over 3 hours with leucovorin rescue (in combination with multi-agent chemotherapy, depending on cycle) for a total of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33684925']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33684925'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="892a32f8-154f-41d0-a59a-cc8169aa39d2">Osteosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteosarcoma: </b>High-dose methotrexate: Children and Adolescents: IV: 12<b> g/</b>m<sup>2</sup> (maximum dose: 20 <b>g</b>/dose) over 4 hours (followed by leucovorin rescue) for 4 doses during induction (before surgery) at weeks 3, 4, 8, and 9, and for 8 doses during maintenance (after surgery) at weeks 15, 16, 20, 21, 25, 26, 30, and 31 (in combination with doxorubicin and cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15774791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15774791'])">Ref</a></span>); reported frequencies and durations have varied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16246977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16246977'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dcf9e857-6c31-4bb0-a628-be80680d4151">Psoriasis, severe; recalcitrant to topical therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriasis, severe; recalcitrant to topical therapy:</b> Limited data available: Children and Adolescents: Oral, SUBQ: Usual reported range: 0.2 to 0.4 mg/<b>kg</b> once weekly; maximum reported dose: 25 mg/dose; reported treatment duration is highly variable: 6 to 178 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15692480','lexi-content-ref-19900732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15692480','lexi-content-ref-19900732'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd98d51e-357d-4e10-9a17-edaf4b7eb5a6">Scleroderma, localized</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Scleroderma, localized (juvenile):</b> Limited data available: Infants, Children, and Adolescents: Oral, SUBQ (preferred): 1 mg/<b>kg</b> once weekly; maximum dose: 25 mg/dose; alone or in combination with corticosteroids; duration of therapy: 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22505322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22505322'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ff802a22-9385-4d6c-8216-a7b3af4a5560">Uveitis, recalcitrant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uveitis, recalcitrant:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">BSA-directed dosing: Oral, SUBQ: Most frequently reported: 15 mg/m<sup>2</sup> once weekly, usual range: 10 to 25 mg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15693100','lexi-content-ref-22879466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15693100','lexi-content-ref-22879466'])">Ref</a></span>); the SUBQ route may be preferred for patients with GI symptoms, poor bioavailability, or doses &gt;15 mg/m<sup>2</sup>; a maximum dose of 25 mg/dose was reported in other pediatric uveitis trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553975','lexi-content-ref-9709718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553975','lexi-content-ref-9709718'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: SUBQ: 0.5 to 1 mg/<b>kg</b> once weekly; maximum dose: 25 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9709718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9709718'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Nonhematologic toxicity: Diarrhea, stomatitis, or vomiting which may lead to dehydration: Discontinue until recovery.</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic toxicity:</p>
<p style="text-indent:-2em;margin-left:6em;">Psoriasis, arthritis (JIA): Significant blood count decrease: Discontinue immediately.</p>
<p style="text-indent:-2em;margin-left:6em;">Oncologic uses:</p>
<p style="text-indent:-2em;margin-left:8em;">Myelosuppression: Withhold, reduce dose, or discontinue methotrexate as appropriate; refer to individual protocol; provide supportive care as needed.</p>
<p style="text-indent:-2em;margin-left:8em;">Profound granulocytopenia and fever: Evaluate immediately; consider broad-spectrum parenteral antimicrobial coverage. Withhold, reduce dose, or discontinue methotrexate as appropriate.</p></div>
<div class="block dorp drugH1Div" id="F51129919"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling. The following adjustments have been recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oncology doses/uses: Refer to specific protocols for adjustments; the higher oncology doses may require more aggressive dosing adjustments than those recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">Nononcology doses/uses: The following have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 30% of dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Hemodialysis: Administer 30% of dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Peritoneal dialysis (PD): Administer 30% of dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous renal replacement therapy (CRRT): Administer 50% of dose.</p></div>
<div class="block dohp drugH1Div" id="F51129920"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">All patients: There are no dosage adjustments provided in the manufacturer's labeling; use with caution in patients with impaired hepatic function or preexisting hepatic dysfunction. In pediatric oncology patients, refer to specific protocols for adjustments; the higher oncology doses may require more aggressive dosing adjustments. The following adjustments have been recommended in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16473644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16473644'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Bilirubin 3.1 to 5 mg/dL <b>or</b> transaminases &gt;3 times ULN: Administer 75% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Bilirubin &gt;5 mg/dL: Avoid use.</p></div>
<div class="block arsc drugH1Div" id="F55211794"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Dermatologic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe dermatologic reactions have been reported with methotrexate use, including <b>erythema multiforme</b>, erythroderma, <b>Stevens-Johnson syndrome </b>(SJS), and <b>toxic epidermal necrolysis </b>(TEN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15811037','lexi-content-ref-22091553','lexi-content-ref-26955111']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15811037','lexi-content-ref-22091553','lexi-content-ref-26955111'])">Ref</a></span>). Skin reactions have been noted with single or multiple low and high doses of methotrexate in patients with neoplastic and non-neoplastic diseases. Methotrexate-induced <b>skin necrosis</b> has been described that mimics SJS/TEN but differs in pathology and presumed mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28499754','lexi-content-ref-9146556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28499754','lexi-content-ref-9146556'])">Ref</a></span>). Mucocutaneous ulcers have been reported within preexisting skin lesions (eg, psoriasis); this may be an initial presenting sign of long-term methotrexate toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29627775','lexi-content-ref-25276442','lexi-content-ref-25046458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29627775','lexi-content-ref-25276442','lexi-content-ref-25046458'])">Ref</a></span>). Other dermatologic reactions reported include <b>pustular rash</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33409982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33409982'])">Ref</a></span>), <b>hyperpigmentation</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33409982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33409982'])">Ref</a></span>), <b>papular rash</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18094347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18094347'])">Ref</a></span>); <b>skin photosensitivity</b> (eg, <b>photodermatitis</b> reactivation, <b>skin abnormalities related to radiation recall</b>, <b>dyschromia</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20334462','lexi-content-ref-24890023','lexi-content-ref-22091553','lexi-content-ref-23571545']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20334462','lexi-content-ref-24890023','lexi-content-ref-22091553','lexi-content-ref-23571545'])">Ref</a></span>); acral erythema (also known as hand-foot syndrome and <b>palmar-plantar erythrodysesthesia</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28493546']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28493546'])">Ref</a></span>); and accelerated nodulosis in patients with rheumatoid arthritis (RA) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12222551']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12222551'])">Ref</a></span>). Compared to classic rheumatoid <b>nodule</b>, accelerated nodules have a more rapid onset, are smaller, and mainly affect the hands (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31497770']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31497770'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> SJS and TEN are delayed type IV hypersensitivity reactions involving a T-cell mediated drug-specific immune response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>). Methotrexate-induced skin necrosis is caused by direct toxicity to keratinocytes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28499754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28499754'])">Ref</a></span>). Similarly, acute mucocutaneous lesions are the result of methotrexate toxicity to the mucosa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29627775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29627775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; SJS and TEN typically occur days to weeks after drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22091553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22091553'])">Ref</a></span>). Skin necrosis occurs 3 to 90 days post-initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28499754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28499754'])">Ref</a></span>); although, may occur after a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19467968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19467968'])">Ref</a></span>). Mucocutaneous ulcerations have occurred with acute and, less commonly, chronic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23221488','lexi-content-ref-22309341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23221488','lexi-content-ref-22309341'])">Ref</a></span>). Symptom onset with photo-recall (also known as UV recall) occurs within weeks to years of ultraviolet (UV) exposure, whereas UV enhancement is observed within 1 week of UV exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26267431']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26267431'])">Ref</a></span>). Accelerated nodulosis typically occurs from 3 months to 12 years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12222551']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12222551'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;55 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25046458','lexi-content-ref-25401478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25046458','lexi-content-ref-25401478'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Drug-drug interactions (eg, nonsteroidal anti-inflammatory agents [NSAIDs], sulfamethoxazole/trimethoprim) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25046458','lexi-content-ref-25401478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25046458','lexi-content-ref-25401478'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Folate deficiency and low serum albumin level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25046458','lexi-content-ref-25401478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25046458','lexi-content-ref-25401478'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Increase in methotrexate dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25046458','lexi-content-ref-25401478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25046458','lexi-content-ref-25401478'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25046458','lexi-content-ref-25401478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25046458','lexi-content-ref-25401478'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Photodermatitis reactivation: Sunburn (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24890023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24890023'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Photosensitivity reactions: Concurrent voriconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23571545']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23571545'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Exposure to UV radiation may aggravate psoriasis</p>
<p style="text-indent:-2em;margin-left:6em;">• Excessive sun exposure</p>
<p style="text-indent:-2em;margin-left:6em;">• Skin necrosis: Age &gt;60 years, chronic kidney disease, high initial methotrexate dose without folic acid supplement, leukopenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28499754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28499754'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">GI toxicity is a frequently occurring adverse reaction of methotrexate. Although <b>stomatitis</b> occurs more frequently with high-dose methotrexate, life-threatening GI events and fatalities have been reported with low-dose methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21707700','lexi-content-ref-33409982','lexi-content-ref-26494588']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21707700','lexi-content-ref-33409982','lexi-content-ref-26494588'])">Ref</a></span>). Other dose-limiting GI manifestations include <b>abdominal distress</b>, <b>diarrhea</b>, <b>gastrointestinal hemorrhage</b>, <b>gastrointestinal ulcer</b>, indigestion, <b>nausea</b>, and <b>vomiting </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18163521','lexi-content-ref-35078225','lexi-content-ref-11465701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18163521','lexi-content-ref-35078225','lexi-content-ref-11465701'])">Ref</a></span>). Stomatitis can be an early sign of methotrexate toxicity, as high tissue turnover rates make GI and mucosal cells especially sensitive to chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4719662','lexi-content-ref-23601229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4719662','lexi-content-ref-23601229'])">Ref</a></span>). Ulcerative stomatitis and diarrhea can progress to life-threatening <b>enteritis</b> and <b>intestinal perforation</b>. GI hemorrhage and ulcers are reported more frequently in patients with a history of ulcerative colitis or peptic ulcer disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27496039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27496039'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Dose-related; mucositis and stomatitis after high-dose methotrexate are caused by cellular damage to rapidly dividing epithelial cells along the entire GI tract; inadequate or delayed leucovorin rescue can lead to impaired epithelial cell growth and regeneration in patients treated with high-dose methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27496039','lexi-content-ref-15330370','lexi-content-ref-30049384']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27496039','lexi-content-ref-15330370','lexi-content-ref-30049384'])">Ref</a></span>). Endothelial and connective tissue insult along with mucosal barrier injury result in early development of mucositis and stomatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27496039','lexi-content-ref-15330370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27496039','lexi-content-ref-15330370'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Non–dose-related; additional reports have been published where intestinal toxicity occurred as a result of inflammatory effects of methotrexate in the intestinal epithelium and submucosal tissues. This mechanism appears to be non-dose-related and explains the toxicity observed with low-dose methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27041864','lexi-content-ref-15330370','lexi-content-ref-30049384']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27041864','lexi-content-ref-15330370','lexi-content-ref-30049384'])">Ref</a></span>). Nausea and vomiting occur as a result of insult to the chemoreceptor trigger zone inducing emesis. Methotrexate has low emetogenic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; nausea, vomiting, and diarrhea occur as early as 24 hours post high-dose methotrexate infusion and as long as 7 days post infusion. Similar symptoms appear 24 hours after low-dose methotrexate weekly dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25172240']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25172240'])">Ref</a></span>). Oral mucositis occurs within the first week of low-dose methotrexate therapy with unintentional overdose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29641725']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29641725'])">Ref</a></span>). high-dose methotrexate-induced stomatitis and mucositis occur after the first course of treatment or up to 14 days post high-dose methotrexate infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25348617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25348617'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">High-dose methotrexate:</p>
<p style="text-indent:-2em;margin-left:8em;">• Drug-drug interactions, especially concomitant use with nonsteroidal anti-inflammatory drugs (NSAIDs)</p>
<p style="text-indent:-2em;margin-left:6em;">Low-dose methotrexate:</p>
<p style="text-indent:-2em;margin-left:8em;">• Drug-drug interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29915656','lexi-content-ref-32170389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29915656','lexi-content-ref-32170389'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• High starting doses (&gt;15 mg/week to 25 mg/week) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7939138']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7939138'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of peptic ulcer disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28565788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28565788'])">Ref</a></span>) or ulcerative colitis</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32170389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32170389'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting folate deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27957282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27957282'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Unintentional daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29641725']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29641725'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher frequency of nausea in adolescents and younger adults, SubQ methotrexate use, and duration of therapy &gt;1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24108504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24108504'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher risk of diarrhea associated with younger age and previous GI events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12695153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12695153'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Unexpectedly severe (sometimes fatal) <b>bone marrow depression</b> with <b>agranulocytosis</b>, <b>anemia</b>, <b>aplastic anemia</b>, <b>leukopenia</b>, <b>neutropenia, </b>
<b>pancytopenia</b>, and <b>thrombocytopenia</b> may occur with low-dose methotrexate used for conditions such as rheumatoid arthritis (RA) or psoriasis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27128679','lexi-content-ref-12560282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27128679','lexi-content-ref-12560282'])">Ref</a></span>). Neutropenia is encountered most frequently, but anemia and thrombocytopenia also occur. May also occur with high-dose methotrexate, most commonly in the presence of kidney dysfunction and specific concurrent medications delaying methotrexate clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27496039','lexi-content-ref-32170389','lexi-content-ref-20944174']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27496039','lexi-content-ref-32170389','lexi-content-ref-20944174'])">Ref</a></span>). Aplastic anemia has been reported when high-dose methotrexate is concomitantly administered with a nonsteroidal anti-inflammatory drug (NSAID). (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27721549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27721549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; hematologic toxicity occurs secondary to methotrexate’s interference with stem cell DNA synthesis. Fast turnover of stem cells together with a high number of cells in the S phase cycle makes these cells especially labile to methotrexate-induced hematologic toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11391029','lexi-content-ref-12560282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11391029','lexi-content-ref-12560282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; with low-dose methotrexate occurring at any time during treatment, from a rapid onset to many years of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11391029','lexi-content-ref-15901903','lexi-content-ref-27128679','lexi-content-ref-12560282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11391029','lexi-content-ref-15901903','lexi-content-ref-27128679','lexi-content-ref-12560282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• <b>Note:</b> Methotrexate bone marrow suppression with low-dose methotrexate, especially pancytopenia, can occur in the absence of identifiable risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8849378','lexi-content-ref-12560282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8849378','lexi-content-ref-12560282'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Absence of supplemental folic acid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27128679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27128679'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25172240','lexi-content-ref-27128679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25172240','lexi-content-ref-27128679'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27128679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27128679'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of NSAIDs, ciprofloxacin, penicillin-type drugs, sulfamethoxazole/trimethoprim, probenecid, phenytoin, and proton pump inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23521709','lexi-content-ref-11972105','lexi-content-ref-16842380','lexi-content-ref-25172240','lexi-content-ref-27128679','lexi-content-ref-20944174','lexi-content-ref-19076159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23521709','lexi-content-ref-11972105','lexi-content-ref-16842380','lexi-content-ref-25172240','lexi-content-ref-27128679','lexi-content-ref-20944174','lexi-content-ref-19076159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dosing errors (ie, administering daily or 2 to 4 days per week) increase toxicity more often than once weekly dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28261918','lexi-content-ref-15901903','lexi-content-ref-12560282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28261918','lexi-content-ref-15901903','lexi-content-ref-12560282'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypoalbuminemia or displacement of methotrexate from albumin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25172240','lexi-content-ref-27128679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25172240','lexi-content-ref-27128679'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Fluid accumulations and third spacing (ie, ascites, pleural effusions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27496039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27496039'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25172240','lexi-content-ref-27128679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25172240','lexi-content-ref-27128679'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate causes frequent <b>increased</b>
<b>liver enzymes</b>. Less frequently, these elevations lead to chronic <b>hepatotoxicity </b>in the form of <b>hepatic fibrosis</b> and <b>hepatic</b>
<b>cirrhosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7685956','lexi-content-ref-27721549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7685956','lexi-content-ref-27721549'])">Ref</a></span>). Acute liver enzyme elevations are transient and asymptomatic and may not be predictive of subsequent hepatic disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17039139','lexi-content-ref-19033291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17039139','lexi-content-ref-19033291'])">Ref</a></span>). Delayed hepatic toxicity in the form of fibrosis or cirrhosis after 2 years or more of low-dose methotrexate use and a total dose of at least 1.5 g can be fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14871278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14871278'])">Ref</a></span>). Cases of fibrosis have also been reported in rheumatoid arthritis (RA) patients receiving regular folic acid supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27721549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27721549'])">Ref</a></span>). Patients being treated for psoriasis may be predisposed to higher reported levels of liver enzymes more frequently than patients treated for RA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17163236']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17163236'])">Ref</a></span>). Fibrosis and cirrhosis may also occur without symptoms or liver enzyme elevations in psoriasis patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1404123','lexi-content-ref-17039139','lexi-content-ref-8123573','lexi-content-ref-19033291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1404123','lexi-content-ref-17039139','lexi-content-ref-8123573','lexi-content-ref-19033291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; impaired function of folate cell transporters leading to excessive methotrexate in liver cells, accumulation of homocysteine causing oxidative stress, and inflammation resulting in fatty liver; depletion of hepatic folate stores and local toxicity due to folate deficiency; direct damage from methotrexate metabolites to hepatocytes and fibrosis forming as a result of adenosine production in response to toxins such as ethanol, viruses, or drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29785393','lexi-content-ref-28989565','lexi-content-ref-27721549','lexi-content-ref-21707700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29785393','lexi-content-ref-28989565','lexi-content-ref-27721549','lexi-content-ref-21707700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; higher frequency of hepatotoxicity after first infusion with high-dose methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30805487']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30805487'])">Ref</a></span>). Patients may exhibit increases in liver enzymes within 7 months of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24470205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24470205'])">Ref</a></span>). Biopsy-proven liver abnormalities have been detected in patients after 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28989565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28989565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol consumption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25139707','lexi-content-ref-29785393','lexi-content-ref-17399848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25139707','lexi-content-ref-29785393','lexi-content-ref-17399848'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of hepatotoxic medications (eg, azathioprine, retinoids, sulfasalazine, leflunomide)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cumulative dose &gt;1.5 g and duration of therapy ≥2 years</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12695153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12695153'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21044440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21044440'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Metabolic syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25139707','lexi-content-ref-29785393','lexi-content-ref-17399848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25139707','lexi-content-ref-29785393','lexi-content-ref-17399848'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21044440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21044440'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting hepatic disease, particularly nonalcoholic steatohepatitis and nonalcoholic fatty liver disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25139707','lexi-content-ref-29785393','lexi-content-ref-17399848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25139707','lexi-content-ref-29785393','lexi-content-ref-17399848'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate rarely increases the risk for developing life-threatening or fatal <b>infection</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30583473','lexi-content-ref-32170389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30583473','lexi-content-ref-32170389'])">Ref</a></span>), including <b>exacerbation of hepatitis B </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12810441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12810441'])">Ref</a></span>), <b>tuberculosis</b> (primary infection or reactivation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11285384']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11285384'])">Ref</a></span>), disseminated <b>herpes zoster</b>
<b>infection</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26508914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26508914'])">Ref</a></span>), and <b>cytomegalovirus</b> disease. Immune suppression may lead to potentially fatal opportunistic infections, especially <b>pneumonia due to</b>
<b>
<i>Pneumocystis jirovecii </i></b>(PJP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21044440','lexi-content-ref-11082754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21044440','lexi-content-ref-11082754'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; immunosuppression may occur due to T-cell apoptosis and clonal deletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9664073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9664073'])">Ref</a></span>). Patients with rheumatoid arthritis (RA) have a high rate of infection when compared to healthy control population; therefore, infections (including opportunistic infections) arising during therapy may be due to RA or the immunosuppressive effects of methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21044440','lexi-content-ref-30583473','lexi-content-ref-19447771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21044440','lexi-content-ref-30583473','lexi-content-ref-19447771'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may occur at any time during treatment; however, most infections occur in the first 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7667645','lexi-content-ref-19060002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7667645','lexi-content-ref-19060002'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Low-dose methotrexate (ie, ≤15 mg per week) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30583473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30583473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8025760','lexi-content-ref-2028435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8025760','lexi-content-ref-2028435'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs), ciprofloxacin, penicillin-type drugs, sulfamethoxazole/trimethoprim, probenecid, phenytoin, and proton pump inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23521709','lexi-content-ref-11972105','lexi-content-ref-16842380','lexi-content-ref-25172240','lexi-content-ref-27128679','lexi-content-ref-20944174','lexi-content-ref-19076159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23521709','lexi-content-ref-11972105','lexi-content-ref-16842380','lexi-content-ref-25172240','lexi-content-ref-27128679','lexi-content-ref-20944174','lexi-content-ref-19076159'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nephrotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate may cause <b>acute kidney injury</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16794248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16794248'])">Ref</a></span>). Increases in serum creatinine may persist more than 4 months after therapy discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18504579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18504579'])">Ref</a></span>). Other kidney adverse reactions reported with methotrexate use include <b>azotemia,</b>
<b>cystitis</b>, <b>proteinuria</b>, and <b>hematuria</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; acute kidney injury arises from 2 primary mechanisms: Crystal nephropathy and direct tubular toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7189691','lexi-content-ref-21146122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7189691','lexi-content-ref-21146122'])">Ref</a></span>). Methotrexate parent drug and metabolite accumulation in renal tubules cause crystal nephropathy and renal tubular obstruction that presents with asymptomatic serum creatinine elevations that progresses to tubular necrosis and kidney injury. Secondly, direct tubular toxicity and cellular injury occur as a result of oxygen radical formation in the kidney (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21146122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21146122'])">Ref</a></span>). A third mechanism of methotrexate-induced kidney injury is hyperhomocysteinemia in patients with deficient folate metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21146122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21146122'])">Ref</a></span>). Methotrexate-induced kidney damage decreases clearance and results in sustained and elevated plasma methotrexate concentrations which then lead to systemic toxicities including further kidney impairment, myelosuppression, hepatotoxicity, stomatitis, and in rare cases, multi-organ failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29541561','lexi-content-ref-27496039','lexi-content-ref-21220601','lexi-content-ref-26024041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29541561','lexi-content-ref-27496039','lexi-content-ref-21220601','lexi-content-ref-26024041'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; occurs as early as 36 hours after high-dose methotrexate infusion and as late as 9 years after chronic low-dose methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16326413','lexi-content-ref-21597286','lexi-content-ref-15520148']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16326413','lexi-content-ref-21597286','lexi-content-ref-15520148'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;49 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18504579','lexi-content-ref-24004183','lexi-content-ref-26152702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18504579','lexi-content-ref-24004183','lexi-content-ref-26152702'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of salicylates, sulfonamides, nonsteroidal anti-inflammatory drugs (NSAIDs), ciprofloxacin, penicillin-type drugs, probenecid, and proton pump inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23521709','lexi-content-ref-21044440','lexi-content-ref-22477728','lexi-content-ref-11972105','lexi-content-ref-18779628','lexi-content-ref-16842380','lexi-content-ref-23737767','lexi-content-ref-20944174','lexi-content-ref-19076159','lexi-content-ref-26152702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23521709','lexi-content-ref-21044440','lexi-content-ref-22477728','lexi-content-ref-11972105','lexi-content-ref-18779628','lexi-content-ref-16842380','lexi-content-ref-23737767','lexi-content-ref-20944174','lexi-content-ref-19076159','lexi-content-ref-26152702'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Conditions associated with extravascular fluid accumulation (eg, ascites, pleural effusions, intracranial fluid) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27496039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27496039'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses or rapid infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16794248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16794248'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low albumin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26152702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26152702'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9613341','lexi-content-ref-32170389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9613341','lexi-content-ref-32170389'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sex (males &gt; females) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18504579','lexi-content-ref-24004183','lexi-content-ref-26152702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18504579','lexi-content-ref-24004183','lexi-content-ref-26152702'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Tumor lysis syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21561350','lexi-content-ref-2004324']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21561350','lexi-content-ref-2004324'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21146122','lexi-content-ref-26152702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21146122','lexi-content-ref-26152702'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acidic urine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21146122','lexi-content-ref-26152702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21146122','lexi-content-ref-26152702'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Neurotoxicity secondary to methotrexate administration has been reported manifesting as <b>encephalopathy</b>, <b>headache</b>, hemiparesis, and<b> leukoencephalopathy</b>. <b>Seizure</b> activity has also been reported. Aseptic meningitis, <b>myelopathy</b>, and <b>chemical arachnoiditis </b>have been reported with intrathecal (IT), intraventricular, or IV methotrexate. Chemical <b>conjunctivitis</b> occurs rarely and can be managed with local treatment and methotrexate can be safely administered intraocular to control autoimmune diseases that affect the eye (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23615343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23615343'])">Ref</a></span>). Chronic leukoencephalopathy is a delayed complication of IT or IV high-dose methotrexate (that can lead to significant long-term neurological impairment). It has been reported in CNS lymphoma patients with repeated cycles of high-dose methotrexate even in the absence of cranial irradiation. Neurotoxicity may be reversible in some instances, but fatalities have occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15162903','lexi-content-ref-25445718','lexi-content-ref-12761601','lexi-content-ref-6693915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15162903','lexi-content-ref-25445718','lexi-content-ref-12761601','lexi-content-ref-6693915'])">Ref</a></span>). Acute neurotoxicity often resolves spontaneously, rarely having long-term sequelae (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24550419','lexi-content-ref-27496039','lexi-content-ref-9697870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24550419','lexi-content-ref-27496039','lexi-content-ref-9697870'])">Ref</a></span>). Acute encephalopathy, aseptic meningitis, and myelopathy often resolve within hours after each episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26019420','lexi-content-ref-14561622','lexi-content-ref-17304378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26019420','lexi-content-ref-14561622','lexi-content-ref-17304378'])">Ref</a></span>). Neurotoxicity rarely occurs with low-dose methotrexate administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; may occur secondary to accumulations of adenosine and homocysteine in the CNS resulting in endothelial injury, ischemia, demyelination, and white matter necrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26055509','lexi-content-ref-15569732','lexi-content-ref-9697870','lexi-content-ref-19538530','lexi-content-ref-19006245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26055509','lexi-content-ref-15569732','lexi-content-ref-9697870','lexi-content-ref-19538530','lexi-content-ref-19006245'])">Ref</a></span>). Methotrexate may also cause direct toxic effects to the nervous system (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24550419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24550419'])">Ref</a></span>). More recently, single nucleotide polymorphisms have been investigated as contributing to the development of leukoencephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24550419','lexi-content-ref-21064136']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24550419','lexi-content-ref-21064136'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; acute neurotoxicity symptoms occur within 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24550419','lexi-content-ref-27496039','lexi-content-ref-9697870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24550419','lexi-content-ref-27496039','lexi-content-ref-9697870'])">Ref</a></span>). Acute encephalopathy, aseptic meningitis, and myelopathy can occur within minutes to hours after IT or IV methotrexate with repeated episodes occurring hours later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26019420','lexi-content-ref-14561622','lexi-content-ref-17304378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26019420','lexi-content-ref-14561622','lexi-content-ref-17304378'])">Ref</a></span>). May also be delayed, like myelopathy developing several days to weeks after treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11754193','lexi-content-ref-15891563','lexi-content-ref-30997053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11754193','lexi-content-ref-15891563','lexi-content-ref-30997053'])">Ref</a></span>). Chronic leukoencephalopathy may begin with gradual impairment of cognitive function months after methotrexate treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31295228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31295228'])">Ref</a></span>). However, intellectual decline is observed at least 1 year after treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12467071']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12467071'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent CNS radiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6948611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6948611'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher cumulative dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24550419','lexi-content-ref-3225584','lexi-content-ref-18831032','lexi-content-ref-17304378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24550419','lexi-content-ref-3225584','lexi-content-ref-18831032','lexi-content-ref-17304378'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher homocysteine levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24550419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24550419'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher plasma methotrexate to leucovorin ratio (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24550419','lexi-content-ref-18831032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24550419','lexi-content-ref-18831032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27942481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27942481'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12467071','lexi-content-ref-27942481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12467071','lexi-content-ref-27942481'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥10 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17170721','lexi-content-ref-12467071','lexi-content-ref-27942481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17170721','lexi-content-ref-12467071','lexi-content-ref-27942481'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Polymorphisms in genes associated with neurodevelopment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24550419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24550419'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Shorter intervals between IT/IV doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17304378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17304378'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methotrexate-induced pulmonary toxicity, including acute, subacute, and chronic <b>interstitial pneumonitis</b> has been reported with low-dose methotrexate treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10706507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10706507'])">Ref</a></span>). Pulmonary toxicity, such as pneumonitis, is rarely observed with high-dose methotrexate; however, cases have been published (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6896467','lexi-content-ref-22550565','lexi-content-ref-27496039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6896467','lexi-content-ref-22550565','lexi-content-ref-27496039'])">Ref</a></span>). Pneumonitis is not always fully reversible, and fatalities have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15611303']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15611303'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Multiple proposed mechanisms; pneumonitis is considered an immune or hypersensitivity reaction related to toxic accumulations of methotrexate in lung tissue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10706507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10706507'])">Ref</a></span>). Others have suggested methotrexate-induced injury to alveolar epithelial walls may play a role (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23762881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23762881'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; classified as either early-onset (&lt;6 months) or late-onset (&gt;6 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25267808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25267808'])">Ref</a></span>). Most often occurs within the first year; however, has occurred as early as days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21044440','lexi-content-ref-10706507','lexi-content-ref-12923285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21044440','lexi-content-ref-10706507','lexi-content-ref-12923285'])">Ref</a></span>) and as late as 30 years after use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28655345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28655345'])">Ref</a></span>). May occur up to 20 months after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24892681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24892681'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Low-dose methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10706507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10706507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;60 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31709258','lexi-content-ref-12923285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31709258','lexi-content-ref-12923285'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31709258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31709258'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31709258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31709258'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypoalbuminemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31709258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31709258'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31709258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31709258'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting lung disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31709258','lexi-content-ref-12923285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31709258','lexi-content-ref-12923285'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous use of disease-modifying antirheumatic drugs (DMARDs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31709258','lexi-content-ref-12923285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31709258','lexi-content-ref-12923285'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F194518"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions vary by route, dosage, and indication.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (16%) (Sherbini 2022), nausea (31%) (Sherbini 2022), oral mucosal ulcer (11%) (Sherbini 2022), vomiting (≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic cirrhosis (chronic therapy; &lt;1% to ≥10%) (Dubey 2016), hepatotoxicity (in patients treated with 1, 2, or 5 g/m<sup>2</sup>, grades ≥3: ≥10%) (Ozdemir 2016), increased liver enzymes (14% to 15%; increased serum alanine aminotransferase: &gt;1 × ULN: 20%; &gt;2 × ULN: 4% [Sherbini 2022])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (13%) (Sherbini 2022), fatigue (31%) (Sherbini 2022), headache (19%) (Sherbini 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (16%) (Sherbini 2022)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (≤10%), burning sensation of skin (psoriasis: 3% to 10%), dermatitis (rheumatoid arthritis: 1% to 3%), pruritus (9%) (Sherbini 2022), skin photosensitivity (3% to 10%), skin rash (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (5%) (Sherbini 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (4%) (Sherbini 2022), stomach pain (9%) (Sherbini 2022), stomatitis (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (3% [Sherbini 2022]; severe anemia [after 2 years of low-dose methotrexate: ≥4% to &lt;10%] [Dubey 2016]), leukopenia (1% to 3%; WBC &lt;3000/mm<sup>3</sup>), neutropenia (≤1%) (Sherbini 2022), pancytopenia (rheumatoid arthritis: 1% to 3%), thrombocytopenia (rheumatoid arthritis: 3% to 10%; platelet count &lt;100,000/mm<sup>3</sup>)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic fibrosis (chronic therapy: ≥4% to &lt;10%) (Dubey 2016; MacDonald 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Chest infection (3%) (Sherbini 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (5%) (Sherbini 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (6%) (Sherbini 2022), interstitial pneumonitis (rheumatoid arthritis: 1%), pharyngitis (8%) (Sherbini 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (3%) (Sherbini 2022)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, dyschromia, exacerbation of psoriasis (plaque erosion)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Aphthous stomatitis, enteritis, gastrointestinal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, infertility, oligospermia, vaginal discharge</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, bone marrow depression, eosinophilia, malignant lymphoma, non-Hodgkin lymphoma (in patients receiving low-dose oral methotrexate), tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Cryptococcosis, cytomegalovirus disease (including cytomegaloviral pneumonia), herpes simplex infection, nocardiosis, sepsis, vaccinia (disseminated; following smallpox immunization)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chemical arachnoiditis (intrathecal; acute), chills, malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Osteonecrosis (with radiotherapy)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye discomfort, transient blindness</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis, pneumonia, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Tissue necrosis (with radiotherapy)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thrombosis, deep vein thrombosis, heart failure (Shah 2022), hypotension, pericarditis (Guevara 2023), pulmonary embolism, thrombophlebitis, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, cutaneous nodule (Kwon 2023), dermal ulcer (Bahnson 2021), ecchymoses, erythema multiforme (Blanes 2005), erythematous rash, exfoliative dermatitis, furunculosis, palmar-plantar erythrodysesthesia (Karol 2017), papular rash (Mebazaa 2008), photodermatitis (reactivation) (DeVore 2010), skin abnormalities related to radiation recall (Lee 2012), skin carcinoma (including basal cell carcinoma of skin, malignant melanoma, squamous cell carcinoma of skin) (Polesie 2023; Solomon 2020), skin necrosis, Stevens-Johnson syndrome (Lee 2012), telangiectasia, toxic epidermal necrolysis (Sancheti 2016), urticaria (Pugi 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (AlEssa 2021), decreased serum albumin, diabetes mellitus, gynecomastia, hyperglycemia, menstrual disease</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (Braun 2008), gastrointestinal ulcer (Tun 2023), gingivitis, hematemesis, hemorrhagic gastroenteritis, intestinal perforation, melena, mesenteric ischemia (acute; Morgan 2011), pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Azotemia, crystalluria (Santiago 2020), cystitis, defective oogenesis, defective spermatogenesis, erectile dysfunction, hematuria, proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia (Dubey 2016), febrile neutropenia (Bayraktar 2021), hypogammaglobulinemia, lymphadenopathy, lymphoproliferative disorder (including intestinal follicular lymphoma, large B-cell lymphoma, T-cell lymphoma [follicular]) (Muto 2021; Osaki 2021), myelodysplastic syndrome (Khan 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Exacerbation of hepatitis B (Ostuni 2003), hepatic failure (Miyata 2023), hepatitis (acute)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Pugi 2012), angioedema (Freeman 1999), hypersensitivity angiitis (Dewan 2021), nonimmune anaphylaxis, severe hypersensitivity reaction (including hyperpigmentation, pustular rash, severe stomatitis) (Shafie 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (Patel 2015), histoplasmosis (LeMense 1994), infection (Ibrahim 2018; Lee 2020), septicemia (Tiewsoh 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Hypersensitivity reaction at injection site (including fixed drug eruption at injection site) (Sadoghi 2021), injection-site reaction (including tissue necrosis at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal cranial sensation (has been reported at low dosage), cerebral thrombosis, cerebrovascular accident (Morgan 2011), cognitive dysfunction (has been reported at low dosage), drowsiness, encephalopathy (Teshima 2021), leukoencephalopathy (may be chronic) (Magge 2015), mood changes (has been reported at low dosage), neurotoxicity (including hemiparesis, stroke-like syndromes) (Dabagh 2020; Leitão Santos 2023; Yap 2016), paresis, seizure (Dabagh 2020), speech disturbance (including aphasia, dysarthria)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, bone fracture (including stress) (Singh 2023), myalgia, myelopathy (intrathecal; subacute) (Bidikian 2021), osteoporosis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, dry eye syndrome, eye irritation (Doroshow 1981), eye pain, optic neuropathy (Clare 2005), retinal thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Gilani 2012; May 2014; Verstappen 2007; Wiczer 2015; Widemann 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress (Morgan 2011), chronic obstructive pulmonary disease, Mycobacterium avium complex (LeMense 1994), pleuritic chest pain (Sharma 1999), pneumonia due to Pneumocystis jirovecii (Albrecht 2010; Krebs 1996), pulmonary alveolitis, pulmonary fibrosis, respiratory failure, thickening of pleura, tuberculosis (Binymin 2001)</p></div>
<div class="block coi drugH1Div" id="F194534"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of severe hypersensitivity (including anaphylaxis) to methotrexate or any component of the formulation; breastfeeding (product-specific; refer to manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications for patients with psoriasis, rheumatoid arthritis or polyarticular-course juvenile idiopathic arthritis: Pregnancy, alcohol use disorder, alcoholic liver disease or other chronic liver disease, immunodeficiency syndromes (overt or laboratory evidence); preexisting blood dyscrasias (eg, bone marrow hypoplasia, leukopenia, thrombocytopenia, significant anemia).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe renal impairment (including end-stage renal disease with or without dialysis); females of childbearing potential (until pregnancy is excluded); concomitant use with nitrous oxide anesthesia.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F194515"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Use methotrexate with extreme caution in patients with an active infection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Dosing adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Nonsteroidal anti-inflammatory drugs: Do not administer nonsteroidal anti-inflammatory drugs (NSAIDs) prior to or during high dose methotrexate therapy; may increase and prolong serum methotrexate levels. Doses used for psoriasis may still lead to unexpected toxicities; use with caution when administering NSAIDs or salicylates with lower doses of methotrexate for rheumatoid arthritis (RA).</p>
<p style="text-indent:-2em;margin-left:4em;">• Proton pump inhibitors: Concomitant use of proton pump inhibitors with methotrexate (primarily high-dose methotrexate) may elevate and prolong serum methotrexate levels and metabolite (hydroxymethotrexate) levels (based on case reports and pharmacokinetic studies). May lead to toxicities; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: Immunization may be ineffective during methotrexate treatment. Immunization with live vaccines is not recommended; cases of disseminated vaccinia infections due to live vaccines have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamins: Vitamins containing folate may decrease response to systemic methotrexate (in patients with neoplastic diseases); folate deficiency may increase methotrexate toxicity. Folic acid supplementation may be indicated in patients receiving methotrexate for non-neoplastic conditions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration schedules: Fatal errors have occurred when methotrexate was administered as a <b>daily</b> dose instead of a <b>weekly</b> dose. Verify the indication before administration; methotrexate is typically only administered daily for an oncology-related indication. The ISMP Targeted Medication Safety Best Practices for Hospitals recommends hospitals use a <b>weekly</b> dosage regimen default for oral methotrexate orders in electronic order entry systems, with a hard stop verification required of appropriate oncology indication for all <b>daily</b> oral methotrexate orders, and provide patient and/or caregiver education for patients discharged on oral methotrexate (ISMP 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Intrathecal safety: When used for intrathecal administration, intrathecal medications should not be prepared during the preparation of any other agents. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as "intrathecal" use only. Delivery of intrathecal medications to the patient should only be with other medications also intended for administration into the CNS, and administer immediately after a time-out/double-check procedure (ASCO/ONS [Neuss 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Methotrexate overexposure: Glucarpidase is an enzyme that rapidly hydrolyzes extracellular methotrexate into inactive metabolites, allowing for a rapid reduction of methotrexate concentrations. Glucarpidase may be used for methotrexate overexposure; it is approved for the treatment of toxic plasma methotrexate concentrations (&gt;1 micromole/L) in patients with delayed clearance due to renal impairment. Refer to Glucarpidase monograph.</p></div>
<div class="block foc drugH1Div" id="F194526"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/10 mL (10 mL); 50 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g/40 mL (40 mL); 250 mg/10 mL (10 mL); 50 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jylamvo: 2 mg/mL (60 mL) [contains ethylparaben, methylparaben sodium, polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xatmep: 2.5 mg/mL (60 mL, 120 mL) [contains methylparaben sodium, propylparaben sodium]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Otrexup: 10 mg/0.4 mL (0.4 mL); 12.5 mg/0.4 mL (0.4 mL); 15 mg/0.4 mL (0.4 mL); 17.5 mg/0.4 mL (0.4 mL); 20 mg/0.4 mL (0.4 mL); 22.5 mg/0.4 mL (0.4 mL); 25 mg/0.4mL (0.4 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rasuvo: 7.5 mg/0.15 mL (0.15 mL); 10 mg/0.2 mL (0.2 mL); 12.5 mg/0.25 mL (0.25 mL); 15 mg/0.3 mL (0.3 mL); 17.5 mg/0.35 mL (0.35 mL); 20 mg/0.4 mL (0.4 mL); 22.5 mg/0.45 mL (0.45 mL); 25 mg/0.5 mL (0.5 mL); 30 mg/0.6 mL (0.6 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RediTrex: 7.5 mg/0.3 mL (0.3 mL [DSC]); 10 mg/0.4 mL (0.4 mL [DSC]); 12.5 mg/0.5 mL (0.5 mL [DSC]); 15 mg/0.6 mL (0.6 mL [DSC]); 17.5 mg/0.7 mL (0.7 mL [DSC]); 20 mg/0.8 mL (0.8 mL [DSC]); 22.5 mg/0.9 mL (0.9 mL [DSC]); 25 mg/mL (1 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trexall: 5 mg, 7.5 mg, 10 mg, 15 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg</p></div>
<div class="block geq drugH1Div" id="F194511"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F194537"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Jylamvo Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $17.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Methotrexate Sodium (PF) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/40mL (per mL): $1.00 - $1.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/2 mL (per mL): $2.02 - $6.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/10 mL (per mL): $1.08 - $1.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Methotrexate Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/2 mL (per mL): $4.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/10 mL (per mL): $4.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Xatmep Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/mL (per mL): $24.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Methotrexate Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $54.00 - $76.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Otrexup Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/0.4 mL (per 0.4 mL): $220.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg/0.4 mL (per 0.4 mL): $220.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg/0.4 mL (per 0.4 mL): $220.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">17.5 mg/0.4 mL (per 0.4 mL): $220.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/0.4 mL (per 0.4 mL): $220.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">22.5 mg/0.4 mL (per 0.4 mL): $220.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/0.4 mL (per 0.4 mL): $220.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Rasuvo Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg/0.15 mL (per 0.15 mL): $163.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/0.2 mL (per 0.2 mL): $163.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg/0.25 mL (per 0.25 mL): $163.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg/0.3 mL (per 0.3 mL): $163.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">17.5 mg/0.35ml (per 0.35 mL): $163.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/0.4 mL (per 0.4 mL): $163.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">22.5 mg/0.45ml (per 0.45 mL): $163.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/0.5 mL (per 0.5 mL): $163.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/0.6 mL (per 0.6 mL): $163.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Methotrexate Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $3.56 - $6.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Trexall Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $25.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $37.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $50.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $75.90</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867513"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/2 mL (2 mL); 10 mg/mL (2 mL); 25 mg/mL (2 mL, 10 mL, 20 mL, 40 mL, 100 mL, 200 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Metoject: 7.5 mg/0.75 mL ([DSC]); 10 mg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 7.5 mg/0.3 mL (0.3 mL); 10 mg/0.4 mL (0.4 mL); 15 mg/0.6 mL (0.6 mL); 20 mg/0.8 mL (0.8 mL); 25 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Metoject: 22.5 mg/0.45 mL (0.45 mL); 25 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 22.5 mg/0.45 mL (0.45 mL); 25 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Metoject: 10 mg/0.2 mL (0.2 mL); 12.5 mg/0.25 mL (0.25 mL); 15 mg/0.3 mL (0.3 mL); 17.5 mg/0.35 mL (0.35 mL); 20 mg/0.4 mL (0.4 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg/0.3 mL (1 ea, 4 ea); 17.5 mg/0.35 mL (0.35 mL); 20 mg/0.4 mL (0.4 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 10 mg</p></div>
<div class="block adm drugH1Div" id="F194531"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;">Doses ≥250 mg/m<sup>2</sup> (IV) are associated with moderate emetic potential; antiemetics may be recommended to prevent nausea and vomiting.</p>
<p style="text-indent:0em;margin-top:2em;">Methotrexate may be administered orally, IM, IV, intrathecally, or SUBQ; IV administration may be as slow push (10 mg/minute), bolus infusion, or 24-hour continuous infusion (route and rate of administration depend on indication and/or protocol; refer to specific references). Must use preservative-free formulation for intrathecal or high-dose methotrexate administration.</p>
<p style="text-indent:0em;margin-top:2em;">When administered IM for indications that may terminate a pregnancy, also consult local policies or regulations related to administration.</p>
<p style="text-indent:0em;margin-top:2em;">Specific dosing schemes vary, but high doses should be followed by leucovorin calcium rescue to prevent toxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Oral solution: Ensure accuracy when dispensing and administering to prevent dosing errors. A calibrated oral syringe/dosing cup that can measure and deliver the prescribed dose accurately should be used; do not use a household teaspoon or tablespoon to measure dose. Jylamvo: Only use the oral syringe that is provided as a measuring device.</p>
<p style="text-indent:0em;margin-top:2em;">Otrexup, Rasuvo, and RediTrex are autoinjectors or prefilled syringes for once-weekly SUBQ use in the abdomen or thigh; patient may self-administer after appropriate training and with appropriate follow-up monitoring. Use a different injectable formulation for administration of routes other than SUBQ or for doses &lt;7.5 mg/week or &gt;25 mg/week. All schedules should be continually tailored to the individual patient. An initial test dose may be given prior to the regular dosing schedule to detect any extreme sensitivity to adverse effects.</p></div>
<div class="block admp drugH1Div" id="F52613286"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Doses ≥12 g/m<sup>2</sup> (IV) are associated with a high emetic potential, while a 5 g/m<sup>2</sup> (IV) dose is associated with a moderate emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637','lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637','lexi-content-ref-30729654'])">Ref</a></span>); antiemetics may be recommended to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Often preferred when low doses are being administered; administer on an empty stomach (at least 1 hour before or 2 hours after food or drink except water). Oral solution (Xatmep) contains 2.5 mg/mL concentrated solution; administer with an accurate measuring device (eg, calibrated oral syringe); do not use a household teaspoon (overdosage may occur).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: May be administered at concentration ≤25 mg/mL; autoinjectors should not be used for IM administration.</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">IV push: May be administered as slow IV push at a concentration ≤25 mg/mL; some have suggested a rate of ≤10 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gahart.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gahart.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Bolus IV infusion, or 24-hour continuous infusion: Route and rate of administration depend upon indication and/or protocol; refer to specific references. For high-dose infusion, preservative-free formulation must be used <b>[US Boxed Warning]</b>. Specific dosing schemes vary, but high dose must be followed by leucovorin calcium to prevent toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">SubQ: May be administered SubQ (dependent upon indication and product).</p>
<p style="text-indent:-2em;margin-left:6em;">Otrexup and Rasuvo are for once weekly subcutaneous use in the abdomen or thigh; do not inject within 2 inches of the navel or in areas where the skin is tender, bruised, red, scaly, hard or has scars or stretch marks. Patient may self-administer after appropriate training on preparation and administration and with appropriate follow-up monitoring. All schedules should be continually tailored to the individual patient. An initial test dose may be given prior to the regular dosing schedule to detect any extreme sensitivity to adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Intrathecal: May be administered intrathecally; must use preservative-free formulation for intrathecal administration.</p></div>
<div class="block hazard drugH1Div" id="F49132858"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F194530"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Oncology uses: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute lymphoblastic leukemia:</b> Treatment of acute lymphoblastic leukemia (as part of a combination chemotherapy regimen) in adults and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Breast cancer: </b>Treatment of breast cancer (as part of a combination chemotherapy regimen) in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cutaneous T-cell lymphoma (mycosis fungoides, advanced): </b>Treatment of advanced mycosis fungoides.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Gestational trophoblastic neoplasia: </b>Treatment of gestational trophoblastic neoplasia (as part of a combination chemotherapy regimen) in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Head and neck cancer, squamous cell carcinoma: </b>Treatment of squamous cell carcinoma of the head and neck (as a single agent) in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Meningeal leukemia, prophylaxis and treatment: </b>Prophylaxis and treatment of meningeal leukemia in adults and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Non-Hodgkin lymphomas: </b>Treatment of non-Hodgkin lymphomas in adults and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Osteosarcoma:</b> Treatment of osteosarcoma (as part of a combination chemotherapy regimen) in adults and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Nononcology uses:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Polyarticular juvenile idiopathic arthritis:</b> Treatment of active polyarticular juvenile idiopathic arthritis in patients whose disease is unresponsive to or who are intolerant of first-line therapy, including full-dose nonsteroidal anti-inflammatory drugs (NSAIDs)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Psoriasis: </b>Symptomatic control of severe, recalcitrant, disabling psoriasis (in adults) that is not adequately responsive to other therapies.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rheumatoid arthritis: </b>Management of severe, active rheumatoid arthritis in adults whose disease is unresponsive to or who are intolerant of first-line therapy, including full-dose NSAIDs.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Otrexup, Rasuvo, and RediTrex are not indicated for the treatment of neoplastic diseases.</p></div>
<div class="block off-label drugH1Div" id="F25469398"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute promyelocytic leukemia, maintenance; Atopic dermatitis or eczema, moderate to severe; Bladder cancer; Bullous pemphigoid; Crohn disease, moderate to severe; Dermatomyositis, cutaneous; Dermatomyositis/Polymyositis; Discoid lupus erythematosus and subacute cutaneous lupus erythematosus, refractory; Eosinophilic granulomatosis with polyangiitis (Churg-Strauss); Giant cell arteritis; Graft-vs-host disease, acute, prophylaxis; Granulomatosis with polyangiitis and microscopic polyangiitis; Large granular lymphocyte leukemia, symptomatic; Lichen sclerosus, extragenital, extensive; Morphea or localized scleroderma; Nonleukemic meningeal cancer; Primary CNS lymphoma, newly diagnosed; Primary cutaneous anaplastic large cell lymphoma; Sarcoidosis, pulmonary; Scleritis, idiopathic, noninfectious; Soft tissue sarcoma (desmoid tumors/aggressive fibromatosis), advanced; Still disease, adult-onset, moderate to severe; Systemic lupus erythematosus; Systemic sclerosis or scleroderma; Takayasu arteritis; Termination of intrauterine pregnancy, first trimester; Tubal ectopic pregnancy</p></div>
<div class="block mst drugH1Div" id="F194611"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Methotrexate may be confused with mercaptopurine, methylPREDNISolone sodium succinate, metOLazone, metroNIDAZOLE, mitoXANTRONE, MXT Patch, PRALAtrexate.</p>
<p style="text-indent:-2em;margin-left:4em;">Trexall may be confused with Paxil.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (with special emphasis on nononcologic uses) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fatal errors have occurred when oral methotrexate was administered as a <b>daily </b>dose instead of a <b>weekly </b>dose. Verify the indication before administration; methotrexate is typically only administered <b>daily</b> for an oncology-related indication (ISMP 2020). The ISMP recommends hospitals use a <b>weekly </b>dosage regimen default for oral methotrexate orders in electronic order entry systems, with a hard stop verification required of appropriate oncology indication for all <b>daily</b> oral methotrexate orders. Provide patient and/or caregiver education for patients discharged on oral methotrexate (ISMP 2020).</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">
<i>Intrathecal medication safety:</i> The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (ASCO/ONS [Neuss 2016]) recommend the following safety measures for intrathecal chemotherapy:</p>
<p style="text-indent:-2em;margin-left:6em;">• Intrathecal medication should not be prepared during the preparation of any other agents.</p>
<p style="text-indent:-2em;margin-left:6em;">• After preparation, keep in an isolated location or container clearly marked with a label identifying as "intrathecal" use only.</p>
<p style="text-indent:-2em;margin-left:6em;">• Delivery to the patient should only be with other medications also intended for administration into the central nervous system.</p>
<p style="text-indent:-2em;margin-left:6em;">• Administer immediately after a time-out/double-check procedure.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MTX is an error-prone abbreviation (mistaken as mitoxantrone or multivitamin).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Trexall [US] may be confused with Trexol brand name for tramadol [Mexico]; Truxal brand name for chlorprothixene [multiple international markets].</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9837690"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, OAT1/3, OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F194520"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Methotrexate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acitretin: May enhance the hepatotoxic effect of Methotrexate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the hepatotoxic effect of Methotrexate. Management: Limit alcohol consumption in patients taking methotrexate. The use of methotrexate for the treatment of psoriasis or rheumatoid arthritis is contraindicated in patients with alcoholism or alcoholic liver disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alitretinoin (Systemic): May enhance the hepatotoxic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Methotrexate may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of methotrexate is reduced. Methotrexate may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: May enhance the hepatotoxic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Methotrexate may enhance the immunosuppressive effect of Baricitinib.  Management: Concomitant use of baricitinib with high-dose or IV methotrexate is not recommended. Use with antirheumatic doses of methotrexate is permitted, and if combined, patients should be monitored for infection.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Methotrexate may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Methotrexate may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Methotrexate may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Methotrexate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capecitabine: Methotrexate may enhance the nephrotoxic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: May diminish the therapeutic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Methotrexate may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Methotrexate may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Methotrexate may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Methotrexate may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing methotrexate several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cola-Containing Drinks: May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: Methotrexate may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Rheumatology guidelines recommend holding methotrexate for 1 to 2 weeks after vaccine administration as permitted by underlying disease. This is specific to patients using methotrexate for rheumatic and musculoskeletal disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May increase the serum concentration of Methotrexate. This may result in nausea, vomiting, oral ulcers, hepatotoxicity and/or nephrotoxicity. Methotrexate may increase the serum concentration of CycloSPORINE (Systemic). This may result in nephrotoxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): May increase the serum concentration of Methotrexate. Management: Avoid coadministration of dapsone and methotrexate if possible. If coadministration is required, monitor closely for methotrexate toxicities (eg, hematological, gastrointestinal, nephrotoxicity toxicities).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Methotrexate may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Methotrexate may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Methotrexate. Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants, such as methotrexate. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Methotrexate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May increase the serum concentration of Methotrexate. Management: Concurrent use of dexketoprofen with methotrexate doses of 15 mg/week or more is inadvisable.  Use with lower methotrexate doses should only be performed with caution and increased monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: May increase the serum concentration of Methotrexate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diethylamine Salicylate: May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: Methotrexate may enhance the adverse/toxic effect of Dipyrone. Specifically, the risk for agranulocytosis and pancytopenia may be increased. Dipyrone may enhance the adverse/toxic effect of Methotrexate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Methotrexate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Febuxostat: May enhance the adverse/toxic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: Methotrexate may enhance the immunosuppressive effect of Filgotinib.  Management: Concomitant use of filgotinib with high-dose or IV methotrexate is not recommended. Use with antirheumatic doses of methotrexate is permitted.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foscarnet: May enhance the nephrotoxic effect of Methotrexate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Methotrexate may decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may increase the serum concentration of Methotrexate. Specifically, fosphenytoin-phenytoin may displace methotrexate from serum proteins, increasing the concentration of free, unbound drug. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydroCHLOROthiazide: May enhance the nephrotoxic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Methotrexate may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Methotrexate may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating methotrexate if possible. If vaccination occurs less than 2 weeks prior to or during methotrexate therapy, revaccinate 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May increase the serum concentration of Methotrexate. Management: Consider temporarily interrupting PPI or PCAB therapy in patients receiving high-dose methotrexate. If coadministered, monitor for increased methotrexate toxicity (eg, mucositis, myalgias) and/or delayed methotrexate elimination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Methotrexate may enhance the adverse/toxic effect of Leflunomide. Specifically, the risks of hepatoxicity and hematologic toxicity may be increased.  Management: If leflunomide is coadministered with methotrexate, initiate leflunomide 20 mg once daily without use of a loading dose. Monitor for methotrexate-induced hepatic toxicity frequently (see monograph for details) and monitor blood counts monthly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LevETIRAcetam: May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Methotrexate may diminish the therapeutic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate. Methotrexate may increase the serum concentration of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mercaptopurine: Methotrexate may increase the serum concentration of Mercaptopurine. Conversely, intracellular concentrations of thioguanine nucleotides may be decreased with the combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mipomersen: May enhance the hepatotoxic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Methotrexate may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Methotrexate may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Methotrexate may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Methotrexate may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neomycin (Systemic): May decrease the serum concentration of Methotrexate. Neomycin (Systemic) may increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitisinone: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrous Oxide: May enhance the adverse/toxic effect of Methotrexate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Methotrexate. Management: Avoid coadministration of higher dose methotrexate (such as that used for the treatment of oncologic conditions) and NSAIDs. Use caution if coadministering lower dose methotrexate and NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Methotrexate may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Methotrexate may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PEMEtrexed: May increase the serum concentration of Methotrexate. Management: Avoid coadministration of pemetrexed and methotrexate if possible. If coadministration is required, monitor closely for methotrexate toxicities (eg, hematological, gastrointestinal, nephrotoxicity toxicities).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Methotrexate may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Methotrexate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Methotrexate may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Methotrexate may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Methotrexate may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Methotrexate may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving methotrexate. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Methotrexate. Management: If possible, the concomitant use of methotrexate and probenecid should be avoided. If used concomitantly, monitor closely for increased methotrexate serum concentrations and toxicities. Methotrexate dose reductions may be needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyrimethamine: May enhance the adverse/toxic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Methotrexate may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Retinoic Acid Derivatives: May enhance the hepatotoxic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Methotrexate may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Methotrexate may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern. Management: Consider avoiding coadministration of methotrexate and salicylates. If coadministration cannot be avoided, monitor for increased toxic effects of methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sapropterin: Methotrexate may decrease the serum concentration of Sapropterin. Specifically, methotrexate may decrease tissue concentrations of tetrahydrobiopterin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Methotrexate may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of methotrexate prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: Methotrexate may enhance the immunosuppressive effect of Sphingosine 1-Phosphate (S1P) Receptor Modulator. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SulfaSALAzine: May enhance the hepatotoxic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonamide Antibiotics: May enhance the adverse/toxic effect of Methotrexate. Management: Consider avoiding concomitant use of methotrexate and therapeutic doses of sulfonamides (eg, trimethoprim/sulfamethoxazole). Patients receiving prophylactic doses of trimethoprim/sulfamethoxazole and methotrexate should be carefully monitored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Methotrexate may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafamidis: May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Methotrexate may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegafur: Methotrexate may enhance the adverse/toxic effect of Tegafur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Methotrexate may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Methotrexate may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Methotrexate may enhance the immunosuppressive effect of Tofacitinib.  Management: Concomitant use of tofacitinib with high-dose or IV methotrexate is not recommended. Use with antirheumatic doses of methotrexate is permitted, and if combined, patients should be monitored for infection.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the adverse/toxic effect of Methotrexate. Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Methotrexate may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Methotrexate may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Methotrexate may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Methotrexate may enhance the immunosuppressive effect of Upadacitinib.  Management: Concomitant use of upadacitinib with high-dose or IV methotrexate is not recommended. Use with antirheumatic doses of methotrexate is permitted, and if combined, patients should be monitored for infection.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Methotrexate may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Administer vaccines at least 2 weeks prior to methotrexate initiation, if possible. If patients are vaccinated less than 14 days prior to or during methotrexate therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Methotrexate may enhance the adverse/toxic effect of Vaccines (Live). Methotrexate may diminish the therapeutic effect of Vaccines (Live).  Management: Low-dose methotrexate (0.4 mg/kg/week or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses of methotrexate should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Methotrexate may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Methotrexate may enhance the photosensitizing effect of Voriconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Methotrexate may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Methotrexate may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F194552"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Methotrexate peak serum levels may be decreased if taken with food. Management: Administer without regard to food.</p></div>
<div class="block rep_considerations drugH1Div" id="F49308178"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">
<i>Patients who could become pregnant:</i></p>
<p style="text-indent:0em;margin-top:2em;">Verify the pregnancy status of patients who could become pregnant prior to initiating therapy. Effective contraception is recommended for patients who may become pregnant during therapy and for 6 months after the final methotrexate dose.</p>
<p style="text-indent:0em;margin-top:2em;">Patients treated with methotrexate for gestational trophoblastic diseases should use reliable contraception during therapy and throughout the follow-up period (SOGC [Eiriksson 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Patients treated for inflammatory bowel disease, psoriasis, or rheumatic and musculoskeletal diseases should discontinue methotrexate at least 3 months prior to becoming pregnant (ACR [Sammaritano 2020]; Mahadevan 2019; Rademaker 2018). However, when methotrexate is used for the treatment of rheumatic and musculoskeletal diseases in patients undergoing ovarian stimulation for oocyte retrieval or embryo cryopreservation, methotrexate may be continued in patients whose rheumatic or musculoskeletal condition is stable and discontinuation of treatment may lead to uncontrolled disease (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">There may be a low risk of amenorrhea associated with methotrexate therapy (ESMO [Lambertini 2020]. Product labeling notes the use of methotrexate may impair fertility and cause menstrual irregularities during treatment and following therapy. It is not known if infertility may be reversed in all affected patients. When used for the medical management of ectopic pregnancy, methotrexate has not been shown to adversely affect fertility or ovarian reserve. Future pregnancies should be delayed until resolution of the ectopic pregnancy has been confirmed and at least 3 months after the last methotrexate dose (ACOG 2018).</p>
<p style="text-indent:0em;margin-top:2em;">
<i>Patients who could father a child:</i></p>
<p style="text-indent:0em;margin-top:2em;">According to the manufacturer, effective contraception is recommended for patients with partners who may become pregnant during therapy and for 3 months after the final dose of methotrexate.</p>
<p style="text-indent:0em;margin-top:2em;">There may be a low risk of azoospermia associated with methotrexate therapy (ESMO [Lambertini 2020]. Product labeling notes that methotrexate may impair fertility and cause oligospermia during treatment and following therapy; it is not known if infertility may be reversed in all affected patients. However, available data are inconclusive (Boussaid 2022). A study evaluating low-dose methotrexate (dosage range 7.5 to 25 mg/week) for the treatment of inflammatory joint disease or inflammatory bowel disorders did not find adverse effects on sperm quality (Grosen 2022). In addition, paternal use of methotrexate has not been found to cause adverse pregnancy outcomes (Bermas 2020, Gubatan 2022). Autoimmune disease may also influence male infertility (Boussaid 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Use of methotrexate may be considered for patients with rheumatic and musculoskeletal diseases or psoriasis who are planning to father a child (recommendation based on limited human data) (ACR [Sammaritano 2020]; Lamb 2019; Rademaker 2018).</p></div>
<div class="block pri drugH1Div" id="F194538"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Methotrexate crosses the placenta (Schleuning 1987).</p>
<p style="text-indent:0em;margin-top:2em;">Following exposure during the first trimester, methotrexate may increase the risk of spontaneous abortion, skull anomalies, facial dysmorphism, CNS, limb and cardiac abnormalities; intellectual impairment may also occur. Intrauterine growth restriction and functional abnormalities may occur following second or third trimester exposure.</p>
<p style="text-indent:0em;margin-top:2em;">Consider the benefits and risks of methotrexate and risks to the fetus when prescribing methotrexate to a pregnant patient with a neoplastic disease. Methotrexate is approved for the treatment of trophoblastic neoplasms (gestational choriocarcinoma, chorioadenoma destruens, and hydatidiform mole). The use of methotrexate for the treatment of non-neoplastic indications including, rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis, and psoriasis, is contraindicated in pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Methotrexate is recommended for the medical management of tubal ectopic pregnancy in appropriately selected patients. Intrauterine pregnancy should be excluded prior to methotrexate use. Various protocols are available; the choice should consider the initial hCG level and the risks and benefits of methotrexate treatment to the individual patient (ACOG 2018). Methotrexate administered by intra-gestational injection with or without systemic methotrexate or other treatments is recommended for the management of cesarean scar pregnancies; however, various protocols have been described and the optimal regimen is not known. Use of systemic methotrexate alone is not recommended for the treatment of cesarean scar pregnancy (Liu 2020; Salari 2020; SMFM [Miller 2020]). Use of methotrexate for other nontubal ectopic pregnancies (eg, cervical or abdominal) has been described; however, data are insufficient to make specific dosing recommendations (RCOG [Elson 2016]; SOGC [Po 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Methotrexate has been used for the medical termination of intrauterine pregnancy with a gestational age up to 49 days when misoprostol/mifepristone is not available or contraindications to that combination are present. A regimen containing methotrexate should not be used in patients with hemoglobin &lt;9.5 g/dL, intrauterine device in place, diagnosis of inflammatory bowel disease, active hepatic or renal disease, hemorrhagic disorders, or concomitant use of anticoagulation therapy (Creinin 1996; SOGC [Costescu 2016]; Stubblefield 2004).</p></div>
<div class="block brc drugH1Div" id="F9259798"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate and 7-hydroxymethotrexate are present in breast milk (Baker 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Outcome data related to the use of methotrexate in patients who are breastfeeding is limited (Baker 2018; Delaney 2017; Johns 1972; Tanaka 2009; Thorne 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate has the potential to cause serious adverse reactions in the breastfed infant. Recommendations for use in patients who wish to breastfeed vary. According to the manufacturer, breastfeeding should be discontinued during treatment and for 1 week after the final methotrexate dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Available guidelines contraindicate breastfeeding in patients taking methotrexate for the treatment of tubal ectopic pregnancy (ACOG 2018). Use of methotrexate is not recommended in breastfeeding patients when used for the treatment of inflammatory bowel disease (Mahadevan 2019), rheumatic and musculoskeletal diseases (ACR [Sammaritano 2020]), or psoriasis (Rademaker 2018). When high doses are used for chemotherapy, it is recommended to discard breast milk for at least 1 week following the last dose of methotrexate (Pistilli 2013). Although lower doses (such as those used for arthritis) may have lower risk to the breastfed infant, alternative medications are recommended in patients who are breastfeeding (Ito 2000). If an infant is exposed to lower doses of methotrexate (maternal doses &lt;0.4 mg/kg/week) via breast milk, consider monitoring the infant CBC at 1 and 3 months of age (Rademaker 2018).</p></div>
<div class="block dic drugH1Div" id="F194539"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F194524"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic toxicity, complications of hematologic toxicity, signs and symptoms of infection (during and after treatment); signs and symptoms of pneumonitis (particularly dry, nonproductive cough; fever, dyspnea, hypoxemia, or pulmonary infiltrate); evaluate pregnancy status prior to use in patients who could become pregnant.</p>
<p style="text-indent:-2em;margin-left:2em;">Oncologic uses: Baseline and frequently during treatment: CBC with differential and platelets, serum creatinine, BUN, LFTs. For high-dose methotrexate regimens, monitor serum creatinine and electrolytes at baseline and at least daily and monitor methotrexate levels, urine output, and urine pH at least daily. Closely monitor fluid and electrolyte status in patients with impaired methotrexate elimination; chest x-ray (baseline); pulmonary function test (if methotrexate-induced lung disease suspected); monitor carefully for toxicities (due to impaired elimination) in patients with ascites, pleural effusion, decreased folate stores, renal impairment, and/or hepatic impairment. The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Psoriasis:</p>
<p style="text-indent:-2em;margin-left:4em;">CBC and LFTs (baseline and every 3 to 6 months, if no abnormal results); hepatitis B and C screening (baseline); pretreatment test for latent TB (baseline); chest radiograph with positive TB test (AAD/NPF [Menter 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with impaired kidney function: BUN and creatine, CBC 5 to 7 days after test dose (AAD/NPF [Menter 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">Liver biopsy: Baseline liver biopsy is not recommended. If persistent elevations in liver enzymes during a 12-month period or decline of serum albumin below the normal range with normal nutritional status, consider a biopsy. If abnormal baseline noninvasive blood serology in patients with risk factors for hepatotoxicity <b>or </b>after cumulative dose of 3.5 to 4 g, consider biopsy based on GI consult or vibration controlled transient elastography (AAD/NPF [Menter 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Rheumatoid arthritis:</p>
<p style="text-indent:-2em;margin-left:4em;">CBC with differential and platelets, serum creatinine, and LFTs: Baseline and every 2 to 4 weeks for 3 months after initiation or following dose increases, then every 8 to 12 weeks during 3 to 6 months of treatment, followed by every 12 weeks beyond 6 months of treatment; monitor more frequently if clinically indicated (Singh [ACR 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">Chest x-ray (within 1 year prior to initiation), Hepatitis B and C serology (if at high risk); tuberculosis testing annually for patients who live, travel or work in areas with likely TB exposure (Kremer 1994).</p>
<p style="text-indent:-2em;margin-left:4em;">Liver biopsy: Baseline (consider only for patients with persistent abnormal baseline LFTs, history of alcoholism, or chronic hepatitis B or C) or during treatment if persistent LFT elevations (6 of 12 tests abnormal over 1 year or 5 of 9 results when LFTs performed at 6-week intervals) (Kremer 1994).</p>
<p style="text-indent:-2em;margin-left:2em;">Polyarticular-course juvenile idiopathic arthritis: Complete blood counts (baseline and at least monthly), renal function (baseline and every 1 to 2 months), liver function (every 1 to 2 months). Increase monitoring frequency during initial dosing, dose changes, or during periods of increased risk of elevated methotrexate blood levels (eg, dehydration). Monitor pulmonary function tests if methotrexate-induced lung disease is suspected, especially if baseline values are available.</p>
<p style="text-indent:-2em;margin-left:2em;">Crohn disease (off-label use; ACG [Lichtenstein 2018]): CBC with differential and platelets (baseline and periodic) and liver function tests (baseline and every 1 to 2 months); baseline liver biopsy (in patients with abnormal baseline LFTs or with chronic liver disease); liver biopsy at 1 year if (over a 1-year span) AST consistently elevated or serum albumin consistently decreased; chest x-ray (baseline); renal function (baseline and periodic).</p>
<p style="text-indent:-2em;margin-left:2em;">Tubal ectopic pregnancy (off-label use):</p>
<p style="text-indent:-2em;margin-left:4em;">Prior to therapy, serial hCG measurements 2 to 7 days apart along with other procedures to exclude the presence of a viable intrauterine pregnancy (ACOG 2018; RCOG [Elson 2016]). Baseline CBC, serum creatinine and LFTs (SOGC [Po 2021]). Evaluate for medical conditions considered absolute contraindications for methotrexate treatment of ectopic pregnancy (ACOG 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-dose regimen:</i> Baseline serum hCG level on day 1 and posttreatment serum hCG levels on days 4 and 7; if the serum hCG decrease from day 4 to 7 is ≥15%, continue to measure serum hCG weekly until reaching a nonpregnant level. Consider surgical management if serum hCG does not decrease adequately after 3 doses. If serum hCG levels plateau or increase during follow-up period, consider methotrexate for treatment of persistent ectopic pregnancy or surgical management (ACOG 2018; Tulandi 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Two-dose regimen:</i> Baseline serum hCG level on day 1 and posttreatment serum hCG level on days 4 and 7; if the decrease between days 4 and 7 is &lt;15%, obtain serum hCG level on day 11; if the decease between days 7 and 11 is &lt;15%, obtain serum hCG on day 14. If the serum hCG decrease is ≥15% at any of the above steps, continue to measure serum hCG weekly until reaching a nonpregnant level; consider surgical management if serum hCG does not decrease adequately after 4 doses. If hCG levels plateau or increase during follow-up period, consider methotrexate for treatment of persistent ectopic pregnancy or surgical management (ACOG 2018; Tulandi 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Multidose regimen (in combination with leucovorin):</i> Measure serum hCG on days of methotrexate administration. Once the serum hCG decrease is ≥15%, continue to measure serum hCG weekly until reaching a nonpregnant level. Consider surgical management if serum hCG does not adequately decrease after 5 doses. If hCG levels plateau or increase during follow-up period, consider methotrexate for treatment of persistent ectopic pregnancy or surgical management (ACOG 2018; Tulandi 2023).</p></div>
<div class="block rer drugH1Div" id="F194527"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Therapeutic levels: Variable; Toxic concentration: Variable; therapeutic range is dependent upon therapeutic approach.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">High-dose regimens produce drug levels that are between 0.1 to 1 micromole/L 24 to 72 hours after drug infusion</p>
<p style="text-indent:-2em;margin-left:4em;">Toxic: Low-dose therapy: &gt;0.2 micromole/L; high-dose therapy: &gt;1 micromole/L</p></div>
<div class="block pha drugH1Div" id="F194514"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate is a folate antimetabolite that inhibits DNA synthesis, repair, and cellular replication. Methotrexate binds to and inhibits dihydrofolate reductase, inhibiting the formation of reduced folates, and thymidylate synthetase, resulting in inhibition of purine and thymidylic acid synthesis, thus interfering with DNA synthesis, repair, and cellular replication. Methotrexate is cell cycle specific for the S phase of the cycle. Actively proliferative tissues are more susceptible to the effects of methotrexate.</p>
<p style="text-indent:-2em;margin-left:2em;">The mechanism in the treatment of rheumatoid arthritis and polyarticular-course juvenile idiopathic arthritis is unknown, but may affect immune function. In psoriasis, methotrexate is thought to target rapidly proliferating epithelial cells in the skin.</p>
<p style="text-indent:-2em;margin-left:2em;">In Crohn disease, it may have immune modulator and anti-inflammatory activity.</p></div>
<div class="block phk drugH1Div" id="F194533"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Antirheumatic: 3 to 6 weeks; additional improvement may continue longer than 12 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Highly variable; dose dependent; decreased absorption at higher doses (pediatric patients: &gt;40 mg/m<sup>2</sup>; adult patients: &gt;80 mg/m<sup>2</sup>); possibly due to saturation effect.</p>
<p style="text-indent:-2em;margin-left:4em;">IM injection: Complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Penetrates slowly into third space fluids (eg, pleural effusions, ascites), exits slowly from these compartments (slower than from plasma); sustained concentrations retained in kidney and liver.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: IV: 0.18 L/kg (initial); 0.4 to 0.8 L/kg (steady state).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Partially metabolized by intestinal flora (after oral administration) to DAMPA by carboxypeptidase; hepatic aldehyde oxidase converts methotrexate to 7-hydroxy methotrexate; polyglutamates are produced intracellularly and are just as potent as methotrexate; their production is dose- and duration-dependent and they are slowly eliminated by the cell once formed. Polyglutamated forms can be converted back to methotrexate.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Children: Highly variable: 23% to 95%; Adults: Low doses (≤30 mg/m<sup>2</sup>): ~60%; in general, bioavailability is dose dependent and decreases as the dose increases (especially at doses &gt;80 mg/m<sup>2</sup> [&gt;40 mg/m<sup>2</sup> in pediatric patients]).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: ALL: 0.7 to 5.8 hours (dose range: 6.3 to 30 mg/m<sup>2</sup>); pJIA: 0.9 to 2.3 hours (dose range: 3.75 to 26.2 mg/m<sup>2</sup>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Low dose (oral): 3 to 10 hours; High dose (IV): 8 to 15 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: Children: 0.7 to 4 hours (reported for a 15 mg/m<sup>2</sup> dose); Adults: 0.75 to 6 hours; IM: Children and Adults: 30 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Dose and route dependent; IV: Urine (80% to 90% as unchanged drug; 5% to 7% as 7-hydroxy methotrexate); feces (≤10%).</p></div>
<div class="block phksp drugH1Div" id="F51159479"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: An increase in serum levels occurs because of decreased elimination in patients with renal function impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F194540"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ebetrexat | Methotrexat</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Artrait | Ervemin | Metotrexate | Metotrexato | Metotrexato asofarma | Metotrexato dosa | Metotrexato eczane | Metotrexato filaxis | Metotrexato martian | Metotrexato microsules | Trixate</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ebetrexat | Methofill | Methotrexat ebewe | Methotrexat lederle | Methotrexate ebewe | Metoject | Mtx ratiopharm | Nordimet</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ledertrexate | Methoblastin | Methotrexate | Trexject</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Meth | Methox | Metorax | Mtx | Trexonate</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Emthexate | Ledertrexate | Methofill | Metoject | Nordimet</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ebetrexat | Methotrexate | Methotrexate accord | Namaxir</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Biometrox | Emthexate | Hytas | Methotrexate | Metotrexato | Metrexato | Metrotex | Reutrexato | Tecnomet | Tevametho | Trexeron | Unitrexate</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Methotrexat accord | Methotrexat lederle | Methotrexat mepha | Methotrexat Orion | Methotrexat pfizer | Methotrexat Proreo | Methotrexat sandoz | Methotrexat Sandoz | Methotrexate farmos | Methrexx | Metoject | Nordimet</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Brexil | Metoject | Metotrexato | Nordimet</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Methotrexate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Emthexate | Methotrexate | Methoven | Metoject | Metotrexato | Metrex | Metrexato | Mexat | Nordixate</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Injexate | Methotrexat accord | Methotrexat ebewe | Methotrexate | Metoject pen | Nordimet | Trexan | Trexan neo</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bendatrexat | Metex | Methofill | Methotrexamed | Methotrexat | Methotrexat 1 A pharma | Methotrexat 1a pharma | Methotrexat al | Methotrexat biosyn | Methotrexat ebewe | Methotrexat Kohne | Methotrexat lederle | Methotrexat Medac | Methotrexat mundipharma | Methotrexate | Metotrexato | Mtx Dura | Mtx hexal | Mtx Medac FS | Mtx mylan | Mtx Orion | Mtx ratiopharm | Mtx sandoz | Neotrexat | Nordimet | Trexject</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Methotrexate singad</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Methotrexat | Methotrexate | Metotrexato | Metoxate</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Methotrexate | Methotrexato | Metotrexato</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ebetrex | Metex | Methotrexat | Methotrexate | Methotrexate Orion | Metoject | Trexan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Methotrexat ebewe | Methotrexate | Metoject</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bertanel | Glofer | Imeth | Methofill | Methotrexate orion pharma | Metoject | Metoject pen | Metotrexato cipla | Metotrexato lederle | Metotrexato Lederle | Nordimet</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Emthex | Unitrexate</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ebetrex | Emthexat | Injexate | Methotrexat accord | Methotrexate | Methotrexate mayne | Metoject | Metoject pen | Nordimet | Trexan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Imeth | Izixate | Ledertrexate | Methotrexate accord | Methotrexate merck | Methotrexate teva | Metoject | Prexate</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ebetrex | Maxtrex | Methofill | Methotrexate | Methotrexate dup | Metoject | Nordimet | Trav methotrexate | Zlatal</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Methotrexate | Methotrexate ebewe | Methox f | Metoject | Nordimet</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Emthexate | Methotrexate</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ebetrexat | Methotrexate lederle | Metoject | Metotreksat cipla | Metotreksat sandoz</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ebetrexat | Methotrexat ebewe | Methotrexate orion | Namaxir | Trexan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Emthexate | Farmitrexat | Ferxate | Methotrexat ebewe | Methotrexate | Rheu trex | Texorate</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Methofill | Metoject</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Emthexate | Methotrexat | Methotrexate</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alltrex | Arthrate | Auratrex | Biotrexate | Caditrex | Carditrex | Cytotrex | Dermatrax | Dermotrex | Ethitrex | Folitrax | Hi trex | Imotrax | Imutrex | Meditrex | Methorex | Methotrexate | Mevotrex | Mexate | Mext | Mxte | Neotrexate | Oncotrex | Oncotrex-pf | Onotrex | Plastomet | Ra mex | Remtrex | Trex | Trexo | Valuxate | Vibzi | Zexate</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Immutrex | Methotrexate | Metother | Metotrexato accord | Metotrexato Addenda | Metotrexato doc generici | Reumaflex | Trexodem | Trexother | Velos</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ebetrexat</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Methotrexate towa | Methotrexate Wyeth | Metolate</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Trexglo</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Emthexate | Emthexate pf | Jeil methotrexate | Kbp methotrexate | M.T.X | Methotrexate koreaunited | Unitrexate | Yuhan methotrexate</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Emthexate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ebetrexat | Imutrex | Methotrexate | Methotrexate ebewe | Metoject</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ebetrex | Ebetrexat | Metex | Methotrexate | Metoject | Metother | Mtx sandoz | Trexan</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ebetrexat | Ledertrexate | Mtx hexal | Nordimet</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ebetrex | Ebetrexat | Methotrexate | Methotrexate accord | Methotrexate ebewe | Metoject | Trexan</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Quinux</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ac vonda | Atrexel | Ifamet | Karxitran | Ledertrexate | Medsatrexate | Methotrexate | Metoject | Metotrexate | Metotrexato | Metotrexato ultra | Texate | Texate t | Tratoben | Trixilem | Ulmextral | Zumotrex</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Emthexate | Methotrexate | Methotrexate ebewe | Mtx | Zexate</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Sjstrex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ebetrex | Emthexate | Emthexate pf | Injexate | Ledertrexate | Methotrexaat | Methotrexaat 5 mg=0,133 ml focus | Methotrexaat accord | Methotrexaat cf | Methotrexaat sandoz | Metoject</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ebetrex | Emthexat | Metex | Methofill | Methotrexat accord | Methotrexate | Methotrexate cipla | Methotrexate singad | Methotrexate teva | Metoject | Nordimet</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Methoblastin | Methotrexate | Methotrexate sandoz | Trexate</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Artrait 10 | Artriplus | Methocel | Methotrexate | Meticil | Metotrex | Metotrexato | Reumatrex</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Emthexate | Hextrate | Methobax | Methotrexate disodium | Mpl methoxil | Pterin | Zexate</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Blutrexate | Cytotrexate | Emthexate | Imutrex | Methobel | Methotrexate | Metrex | Mtx | Neumethoxate | Pharmatrexate | Trexate | Unitrexate</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ebetrexat | Metex | Methofill | Methofill SD | Methotrexat Medac | Methotrexate | Methotrexate ebewe | Methotrexate knoll | Metoject | Metotab | Namaxir | Trexan | Trexan neo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Methotrexate | Reditrex | Trexall</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ledertrexato | Metex | Methofill | Metoject | Metotrexato | Nordimet</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Metotrexato cipla | Metotrexato dosa | Metotrexato imedic | Metotrexato microsules | Metrex</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Methotrexate Ebewe</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Antifolan | Methotrexate pch | Metorthrit | Namaxir | Nordimet</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Methortrit | Methotrexat ronc | Methotrexate | Methotrexate ebewe | Methotrexate Ferein | Methotrexate lachema | Methotrexate sz | Metoject | Metortrit | Vero methotrexate | Zexate</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo methotrexate | Methotrexate | Methotrexate spc | Metoject</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ebetrex | Injexate | Metex | Methotrexate | Methotrexate ebewe | Methotrexate mayne | Methotrexate Orion | Methotrexate paranova | Methotrexate pfizer | Methotrexate pharmacia | Methotrexate sandoz | Methotrexate teva | Metoject | Metojectpen | Metotab | Metotrexat | Metotrexat ebb | Nordimet | Tremetex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Abitrexate | Emthexate | Methotrexate pfizer | Mtx</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Methotrexat ebewe | Methotrexate | Metoject | Metotreksat ebewe | Metotreksat Lederle</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Methotrexat | Methotrexat ebewe | Methotrexate | Metoject | Nordimet | Trexan | Trexan neo</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Abitrexate | Biotrexate | Emthexate | Methotrexate ebewe | Methotrexate remedica | Onkomet | Unitrexate</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ebetrexat | Methotrexate | Methotrexate ebewe | Methotrexate mylan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Artroject | Emthexate s | Meksratu | Methotrexate | Methotrexate r | Metoart | Metoart con | Mextu | Mtx hexal | Trexan</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Emthexate | Emthexate pf | Methopterin | Methotrexate | Trexan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Methotrexat Orion | Methotrexate | Metoject | Metortrat romfarm | Metotab</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Artrait | Ervemin | Methotrexate | Metotrexate | Metotrexato | Metotrexato libra</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mebiotrexato | Trixate | Zexate</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Abitrexate | Emthexate | Methoblastin | Methotrexate accord</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Biotrexate | Emthex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17975017">
<a name="17975017"></a>Adès L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. <i>Blood.</i> 2008;111(3):1078-1084.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17975017/pubmed" id="17975017" target="_blank">17975017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33998691">
<a name="33998691"></a>AlEssa RK, AlJasser MI. Methotrexate-associated reduced libido: a case report and review of the literature. <i>Clin Exp Dermatol</i>. 2021;46(7):1350-1352. doi:10.1111/ced.14745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/33998691/pubmed" id="33998691" target="_blank">33998691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14871278">
<a name="14871278"></a>Aithal GP, Haugk B, Das S, Card T, Burt AD, Record CO. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? <i>Aliment Pharmacol Ther</i>. 2004;19(4):391-399. doi:10.1046/j.1365-2036.2004.01819.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/14871278/pubmed" id="14871278" target="_blank">14871278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28261918">
<a name="28261918"></a>Ajmani S, Preet Singh Y, Prasad S, et al. Methotrexate-induced pancytopenia: a case series of 46 patients. <i>Int J Rheum Dis</i>. 2017;20(7):846-851. doi:10.1111/1756-185X.13004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28261918/pubmed" id="28261918" target="_blank">28261918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21833520">
<a name="21833520"></a>Al-Hasani H, Roussou E. Methotrexate for rheumatoid arthritis patients who are on hemodialysis. <i>Rheumatol Int.</i> 2011;31(12):1545-1547. doi:10.1007/s00296-011-2041-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21833520/pubmed" id="21833520" target="_blank">21833520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hashash.1">
<a name="Hashash.1"></a>Al Hashash J, Regueiro M. Medical management of moderate to severe Crohn disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23521709">
<a name="23521709"></a>Al-Quteimat OM, Al-Badaineh MA. Methotrexate and trimethoprim-sulphamethoxazole: extremely serious and life-threatening combination. <i>J Clin Pharm Ther</i>. 2013;38(3):203-205. doi:10.1111/jcpt.12060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23521709/pubmed" id="23521709" target="_blank">23521709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21044440">
<a name="21044440"></a>Albrecht K, Müller-Ladner U. Side effects and management of side effects of methotrexate in rheumatoid arthritis. <i>Clin Exp Rheumatol</i>. 2010;28(5 Suppl 61):S95-S101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21044440/pubmed" id="21044440" target="_blank">21044440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15674908">
<a name="15674908"></a>Alfadhli AA, McDonald JW, and Feagan BG, “Methotrexate for Induction of Remission in Refractory Crohn's Disease,” <i>Cochrane Database Syst Rev</i>, 2005, 25(1):CD003459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15674908/pubmed" id="15674908" target="_blank">15674908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29470343">
<a name="29470343"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Gynecology. ACOG practice bulletin No. 193: tubal ectopic pregnancy. <i>Obstet Gynecol</i>. 2018;131(3):e91-e103. doi:10.1097/AOG.0000000000002560<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/29470343/pubmed" id="29470343" target="_blank">29470343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32804884">
<a name="32804884"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Gynecology, Society of Family Planning. Medication abortion up to 70 days of gestation: ACOG practice bulletin, number 225. <i>Obstet Gynecol</i>. 2020;136(4):e31-e47. doi:10.1097/AOG.0000000000004082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/32804884/pubmed" id="32804884" target="_blank">32804884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11840435">
<a name="11840435"></a>American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. <i>Arthritis Rheum.</i> 2002;46(2):328–346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11840435/pubmed" id="11840435" target="_blank">11840435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11754193">
<a name="11754193"></a>Anderson SC, Baquis GD, Jackson A, Monteleone P, Kirkwood JR. Ventral polyradiculopathy with pediatric acute lymphocytic leukemia. <i>Muscle Nerve</i>. 2002;25(1):106-110. doi:10.1002/mus.1219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11754193/pubmed" id="11754193" target="_blank">11754193</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  APO-Methotrexate (methotrexate) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 101.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21474675">
<a name="21474675"></a>Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). <i>Blood</i>. 2011;118(4):874-883. doi:10.1182/blood-2010-06-292615<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21474675/pubmed" id="21474675" target="_blank">21474675</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Auro-Methotrexate [product monograph]. Woodbridge, Ontario, Canada: Auro Pharma Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11571741">
<a name="11571741"></a>Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. <i>Cancer.</i> 2001;92(5):1259-1264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11571741/pubmed" id="11571741" target="_blank">11571741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12853357">
<a name="12853357"></a>Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. <i>Ann Oncol</i>. 2003;14(7):1126-1134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12853357/pubmed" id="12853357" target="_blank">12853357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11118462">
<a name="11118462"></a>Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 protocol: an updated report. <i>J Clin Oncol</i>. 2000;18(24):4016-4027. doi:10.1200/JCO.2000.18.24.4016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11118462/pubmed" id="11118462" target="_blank">11118462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34449990">
<a name="34449990"></a>Bahnson AB, Sturm T. Methotrexate-induced cutaneous ulcers: a rare side effect. <i>S D Med</i>. 2021;74(7):304-305.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34449990/pubmed" id="34449990" target="_blank">34449990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29985651">
<a name="29985651"></a>Baker T, Datta P, Rewers-Felkins K, Hale TW. High-dose methotrexate treatment in a breastfeeding mother with placenta accreta: a case report. <i>Breastfeed Med</i>. 2018;13(6):450-452. doi:10.1089/bfm.2018.0078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/29985651/pubmed" id="29985651" target="_blank">29985651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14665607">
<a name="14665607"></a>Bamias A, Aravantinos G, Deliveliotis C, et al; Hellenic Cooperative Oncology Group. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. <i>J Clin Oncol</i>. 2004;22(2):220-228. doi:10.1200/JCO.2004.02.152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/14665607/pubmed" id="14665607" target="_blank">14665607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20378561">
<a name="20378561"></a>Bareau B, Rey J, Hamidou M, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. <i>Haematologica</i>. 2010;95(9):1534-1541. doi:10.3324/haematol.2009.018481<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/20378561/pubmed" id="20378561" target="_blank">20378561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21339382">
<a name="21339382"></a>Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. <i>Ann Oncol</i>. 2011;22(8):1859-1864. doi:10.1093/annonc/mdq677<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21339382/pubmed" id="21339382" target="_blank">21339382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19625718">
<a name="19625718"></a>Barnhart KT. Clinical practice. Ectopic pregnancy.<i> N Engl J Med</i>. 2009;361(4):379-87. doi:10.1056/NEJMcp0810384<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19625718/pubmed" id="19625718" target="_blank">19625718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12681886">
<a name="12681886"></a>Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. <i>Obstet Gynecol</i>. 2003;101(4):778-784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12681886/pubmed" id="12681886" target="_blank">12681886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17097649">
<a name="17097649"></a>Barnhart K, Hummel AC, Sammel MD, Menon S, Jain J, Chakhtoura N. Use of "2-dose" regimen of methotrexate to treat ectopic pregnancy. <i>Fertil Steril</i>. 2007;87(2):250-256. doi:10.1016/j.fertnstert.2006.06.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17097649/pubmed" id="17097649" target="_blank">17097649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19407520">
<a name="19407520"></a>Bartz D, Goldberg A. Medication abortion. <i>Clin Obstet Gynecol</i>. 2009;52(2):140-150. doi:10.1097/GRF.0b013e3181a2b026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19407520/pubmed" id="19407520" target="_blank">19407520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bartz.1">
<a name="Bartz.1"></a>Bartz DA. First-trimester pregnancy termination: medication abortion. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Based on manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11865117">
<a name="11865117"></a>Basile C, Montanaro A, Semeraro A. Should low-dose methotrexate therapy be prescribed to dialysis patients? <i>Nephrol Dial Transplant.</i> 2002;17(3):530-531. doi:10.1093/ndt/17.3.530<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11865117/pubmed" id="11865117" target="_blank">11865117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12637469">
<a name="12637469"></a>Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. <i>J Clin Oncol</i>. 2003;21(6):1044-1049. doi:10.1200/JCO.2003.03.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12637469/pubmed" id="12637469" target="_blank">12637469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25139707">
<a name="25139707"></a>Bath RK, Brar NK, Forouhar FA, Wu GY. A review of methotrexate-associated hepatotoxicity. <i>J Dig Dis</i>. 2014;15(10):517-524. doi:10.1111/1751-2980.12184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25139707/pubmed" id="25139707" target="_blank">25139707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34140301">
<a name="34140301"></a>Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. <i>Eur Respir J.</i> 2021;58(6):2004079. doi:10.1183/13993003.04079-2020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34140301/pubmed" id="34140301" target="_blank">34140301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10746262">
<a name="10746262"></a>Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. <i>Sarcoidosis Vasc Diffuse Lung Dis</i>. 2000;17(1):60-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10746262/pubmed" id="10746262" target="_blank">10746262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15891563">
<a name="15891563"></a>Bay A, Oner AF, Etlik O, Yilmaz C, Caksen H. Myelopathy due to intrathecal chemotherapy: report of six cases. <i>J Pediatr Hematol Oncol</i>. 2005;27(5):270-272. doi:10.1097/01.mph.0000162527.85024.e9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15891563/pubmed" id="15891563" target="_blank">15891563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34567344">
<a name="34567344"></a>Bayraktar B. Febrile neutropenia following with single-low-dose methotrexate for the treatment of ectopic pregnancy: a case report. <i>Pan Afr Med J</i>. 2021;38:17. doi:10.11604/pamj.2021.38.17.27507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34567344/pubmed" id="34567344" target="_blank">34567344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31727565">
<a name="31727565"></a>Bermas BL. Paternal safety of anti-rheumatic medications. <i>Best Pract Res Clin Obstet Gynaecol</i>. 2020;64:77-84. doi:10.1016/j.bpobgyn.2019.09.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/31727565/pubmed" id="31727565" target="_blank">31727565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6896467">
<a name="6896467"></a>Bernstein ML, Sobel DB, Wimmer RS. Noncardiogenic pulmonary edema following injection of methotrexate into the cerebrospinal fluid. <i>Cancer</i>. 1982;50(5):866-868. doi:10.1002/1097-0142(19820901)50:5&lt;866::aid-cncr2820500510&gt;3.0.co;2-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/6896467/pubmed" id="6896467" target="_blank">6896467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23504948">
<a name="23504948"></a>Bernstein SH, Epner E, Unger JM, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. <i>Ann Oncol</i>. 2013;24(6):1587-1593. doi:10.1093/annonc/mdt070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23504948/pubmed" id="23504948" target="_blank">23504948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22477728">
<a name="22477728"></a>Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. <i>Oncologist</i>. 2012;17(4):550-554. doi:10.1634/theoncologist.2011-0431<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22477728/pubmed" id="22477728" target="_blank">22477728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24550419">
<a name="24550419"></a>Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 2014;32(9):949-959. doi:10.1200/JCO.2013.53.0808<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24550419/pubmed" id="24550419" target="_blank">24550419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34139603">
<a name="34139603"></a>Bidikian AH, Bazarbachi A, Hourani R, El-Cheikh J, Abou Dalle I. Intrathecal methotrexate induced myelopathy, rare yet serious complication: A case report and review of the literature. <i>Curr Res Transl Med</i>. 2021;69(3):103296. doi:10.1016/j.retram.2021.103296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34139603/pubmed" id="34139603" target="_blank">34139603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26033801">
<a name="26033801"></a>Bielack SS, Smeland S, Whelan JS, et al; EURAMOS-1 Investigators. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. <i>J Clin Oncol</i>. 2015;33(20):2279-2287.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26033801/pubmed" id="26033801" target="_blank">26033801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11285384">
<a name="11285384"></a>Binymin K, Cooper RG. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. <i>Rheumatology (Oxford)</i>. 2001;40(3):341-342. doi:10.1093/rheumatology/40.3.341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11285384/pubmed" id="11285384" target="_blank">11285384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15811037">
<a name="15811037"></a>Blanes M, Silvestre JF, Albares MP, Pascual JC, Pastor N. Erythema multiforme due to methotrexate reproduced with patch test. <i>Contact Dermatitis</i>. 2005;52(3):164-165. doi:10.1111/j.0105-1873.2005.0548f.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15811037/pubmed" id="15811037" target="_blank">15811037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6948611">
<a name="6948611"></a>Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. <i>Cancer Treat Rep</i>. 1981a;65(suppl 1):89-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/6948611/pubmed" id="6948611" target="_blank">6948611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-342086">
<a name="342086"></a>Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. <i>Cancer</i>. 1978;41(1):36-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/342086/pubmed" id="342086" target="_blank">342086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bleyer.1">
<a name="Bleyer.1"></a>Bleyer WA. Therapeutic monitoring of methotrexate and other antineoplastic drugs. In: Baer DM, Dita WR, eds. <i>Interpretations in Therapeutic Drug Monitoring</i>. Chicago, IL: American Society of Clinical Pathology; 1981b:169-181.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6366138">
<a name="6366138"></a>Bleyer WA, Coccia PF, Sather HN, et al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. <i>J Clin Oncol</i>. 1983;1(5):317-325. doi:10.1200/JCO.1983.1.5.317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/6366138/pubmed" id="6366138" target="_blank">6366138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7667645">
<a name="7667645"></a>Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. <i>Semin Arthritis Rheum</i>. 1995;24(6):411-421. doi:10.1016/s0049-0172(95)80009-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/7667645/pubmed" id="7667645" target="_blank">7667645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7877646">
<a name="7877646"></a>Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. <i>N Engl J Med</i>. 1995;332(14):901-906. doi:10.1056/NEJM199504063321401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/7877646/pubmed" id="7877646" target="_blank">7877646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3225584">
<a name="3225584"></a>Boogerd W, vd Sande JJ, Moffie D. Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. <i>J Neurol Neurosurg Psychiatry</i>. 1988;51(10):1277-1283. doi:10.1136/jnnp.51.10.1277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/3225584/pubmed" id="3225584" target="_blank">3225584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29627775">
<a name="29627775"></a>Borda LJ, Ross A, Villada G, Milikowski C. Acute mucocutaneous methotrexate toxicity with marked tissue eosinophilia. <i>BMJ Case Rep</i>. 2018;2018:bcr2017221489. doi:10.1136/bcr-2017-221489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/29627775/pubmed" id="29627775" target="_blank">29627775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35766904">
<a name="35766904"></a>Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). <i>J Eur Acad Dermatol Venereol.</i> 2022;36(10):1689-1704. doi:10.1111/jdv.18220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/35766904/pubmed" id="35766904" target="_blank">35766904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34998078">
<a name="34998078"></a>Boussaid S, Makhlouf Y, Rekik S, et al The effects of autoimmune rheumatic-related diseases on male reproductive health: a systematic review. <i>J Reprod Immunol</i>. 2022;150:103472. doi:10.1016/j.jri.2021.103472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34998078/pubmed" id="34998078" target="_blank">34998078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18163521">
<a name="18163521"></a>Braun J, Kästner P, Flaxenberg P, et al; MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. <i>Arthritis Rheum</i>. 2008;58(1):73-81. doi:10.1002/art.23144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18163521/pubmed" id="18163521" target="_blank">18163521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9613341">
<a name="9613341"></a>Bressolle F, Bologna C, Kinowski JM, Sany J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. <i>Ann Rheum Dis</i>. 1998;57(2):110-113. doi:10.1136/ard.57.2.110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/9613341/pubmed" id="9613341" target="_blank">9613341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12895397">
<a name="12895397"></a>Briemberg HR, Amato AA. Dermatomyositis and polymyositis. <i>Curr Treat Options Neurol</i>. 2003;5(5):349-356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12895397/pubmed" id="12895397" target="_blank">12895397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15162903">
<a name="15162903"></a>Brock S, Jennings HR. Fatal acute encephalomyelitis after a single dose of intrathecal methotrexate. <i>Pharmacotherapy</i>. 2004;24(5):673-676. doi:10.1592/phco.24.6.673.34742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15162903/pubmed" id="15162903" target="_blank">15162903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18831032">
<a name="18831032"></a>Brugnoletti F, Morris EB, Laningham FH, et al. Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings. <i>Pediatr Blood Cancer</i>. 2009;52(2):293-295. doi:10.1002/pbc.21764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18831032/pubmed" id="18831032" target="_blank">18831032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17138821">
<a name="17138821"></a>Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. <i>Blood</i>. 2007;109(7):2736-2743.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17138821/pubmed" id="17138821" target="_blank">17138821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4719662">
<a name="4719662"></a>Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. <i>J Clin Invest</i>. 1973;52(8):1804-1811. doi:10.1172/JCI107362<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/4719662/pubmed" id="4719662" target="_blank">4719662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20689429">
<a name="20689429"></a>Chamberlain MC. Leptomeningeal metastasis. <i>Curr Opin Oncol</i>. 2010;22(6):627-635. doi:10.1097/CCO.0b013e32833de986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/20689429/pubmed" id="20689429" target="_blank">20689429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28456635">
<a name="28456635"></a>Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. <i>J Urol</i>. 2017;198(3):552-559.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28456635/pubmed" id="28456635" target="_blank">28456635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8413388">
<a name="8413388"></a>Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. <i>N Engl J Med</i>. 1993;329(17):1225-1230. doi:10.1056/NEJM199310213291703<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8413388/pubmed" id="8413388" target="_blank">8413388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10871150">
<a name="10871150"></a>Chao NJ, Snyder DS, Jain M, et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.<i> Biol Blood Marrow Transplant</i>. 2000;6(3):254-261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10871150/pubmed" id="10871150" target="_blank">10871150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28499754">
<a name="28499754"></a>Chen TJ, Chung WH, Chen CB, et al. Methotrexate-induced epidermal necrosis: A case series of 24 patients. <i>J Am Acad Dermatol</i>. 2017;77(2):247-255.e2. doi:10.1016/j.jaad.2017.02.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28499754/pubmed" id="28499754" target="_blank">28499754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29785393">
<a name="29785393"></a>Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. <i>Psoriasis (Auckl)</i>. 2018;8:21-29. doi:10.2147/PTT.S141629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/29785393/pubmed" id="29785393" target="_blank">29785393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6496516">
<a name="6496516"></a>Cheung YW, Vishnuvajjala BR, Flora KP. Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures. <i>Am J Hosp Pharm</i>. 1984;41(9):1802-1806.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/6496516/pubmed" id="6496516" target="_blank">6496516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22550565">
<a name="22550565"></a>Chhabra P, Law AD, Suri V, Malhotra P, Varma S. Methotrexate induced lung injury in a patient with primary CNS lymphoma: a case report. <i>Mediterr J Hematol Infect Dis</i>. 2012;4(1):e2012020. doi:10.4084/MJHID.2012.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22550565/pubmed" id="22550565" target="_blank">22550565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15611503">
<a name="15611503"></a>Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. <i>J Clin Oncol</i>. 2004;22(24):4881-4887.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15611503/pubmed" id="15611503" target="_blank">15611503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24821883">
<a name="24821883"></a>Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. <i>J Clin Oncol.</i> 2014;32(18):1889-1894.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24821883/pubmed" id="24821883" target="_blank">24821883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34235894">
<a name="34235894"></a>Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Rheumatol</i>. 2021;73(8):1366-1383. doi:10.1002/art.41773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34235894/pubmed" id="34235894" target="_blank">34235894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15937433">
<a name="15937433"></a>Clare G, Colley S, Kennett R, Elston JS. Reversible optic neuropathy associated with low-dose methotrexate therapy. <i>J Neuroophthalmol</i>. 2005;25(2):109-112. doi:10.1097/01.wno.0000166061.73483.ce<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15937433/pubmed" id="15937433" target="_blank">15937433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cohen.1">
<a name="Cohen.1"></a>Cohen S, Cannella A. Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28989565">
<a name="28989565"></a>Conway R, Carey JJ. Risk of liver disease in methotrexate treated patients. <i>World J Hepatol</i>. 2017;9(26):1092-1100. doi:10.4254/wjh.v9.i26.1092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28989565/pubmed" id="28989565" target="_blank">28989565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27208607">
<a name="27208607"></a>Costescu D, Guilbert E, Bernardin J, et al; Society of Obstetricians and Gynecologists of Canada. Medical abortion. <i>J Obstet Gynaecol Can</i>. 2016;38(4):366-389. doi:10.1016/j.jogc.2016.01.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27208607/pubmed" id="27208607" target="_blank">27208607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8773418">
<a name="8773418"></a>Creinin MD, Vittinghoff E, Keder L, Darney PD, Tiller G. Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. <i>Contraception</i>. 1996;53(6):321-327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8773418/pubmed" id="8773418" target="_blank">8773418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23880702">
<a name="23880702"></a>Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. <i>Curr Opin Pulm Med</i>. 2013;19(5):545-561. doi:10.1097/MCP.0b013e3283642a7a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23880702/pubmed" id="23880702" target="_blank">23880702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7685956">
<a name="7685956"></a>Cuthbert RJ, Craig JI, Ludlam CA. Stevens-Johnson syndrome associated with methotrexate treatment for non-Hodgkin's lymphoma. <i>Ulster Med J</i>. 1993;62(1):95-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/7685956/pubmed" id="7685956" target="_blank">7685956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31876782">
<a name="31876782"></a>Dabagh S, David H, Young S, Doan A, Bhojwani D. Severe, fatal methotrexate-related neurotoxicity in 2 adolescent patients with ALL. <i>J Pediatr Hematol Oncol</i>. 2020;42(8):e839-e844. doi:10.1097/MPH.0000000000001706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/31876782/pubmed" id="31876782" target="_blank">31876782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15692480">
<a name="15692480"></a>Dadlani C, Orlow SJ. Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature.<i> J Am Acad Dermatol</i>. 2005;52:316-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15692480/pubmed" id="15692480" target="_blank">15692480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11972105">
<a name="11972105"></a>Dalle JH, Auvrignon A, Vassal G, Leverger G. Interaction between methotrexate and ciprofloxacin. <i>J Pediatr Hematol Oncol</i>. 2002;24(4):321-322. doi:10.1097/00043426-200205000-00021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11972105/pubmed" id="11972105" target="_blank">11972105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dana.1">
<a name="Dana.1"></a>Dana R, Papaliodis GN. Treatment of scleritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24267475">
<a name="24267475"></a>Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. <i>Gastroenterology</i>. 2013;145(6):1464-1478. doi:10.1053/j.gastro.2013.10.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24267475/pubmed" id="24267475" target="_blank">24267475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18779628">
<a name="18779628"></a>de Miguel D, García-Suárez J, Martín Y, Gil-Fernández JJ, Burgaleta C. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. <i>Nephrol Dial Transplant</i>. 2008;23(12):3762-3766. doi:10.1093/ndt/gfn503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18779628/pubmed" id="18779628" target="_blank">18779628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18772215">
<a name="18772215"></a>de Lemos ML, Monfared S, Denyssevych T, et al. Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration. <i>J Oncol Pharm Pract</i>. 2009;15(1):45-52. doi:10.1177/1078155208096902<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18772215/pubmed" id="18772215" target="_blank">18772215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19900732">
<a name="19900732"></a>de Jager MEA, deJong EMGJ, van de Kerkhof PCM, et al. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. <i>J Am Acad Dermatol</i>. 2010;62:1013-1030.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19900732/pubmed" id="19900732" target="_blank">19900732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28503765">
<a name="28503765"></a>Delaney S, Colantonio D, Ito S. 57th Annual Teratology Society Meeting. Methotrexate in breast milk.<i> Birth Defects Res</i>. 2017;109(9):579-718. doi:10.1002/bdr2.1061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28503765/pubmed" id="28503765" target="_blank">28503765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26190242">
<a name="26190242"></a>Delyon J, Ortonne N, Benayoun E, et al. Low-dose methotrexate-induced skin toxicity: Keratinocyte dystrophy as a histologic marker. <i>J Am Acad Dermatol</i>. 2015;73(3):484-490. doi:10.1016/j.jaad.2015.06.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26190242/pubmed" id="26190242" target="_blank">26190242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25348617">
<a name="25348617"></a>den Hoed MA, Lopez-Lopez E, te Winkel ML, et al. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. <i>Pharmacogenomics J</i>. 2015;15(3):248-254. doi:10.1038/tpj.2014.63<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25348617/pubmed" id="25348617" target="_blank">25348617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Denton.1">
<a name="Denton.1"></a>Denton CP. Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20334462">
<a name="20334462"></a>DeVore KJ. Solar burn reactivation induced by methotrexate. <i>Pharmacotherapy</i>. 2010;30(4):123e-6e. doi:10.1592/phco.30.4.419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/20334462/pubmed" id="20334462" target="_blank">20334462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34430130">
<a name="34430130"></a>Dewan P, Gomber S, Trivedi M, Diwaker P, Madan U. Methotrexate-induced leukocytoclastic vasculitis. <i>Cureus</i>. 2021;13(7):e16519. doi:10.7759/cureus.16519<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34430130/pubmed" id="34430130" target="_blank">34430130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22290637">
<a name="22290637"></a>DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(7):1001-1010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22290637/pubmed" id="22290637" target="_blank">22290637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19754409">
<a name="19754409"></a>Díaz-Llopis M, Gallego-Pinazo R, García-Delpech S, Salom-Alonso D. General principles for the treatment of non-infectious uveitis. <i>Inflamm Allergy Drug Targets</i>. 2009;8(4):260-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19754409/pubmed" id="19754409" target="_blank">19754409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16969149">
<a name="16969149"></a>Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Removal of methotrexate by peritoneal dialysis and hemodialysis in a single patient with end-stage renal disease. <i>Am J Med Sci.</i> 2006;332(3):156-158. doi:10.1097/00000441-200609000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16969149/pubmed" id="16969149" target="_blank">16969149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7296473">
<a name="7296473"></a>Doroshow JH, Locker GY, Gaasterland DE, Hubbard SP, Young RC, Myers CE. Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film. <i>Cancer</i>. 1981;48(10):2158-2162. doi:10.1002/1097-0142(19811115)48:10&lt;2158::aid-cncr2820481007&gt;3.0.co;2-i<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/7296473/pubmed" id="7296473" target="_blank">7296473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25399948">
<a name="25399948"></a>Dreyer ZE, Hilden JM, Jones TL, et al. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). <i>Pediatr Blood Cancer</i>. 2015;62(3):419-426.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25399948/pubmed" id="25399948" target="_blank">25399948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27721549">
<a name="27721549"></a>Dubey L, Chatterjee S, Ghosh A. Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study. <i>Indian J Pharmacol</i>. 2016;48(5):591-594. doi:10.4103/0253-7613.190761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27721549/pubmed" id="27721549" target="_blank">27721549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17170721">
<a name="17170721"></a>Dufourg MN, Landman-Parker J, Auclerc MF, et al. Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children. <i>Leukemia</i>. 2007;21(2):238-247. doi:10.1038/sj.leu.2404495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17170721/pubmed" id="17170721" target="_blank">17170721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32813610">
<a name="32813610"></a>Dunsmore KP, Winter SS, Devidas M, et al. Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed t-cell acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 2020;38(28):3282-3293. doi:10.1200/JCO.20.00256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/32813610/pubmed" id="32813610" target="_blank">32813610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10594394">
<a name="10594394"></a>Egan LJ, Sandborn WJ, Tremaine WJ, et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. <i>Aliment Pharmacol Ther</i>. 1999;13(12):1597-1604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10594394/pubmed" id="10594394" target="_blank">10594394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33384141">
<a name="33384141"></a>Eiriksson L, Dean E, Sebastianelli A, et al. Guideline No. 408: management of gestational trophoblastic diseases. <i>J Obstet Gynaecol Can</i>. 2021;43(1):91-105.e1. doi:10.1016/j.jogc.2020.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/33384141/pubmed" id="33384141" target="_blank">33384141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27041864">
<a name="27041864"></a>El-Sheikh AA, Morsy MA, Hamouda AH. Protective mechanisms of thymoquinone on methotrexate-induced intestinal toxicity in rats. <i>Pharmacogn Mag</i>. 2016;12(suppl 1):S76-S81. doi:10.4103/0973-1296.176106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27041864/pubmed" id="27041864" target="_blank">27041864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27813249">
<a name="27813249"></a>Elson CJ, Salim R, Potdar N, Chetty M, Ross JA, Kirk EJ on behalf of the Royal College of Obstetricians and Gynaecologists (RCOG). Diagnosis and management of ectopic pregnancy: Green-top guideline No. 21. <i>BJOG</i>. 2016;123(13):e15-e55. doi:10.1111/1471-0528.14189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27813249/pubmed" id="27813249" target="_blank">27813249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31497770">
<a name="31497770"></a>Enginar AÜ, Nur H, Gilgil E, Kaçar C. Accelerated nodulosis in a patient with rheumatoid arthritis. <i>Arch Rheumatol</i>. 2018;34(2):225-228. doi:10.5606/ArchRheumatol.2019.7020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/31497770/pubmed" id="31497770" target="_blank">31497770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14675675">
<a name="14675675"></a>Escobar PF, Lurain JR, Singh DK, Bozorgi K, Fishman DA. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. <i>Gynecol Oncol</i>. 2003;91(3):552-557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/14675675/pubmed" id="14675675" target="_blank">14675675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1404123">
<a name="1404123"></a>Espinoza LR, Zakraoui L, Espinoza CG, et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. <i>J Rheumatol</i>. 1992;19(6):872-877.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/1404123/pubmed" id="1404123" target="_blank">1404123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-316744">
<a name="316744"></a>Evans WE, Pratt CB, Taylor RH, et al, “Pharmacokinetic Monitoring of High-Dose Methotrexate: Early Recognition of High-Risk Patients,” <i>Cancer Chemother Pharmacol</i>, 1979, 3:161-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/316744/pubmed" id="316744" target="_blank">316744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30926722">
<a name="30926722"></a>Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Ann Rheum Dis.</i> 2019;78(6):736-745. doi:10.1136/annrheumdis-2019-215089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/30926722/pubmed" id="30926722" target="_blank">30926722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10833208">
<a name="10833208"></a>Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. <i>N Engl J Med.</i> 2000;342(22):1627-1632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10833208/pubmed" id="10833208" target="_blank">10833208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29541561">
<a name="29541561"></a>Feinsilber D, Leoni RJ, Siripala D, Leuck J, Mears KA. Evaluation, identification, and management of acute methotrexate toxicity in high-dose methotrexate administration in hematologic malignancies. <i>Cureus</i>. 2018;10(1):e2040. doi:10.7759/cureus.2040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/29541561/pubmed" id="29541561" target="_blank">29541561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feldman.1">
<a name="Feldman.1"></a>Feldman SR. Treatment of psoriasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10438706">
<a name="10438706"></a>Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. <i>Blood</i>. 1999; 94(4):1192-1200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10438706/pubmed" id="10438706" target="_blank">10438706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23221488">
<a name="23221488"></a>Ferguson NN, Asarch A, VanBeek M, Swick BL. Acute mucocutaneous methotrexate toxicity associated with interface dermatitis and numerous eosinophils. <i>Am J Dermatopathol</i>. 2013;35(4):e63-e66. doi:10.1097/DAD.0b013e31827b7674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23221488/pubmed" id="23221488" target="_blank">23221488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16246977">
<a name="16246977"></a>Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. <i>J Clin Oncol</i>. 2005;23(34):8845-8852.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16246977/pubmed" id="16246977" target="_blank">16246977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34051983">
<a name="34051983"></a>Feuerstein JD, Ho EY, Shmidt E, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. <i>Gastroenterology</i>. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34051983/pubmed" id="34051983" target="_blank">34051983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, et al, “Hepatotoxicity of Chemotherapy,” <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234530">
<a name="16234530"></a>Floyd JD, Nguyen DT, Lobins RL, et al, “Cardiotoxicity of Cancer Therapy,” <i>J Clin Oncol</i>, 2005, 23(30):7685-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16234530/pubmed" id="16234530" target="_blank">16234530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15693100">
<a name="15693100"></a>Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. <i>J Rheumatol</i>. 2005;32(2):362-365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15693100/pubmed" id="15693100" target="_blank">15693100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16326413">
<a name="16326413"></a>Fong CM, Lee AC. High-dose methotrexate-associated acute renal failure may be an avoidable complication. <i>Pediatr Hematol Oncol</i>. 2006;23(1):51-57. doi:10.1080/08880010500313421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16326413/pubmed" id="16326413" target="_blank">16326413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1634913">
<a name="1634913"></a>Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. <i>J Clin Oncol</i>. 1992;10(8):1245-1251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/1634913/pubmed" id="1634913" target="_blank">1634913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19035431">
<a name="19035431"></a>Fortin PR, Abrahamowicz M, Ferland D, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. <i>Arthritis Rheum</i>. 2008;59(12):1796-1804.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19035431/pubmed" id="19035431" target="_blank">19035431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34101387">
<a name="34101387"></a>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.<i> Arthritis Care Res (Hoboken).</i> 2021;73(7):924-939. doi:10.1002/acr.24596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34101387/pubmed" id="34101387" target="_blank">34101387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31709258">
<a name="31709258"></a>Fragoulis GE, Nikiphorou E, Larsen J, Korsten P, Conway R. Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment. <i>Front Med (Lausanne)</i>. 2019;6:238. doi:10.3389/fmed.2019.00238<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/31709258/pubmed" id="31709258" target="_blank">31709258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20506370">
<a name="20506370"></a>Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. <i>Arthritis Rheum</i>. 2010;62(8):2530-2535. doi:10.1002/art.27532<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/20506370/pubmed" id="20506370" target="_blank">20506370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10515658">
<a name="10515658"></a>Freeman AM, Dasgupta B. Angio-neurotic oedema associated with methotrexate treatment in rheumatoid arthritis. <i>Rheumatology (Oxford)</i>. 1999;38(9):908. doi:10.1093/rheumatology/38.9.908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10515658/pubmed" id="10515658" target="_blank">10515658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27843136">
<a name="27843136"></a>Fritsch K, Kasenda B, Schorb E, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). <i>Leukemia</i>. 2017;31(4):846-852. doi:10.1038/leu.2016.334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27843136/pubmed" id="27843136" target="_blank">27843136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gahart.1">
<a name="Gahart.1"></a>Gahart BL and Nazareno AR, <i>2014 Intravenous Medications: A Handbook for Nurses and Health Professionals</i>, 30th ed, St Louis, MO: Elsevier/Mosby, 2014, 780-785.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18579209">
<a name="18579209"></a>Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. <i>Ophthalmology</i>. 2008;115(10):1826-1832.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18579209/pubmed" id="18579209" target="_blank">18579209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19748676">
<a name="19748676"></a>Gangaputra S, Newcomb CW, Liesegang TL, et al; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases. <i>Ophthalmology</i>. 2009;116(11):2188-2198.e1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19748676/pubmed" id="19748676" target="_blank">19748676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17008697">
<a name="17008697"></a>Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. <i>J Clin Oncol</i>. 2006;24(28):4570-4574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17008697/pubmed" id="17008697" target="_blank">17008697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9664073">
<a name="9664073"></a>Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. <i>J Clin Invest</i>. 1998;102(2):322-328. doi:10.1172/JCI2676<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/9664073/pubmed" id="9664073" target="_blank">9664073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16972068">
<a name="16972068"></a>Gerber DE, Grossman SA, Batchelor T, Ye X. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma. <i>Cancer Chemother Pharmacol.</i> 2007;59(6):817-823. doi:10.1007/s00280-006-0339-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16972068/pubmed" id="16972068" target="_blank">16972068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15086738">
<a name="15086738"></a>Ghaemmaghami F, Modares M, Arab M, et al. EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV). <i>Int J Gynecol Cancer</i>. 2004;14(2):360-365. doi:10.1111/j.1048-891X.2004.014222.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15086738/pubmed" id="15086738" target="_blank">15086738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22313647">
<a name="22313647"></a>Gilani ST, Khan DA, Khan FA, Ahmed M. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. <i>J Coll Physicians Surg Pak</i>. 2012;22(2):101-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22313647/pubmed" id="22313647" target="_blank">22313647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9552066">
<a name="9552066"></a>Glantz MJ, Cole BF, Recht L, Akerley W, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? <i>J Clin Oncol.</i> 1998;16(4):1561-1567.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/9552066/pubmed" id="9552066" target="_blank">9552066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10589750">
<a name="10589750"></a>Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. <i>Clin Cancer Res.</i> 1999;5(11):3394-3402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10589750/pubmed" id="10589750" target="_blank">10589750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27022122">
<a name="27022122"></a>Glass J, Won M, Schultz CJ, et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. <i>J Clin Oncol.</i> 2016;34(14):1620-1625. doi:10.1200/JCO.2015.64.8634<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27022122/pubmed" id="27022122" target="_blank">27022122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22940833">
<a name="22940833"></a>Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. <i>Leukemia</i>. 2013;27(5):1174-1177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22940833/pubmed" id="22940833" target="_blank">22940833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25066629">
<a name="25066629"></a>Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. <i>Br J Haematol</i>. 2014;167(3):394-401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25066629/pubmed" id="25066629" target="_blank">25066629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28967549">
<a name="28967549"></a>Goujon C, Viguier M, Staumont-Sallé D, et al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial. <i>J Allergy Clin Immunol Pract.</i> 2018;6(2):562-569.e3. doi:10.1016/j.jaip.2017.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28967549/pubmed" id="28967549" target="_blank">28967549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18504579">
<a name="18504579"></a>Green MR, Chamberlain MC. Renal dysfunction during and after high-dose methotrexate. <i>Cancer Chemother Pharmacol</i>. 2009;63(4):599-604. doi:10.1007/s00280-008-0772-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18504579/pubmed" id="18504579" target="_blank">18504579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3286880">
<a name="3286880"></a>Grem JL, King SA, Wittes RE, et al, “The Role of Methotrexate in Osteosarcoma,” <i>J Natl Cancer Inst</i>, 1988, 80(9):626-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/3286880/pubmed" id="3286880" target="_blank">3286880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21502557">
<a name="21502557"></a>Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. <i>J Clin Oncol</i>. 2011;29(16):2171-2177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21502557/pubmed" id="21502557" target="_blank">21502557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17039139">
<a name="17039139"></a>Grismer LE, Gill SA, Harris MD. Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. <i>J Clin Rheumatol</i>. 2001;7(4):224-227. doi:10.1097/00124743-200108000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17039139/pubmed" id="17039139" target="_blank">17039139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34463329">
<a name="34463329"></a>Grosen A, Bellaguarda E, Nersting J, et al. Low-dose methotrexate therapy does not affect semen parameters and sperm DNA. <i>Inflamm Bowel Dis</i>. 2022;28(7):1012-1018. doi:10.1093/ibd/izab205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34463329/pubmed" id="34463329" target="_blank">34463329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12944571">
<a name="12944571"></a>Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. <i>N Engl J Med</i>. 2003;349(9):859-866.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12944571/pubmed" id="12944571" target="_blank">12944571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8445432">
<a name="8445432"></a>Grossman SA, Finkelstein DM, Ruckeschel JC, et al, “Randomized Prospective Comparison of Intraventricular Methotrexate and Thiotepa in Patients With Previously Untreated Neoplastic Meningitis. Eastern Cooperative Oncology Group,” <i>J Clin Oncol,</i> 1993, 11(3):561-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8445432/pubmed" id="8445432" target="_blank">8445432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11391029">
<a name="11391029"></a>Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. <i>QJM</i>. 2001;94(6):309-319. doi:10.1093/qjmed/94.6.309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11391029/pubmed" id="11391029" target="_blank">11391029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15341981">
<a name="15341981"></a>Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. <i>Eur J Cancer</i>. 2004;40(14):2071-2076.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15341981/pubmed" id="15341981" target="_blank">15341981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35870769">
<a name="35870769"></a>Gubatan J, Barber GE, Nielsen OH, et al. Paternal medications in inflammatory bowel disease and male fertility and reproductive outcomes: a systematic review and meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2022:S1542-3565(22)00675-9. doi:10.1016/j.cgh.2022.07.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/35870769/pubmed" id="35870769" target="_blank">35870769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10513791">
<a name="10513791"></a>“Guidelines for Referral and Management of Systemic Lupus Erythematosus in Adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines,” <i>Arthritis Rheum</i>, 1999, 42(9):1785-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10513791/pubmed" id="10513791" target="_blank">10513791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8849378">
<a name="8849378"></a>Gutierrez-Ureña S, Molina JF, García CO, Cuéllar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. <i>Arthritis Rheum</i>. 1996;39(2):272-276. doi:10.1002/art.1780390214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8849378/pubmed" id="8849378" target="_blank">8849378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29915656">
<a name="29915656"></a>Hamid M, Lashari B, Ahsan I, Micaily I, Sarwar U, Crocetti J. A deadly prescription: combination of methotrexate and trimethoprim-sulfamethoxazole. <i>J Community Hosp Intern Med Perspect</i>. 2018;8(3):149-151. doi:10.1080/20009666.2018.1466598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/29915656/pubmed" id="29915656" target="_blank">29915656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10321603">
<a name="10321603"></a>Heilborn JD, Ståhle-Bäckdahl M, Albertioni F, Vassilaki I, Peterson C, Stephansson E. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. <i>J Am Acad Dermatol.</i> 1999;40(5, pt 1):741-749. doi:10.1016/s0190-9622(99)70156-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10321603/pubmed" id="10321603" target="_blank">10321603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31270110">
<a name="31270110"></a>Hellmich B, Agueda A, Monti S, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. <i>Ann Rheum Dis.</i> 2020;79(1):19-30. doi:10.1136/annrheumdis-2019-215672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/31270110/pubmed" id="31270110" target="_blank">31270110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12860951">
<a name="12860951"></a>Hoang-Xuan K, Taillandier L, Chinot O, et al, “Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group,” <i>J Clin Oncol</i>, 2003, 21(14):2726-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12860951/pubmed" id="12860951" target="_blank">12860951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12695153">
<a name="12695153"></a>Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. <i>Ann Rheum Dis</i>. 2003;62(5):423-426. doi:10.1136/ard.62.5.423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12695153/pubmed" id="12695153" target="_blank">12695153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7908520">
<a name="7908520"></a>Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. <i>Arthritis Rheum.</i> 1994;37(4):578-582. doi:10.1002/art.1780370420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/7908520/pubmed" id="7908520" target="_blank">7908520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26267431">
<a name="26267431"></a>Holahan HM, Ferguson NN, Farah RS, Liu V. Methotrexate ultraviolet reactivation reaction in the setting of voriconazole-induced phototoxicity. <i>Int J Dermatol</i>. 2015;54(11):e496-e497. doi:10.1111/ijd.12913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26267431/pubmed" id="26267431" target="_blank">26267431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21707700">
<a name="21707700"></a>Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. <i>Br J Clin Pharmacol</i>. 2012;73(1):106-114. doi:10.1111/j.1365-2125.2011.04054.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21707700/pubmed" id="21707700" target="_blank">21707700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21981743">
<a name="21981743"></a>Hornung T, Ko A, Tüting T, Bieber T, Wenzel J. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions.<i> Clin Exp Dermatol.</i> 2012;37(2):139-142. doi:10.1111/j.1365-2230.2011.04188.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21981743/pubmed" id="21981743" target="_blank">21981743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21561350">
<a name="21561350"></a>Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. <i>N Engl J Med</i>. 2011;364(19):1844-1854. doi:10.1056/NEJMra0904569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21561350/pubmed" id="21561350" target="_blank">21561350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27496039">
<a name="27496039"></a>Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. <i>Oncologist</i>. 2016;21(12):1471-1482. doi:10.1634/theoncologist.2015-0164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27496039/pubmed" id="27496039" target="_blank">27496039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20191521">
<a name="20191521"></a>Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. <i>Arthritis Care Res (Hoboken)</i>. 2010;62(2):219-225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/20191521/pubmed" id="20191521" target="_blank">20191521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30583473">
<a name="30583473"></a>Ibrahim A, Ahmed M, Conway R, Carey JJ. Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis. <i>J Clin Med</i>. 2018;8(1):15. doi:10.3390/jcm8010015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/30583473/pubmed" id="30583473" target="_blank">30583473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16864853">
<a name="16864853"></a>Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. <i>J Clin Oncol</i>. 2006;24(24):3865-3870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16864853/pubmed" id="16864853" target="_blank">16864853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10706507">
<a name="10706507"></a>Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. <i>Eur Respir J</i>. 2000;15(2):373-381. doi:10.1034/j.1399-3003.2000.15b25.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10706507/pubmed" id="10706507" target="_blank">10706507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medicine Practices (ISMP). <i>ISMP Targeted Medication Safety Best Practices for Hospitals</i>. https://www.ismp.org/sites/default/files/attachments/2020-02/2020-2021%20TMSBP-%20FINAL_1.pdf. Published February 21, 2020. Accessed January 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women [published correction appears in<i> N Engl J Med</i> 2000;343(18):1348].<i> N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12467071">
<a name="12467071"></a>Iuvone L, Mariotti P, Colosimo C, Guzzetta F, Ruggiero A, Riccardi R. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. <i>Cancer</i>. 2002;95(12):2562-2570. doi:10.1002/cncr.10999<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12467071/pubmed" id="12467071" target="_blank">12467071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26019420">
<a name="26019420"></a>Jacob LA, Sreevatsa A, Chinnagiriyappa LK, Dasappa L, Suresh TM, Babu G. Methotrexate-induced chemical meningitis in patients with acute lymphoblastic leukemia/lymphoma. <i>Ann Indian Acad Neurol</i>. 2015;18(2):206-209. doi:10.4103/0972-2327.150586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26019420/pubmed" id="26019420" target="_blank">26019420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jacobe.2">
<a name="Jacobe.2"></a>Jacobe H. Extragenital lichen sclerosus: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jacobe.1">
<a name="Jacobe.1"></a>Jacobe H. Morphea (localized scleroderma) in adults: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19786650">
<a name="19786650"></a>Jacobson JO, Polovich M, McNiff KK, et al; American Society of Clinical Oncology; Oncology Nursing Society. American Society Of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. <i>J Clin Oncol</i>. 2009;27(32):5469-5475. doi:10.1200/JCO.2009.25.1264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19786650/pubmed" id="19786650" target="_blank">19786650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23762881">
<a name="23762881"></a>Jakubovic BD, Donovan A, Webster PM, Shear NH. Methotrexate-induced pulmonary toxicity. <i>Can Respir J</i>. 2013;20(3):153-155. doi:10.1155/2013/527912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23762881/pubmed" id="23762881" target="_blank">23762881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Ann Oncol</i>. 2010;21(7):1395-1403. doi:10.1093/annonc/mdp598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25276442">
<a name="25276442"></a>Jariwala P, Kumar V, Kothari K, Thakkar S, Umrigar DD. Acute methotrexate toxicity: a fatal condition in two cases of psoriasis. <i>Case Rep Dermatol Med</i>. 2014;2014:946716. doi:10.1155/2014/946716<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25276442/pubmed" id="25276442" target="_blank">25276442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16842380">
<a name="16842380"></a>Joerger M, Huitema AD, van den Bongard HJ, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. <i>Br J Clin Pharmacol</i>. 2006;62(1):71-80. doi:10.1111/j.1365-2125.2005.02513.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16842380/pubmed" id="16842380" target="_blank">16842380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8386437">
<a name="8386437"></a>Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. <i>Am J Med</i>. 1993;94(4):379-387.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8386437/pubmed" id="8386437" target="_blank">8386437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5042796">
<a name="5042796"></a>Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. <i>Am J Obstet Gynecol</i>. 1972;112(7):978-980.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/5042796/pubmed" id="5042796" target="_blank">5042796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19040308">
<a name="19040308"></a>Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. <i>J </i>
<i>Rheumatol</i>. 2009;36(2):323-329. doi:10.3899/jrheum.071169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19040308/pubmed" id="19040308" target="_blank">19040308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6353235">
<a name="6353235"></a>Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. <i>N Engl J Med</i>. 1983;309(18):1094-1104. doi:10.1056/NEJM198311033091805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/6353235/pubmed" id="6353235" target="_blank">6353235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29023594">
<a name="29023594"></a>Jones HE, O'Connell White K, Norman WV, Guilbert E, Lichtenberg ES, Paul M. First trimester medication abortion practice in the United States and Canada. <i>PLoS One</i>. 2017;12(10):e0186487. doi:10.1371/journal.pone.0186487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/29023594/pubmed" id="29023594" target="_blank">29023594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11177313">
<a name="11177313"></a>Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. <i>Ann Intern Med</i>. 2001;134(2):106-114. doi:10.7326/0003-4819-134-2-200101160-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11177313/pubmed" id="11177313" target="_blank">11177313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22495110">
<a name="22495110"></a>Judson MA. The treatment of pulmonary sarcoidosis. <i>Respir Med</i>. 2012;106(10):1351-1361. doi:10.1016/j.rmed.2012.01.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22495110/pubmed" id="22495110" target="_blank">22495110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jylamvo.1">
<a name="Jylamvo.1"></a>Jylamvo (methotrexate) oral solution [prescribing information]. Cambridge, MA: Shorla Oncology Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10653870">
<a name="10653870"></a>Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>J Clin Oncol</i>. 2000;18(3): 547-561.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10653870/pubmed" id="10653870" target="_blank">10653870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14533032">
<a name="14533032"></a>Kaplan-Messas A, Barkana Y, Avni I, Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. <i>Ocul Immunol Inflamm</i>. 2003;11(2):131-139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/14533032/pubmed" id="14533032" target="_blank">14533032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28493546">
<a name="28493546"></a>Karol SE, Yang W, Smith C, et al. Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. <i>Cancer</i>. 2017;123(18):3602-3608. doi:10.1002/cncr.30762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28493546/pubmed" id="28493546" target="_blank">28493546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8996263">
<a name="8996263"></a>Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. <i>J Am Acad Dermatol</i>. 1997;36(1):67-71. doi:10.1016/s0190-9622(97)70327-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8996263/pubmed" id="8996263" target="_blank">8996263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27957282">
<a name="27957282"></a>Katsoulas N, Chrysomali E, Piperi E, Levidou G, Sklavounou-Andrikopoulou A. Atypical methotrexate ulcerative stomatitis with features of lymphoproliferative like disorder: Report of a rare ciprofloxacin-induced case and review of the literature. <i>J Clin Exp Dent</i>. 2016;8(5):e629-e633. doi:10.4317/jced.52909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27957282/pubmed" id="27957282" target="_blank">27957282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11248578">
<a name="11248578"></a>Kerr JZ, Berg S, Blaney SM. Intrathecal chemotherapy. <i>Crit Rev Oncol Hematol. </i>2001;37(3):227-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11248578/pubmed" id="11248578" target="_blank">11248578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9850025">
<a name="9850025"></a>Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. <i>J Clin Oncol</i>. 1998;16(12):3803-3809. doi:10.1200/JCO.1998.16.12.3803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/9850025/pubmed" id="9850025" target="_blank">9850025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15611303">
<a name="15611303"></a>Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. <i>Rheumatology (Oxford)</i>. 2005;44(1):61-66. doi:10.1093/rheumatology/keh512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15611303/pubmed" id="15611303" target="_blank">15611303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-King.1">
<a name="King.1"></a>King TE Jr. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-King.2">
<a name="King.2"></a>King TE Jr. Treatment of pulmonary sarcoidosis refractory to initial therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 1, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. <i>Cancer Treat Rev</i>. 1995;21(1):33-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25172240">
<a name="25172240"></a>Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, Mayan H. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. <i>Autoimmun Rev</i>. 2014;13(11):1109-1113. doi:10.1016/j.autrev.2014.08.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25172240/pubmed" id="25172240" target="_blank">25172240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18490587">
<a name="18490587"></a>Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. <i>Arch Dermatol</i>. 2008;144(5):612-616. doi:10.1001/archderm.144.5.612<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18490587/pubmed" id="18490587" target="_blank">18490587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28792092">
<a name="28792092"></a>Knobler R, Moinzadeh P, Hunzelmann N, et al. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 1: localized scleroderma, systemic sclerosis and overlap syndromes. <i>J Eur Acad Dermatol Venereol</i>. 2017;31(9):1401-1424. doi:10.1111/jdv.14458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28792092/pubmed" id="28792092" target="_blank">28792092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24890023">
<a name="24890023"></a>Kocatürk E, Köklü N, Güngör S, Ulkümen PK, Bahçetepe N, Erhan SŞ. Solar burn reactivation reaction: an unusual side effect of methotrexate. <i>Photodermatol Photoimmunol Photomed</i>. 2014;30(6):338-339. doi:10.1111/phpp.12128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24890023/pubmed" id="24890023" target="_blank">24890023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann </i>
<i>Rheum Dis</i>. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11082754">
<a name="11082754"></a>Krebs S, Gibbons RB. Low-dose methotrexate as a risk factor for <i>Pneumocystis carinii</i> pneumonia. <i>Mil Med</i>. 1996;161(1):58-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11082754/pubmed" id="11082754" target="_blank">11082754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kremer.1">
<a name="Kremer.1"></a>Kremer JM. Use of methotrexate in the treatment of rheumatoid arthritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8129787">
<a name="8129787"></a>Kremer JM, Alarcón GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. <i>Arthritis Rheum</i>. 1994;37(3):316-328.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8129787/pubmed" id="8129787" target="_blank">8129787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19917961">
<a name="19917961"></a>Kreuter A, Tigges C, Gaifullina R, Kirschke J, Altmeyer P, Gambichler T. Pulsed high-dose corticosteroids combined with low-dose methotrexate treatment in patients with refractory generalized extragenital lichen sclerosus. <i>Arch Dermatol</i>. 2009;145(11):1303-1308. doi:10.1001/archdermatol.2009.235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19917961/pubmed" id="19917961" target="_blank">19917961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19210503">
<a name="19210503"></a>Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM. Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. <i>Br J Dermatol</i>. 2009;160(5):1075-1082. doi:10.1111/j.1365-2133.2008.09017.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19210503/pubmed" id="19210503" target="_blank">19210503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27859683">
<a name="27859683"></a>Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). <i>J Eur Acad Dermatol Venereol</i>. 2017;31(3):389-404. doi:10.1111/jdv.14053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27859683/pubmed" id="27859683" target="_blank">27859683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20800319">
<a name="20800319"></a>Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. <i>J Am Acad Dermatol</i>. 2011;65(6):e195-e213. doi:10.1016/j.jaad.2010.06.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/20800319/pubmed" id="20800319" target="_blank">20800319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22071804">
<a name="22071804"></a>Kulier R, Kapp N, Gülmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. <i>Cochrane Database Syst Rev</i>. 2011;2011(11):CD002855. doi:10.1002/14651858.CD002855.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22071804/pubmed" id="22071804" target="_blank">22071804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21962187">
<a name="21962187"></a>Kurian A, Haber R. Methotrexate-induced cutaneous ulcers in a nonpsoriatic patient: case report and review of the literature. <i>J Cutan Med Surg</i>. 2011;15(5):275-279. doi:10.2310/7750.2011.10078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21962187/pubmed" id="21962187" target="_blank">21962187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15160953">
<a name="15160953"></a>Lacasce A, Howard O, Lib S, et al. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. <i>Leuk Lymphoma</i>. 2004;45(4):761-767. doi:10.1080/1042819031000141301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15160953/pubmed" id="15160953" target="_blank">15160953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21275495">
<a name="21275495"></a>Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-192. doi:10.1592/phco.31.2.164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21275495/pubmed" id="21275495" target="_blank">21275495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31562236">
<a name="31562236"></a>Lamb CA, Kennedy NA, Raine T, et al; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <i>Gut</i>. 2019;68(suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/31562236/pubmed" id="31562236" target="_blank">31562236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32976936">
<a name="32976936"></a>Lambertini M, Peccatori FA, Demeestere I, et al; ESMO Guidelines Committee. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. <i>Ann Oncol.</i> 2020;31(12):1664-1678. doi:10.1016/j.annonc.2020.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/32976936/pubmed" id="32976936" target="_blank">32976936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190991">
<a name="21190991"></a>Lamy T, Loughran TP Jr. How I treat LGL leukemia. <i>Blood</i>. 2011;117(10):2764-2774. doi:10.1182/blood-2010-07-296962<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21190991/pubmed" id="21190991" target="_blank">21190991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12727579">
<a name="12727579"></a>Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. <i>Am J Med</i>. 2003;114(6):463-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12727579/pubmed" id="12727579" target="_blank">12727579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7189691">
<a name="7189691"></a>Lankelma J, van der Klein E, Ramaekers F. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. <i>Cancer Lett</i>. 1980;9(2):133-142. doi:10.1016/0304-3835(80)90117-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/7189691/pubmed" id="7189691" target="_blank">7189691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27114587">
<a name="27114587"></a>Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232. <i>J Clin Oncol</i>. 2016;34(20):2380-2388.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27114587/pubmed" id="27114587" target="_blank">27114587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7718875">
<a name="7718875"></a>Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. <i>Blood</i>. 1995;85(8):2025-2037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/7718875/pubmed" id="7718875" target="_blank">7718875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17267204">
<a name="17267204"></a>Le Deley MC, Guinebretière JM, Gentet JC, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. <i>Eur J Cancer</i>. 2007;43(4):752-761.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17267204/pubmed" id="17267204" target="_blank">17267204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11600602">
<a name="11600602"></a>Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of Cancer and Leukemia Group B study 9251. <i>J Clin Oncol</i>. 2001;19(20):4014-4022. doi:10.1200/JCO.2001.19.20.4014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11600602/pubmed" id="11600602" target="_blank">11600602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22091553">
<a name="22091553"></a>Lee HY, Philippidou M, Marcus R, Walsh S, Creamer D. Sequential Stevens-Johnson syndrome and photo-recall phenomenon. <i>Br J Dermatol</i>. 2012;166(5):1145-1146. doi:10.1111/j.1365-2133.2011.10734.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22091553/pubmed" id="22091553" target="_blank">22091553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32170389">
<a name="32170389"></a>Lee JS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S. Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction. <i>Rheumatol Int</i>. 2020;40(5):765-770. doi:10.1007/s00296-020-04547-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/32170389/pubmed" id="32170389" target="_blank">32170389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19688702">
<a name="19688702"></a>Lee SL, Neskey D, Mouzakes J. Potential predisposition for nasal septal perforation with methotrexate use: report of 2 cases and literature review. <i>Ear Nose Throat J. </i>2009;88(8):E12-E14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19688702/pubmed" id="19688702" target="_blank">19688702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16336326">
<a name="16336326"></a>Lehmann J, Franzaring L, Thuroff J, et al. Complete long-term survival data from a trial of adjuvant chemotherapy vs. control after radical cystectomy for locally advanced bladder cancer. <i>BJU Int</i>. 2006;97(1):42-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16336326/pubmed" id="16336326" target="_blank">16336326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8025760">
<a name="8025760"></a>LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. <i>Am J Respir Crit Care Med</i>. 1994;150(1):258-260. doi:10.1164/ajrccm.150.1.8025760<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8025760/pubmed" id="8025760" target="_blank">8025760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28134073">
<a name="28134073"></a>Leon L, Rodriguez-Rodriguez L, Freites D, et al. Long-term continuation of methotrexate therapy in giant cell arteritis patients in clinical practice. <i>Clin Exp Rheumatol.</i> 2017;(35)(suppl 103):165-170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28134073/pubmed" id="28134073" target="_blank">28134073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9704715">
<a name="9704715"></a>Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.<i> J Clin Oncol</i>. 1998;16(8):2651-2658. doi:10.1200/JCO.1998.16.8.2651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/9704715/pubmed" id="9704715" target="_blank">9704715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29313888">
<a name="29313888"></a>Lewis FM, Tatnall FM, Velangi SS, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. <i>Br J Dermatol</i>. 2018;178(4):839-853. doi:10.1111/bjd.16241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/29313888/pubmed" id="29313888" target="_blank">29313888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22505322">
<a name="22505322"></a>Li SC, Torok KS, Pope E, et al. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. <i>Arthrit Care Res</i>. 2012;64(8):1175-1185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22505322/pubmed" id="22505322" target="_blank">22505322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. <i>Am J Gastroenterol</i>. 2018;113(4):481-517. doi:10.1038/ajg.2018.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26755510">
<a name="26755510"></a>Lichtman SM, Cirrincione CT, Hurria A, et al. Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: alliance A171201, an Ancillary Study of CALGB/CTSU 49907.<i> J Clin Oncol.</i> 2016;34(7):699-705. doi:10.1200/JCO.2015.62.6341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26755510/pubmed" id="26755510" target="_blank">26755510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15901903">
<a name="15901903"></a>Lim AY, Gaffney K, Scott DG. Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. <i>Rheumatology (Oxford)</i>. 2005;44(8):1051-1055. doi:10.1093/rheumatology/keh685<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15901903/pubmed" id="15901903" target="_blank">15901903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17455314">
<a name="17455314"></a>Lin WY, Liu HC, Yeh TC, Wang LY, Liang DC. Triple intrathecal therapy without cranial irradiation for central nervous system preventive therapy in childhood acute lymphoblastic leukemia. <i>Pediatr Blood Cancer</i>. 2008;50(3):523-527. doi:10.1002/pbc.21212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17455314/pubmed" id="17455314" target="_blank">17455314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12011123">
<a name="12011123"></a>Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 2002;20(10):2464-2471. doi:10.1200/JCO.2002.07.116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12011123/pubmed" id="12011123" target="_blank">12011123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32618745">
<a name="32618745"></a>Liu L, Ross WT, Chu AL, Deimling TA. An updated guide to the diagnosis and management of cesarean scar pregnancies. <i>Curr Opin Obstet Gynecol</i>. 2020;32(4):255-262. doi:10.1097/GCO.0000000000000644<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/32618745/pubmed" id="32618745" target="_blank">32618745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24892681">
<a name="24892681"></a>Liu YC, Tu YL, Wu RC, Huang JL, Yao TC. Life-threatening pneumonitis complicating low-dose methotrexate treatment for juvenile idiopathic arthritis in a child. <i>Pediatr Emerg Care</i>. 2014;30(6):415-417. doi:10.1097/PEC.0000000000000151<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24892681/pubmed" id="24892681" target="_blank">24892681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33090966">
<a name="33090966"></a>Lojo-Rocamonde SA, Bravo-López SB. Low-dose oral methotrexate-induced crystalluria. <i>Clin Chem Lab Med</i>. 2020;59(4):e165-e167. doi:10.1515/cclm-2020-1268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/33090966/pubmed" id="33090966" target="_blank">33090966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22948700">
<a name="22948700"></a>Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, “Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,” <i>JAMA</i>, 2012, 308(9): 898-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22948700/pubmed" id="22948700" target="_blank">22948700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7919331">
<a name="7919331"></a>Loughran TP Jr, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. <i>Blood</i>. 1994;84(7):2164-2170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/7919331/pubmed" id="7919331" target="_blank">7919331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25306898">
<a name="25306898"></a>Loughran TP Jr, Zickl L, Olson TL, e al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). <i>Leukemia</i>. 2015;29(4):886-894. doi:10.1038/leu.2014.298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25306898/pubmed" id="25306898" target="_blank">25306898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33684925">
<a name="33684925"></a>Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. <i>Blood</i>. 2021;137(26):3595-3603. doi:10.1182/blood.2020009806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/33684925/pubmed" id="33684925" target="_blank">33684925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31276602">
<a name="31276602"></a>Lucas CJ, Dimmitt SB, Martin JH. Optimising low-dose methotrexate for rheumatoid arthritis- a review. <i>Br J Clin Pharmacol.</i> 2019;85(10):2228-2234. doi:10.1111/bcp.14057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/31276602/pubmed" id="31276602" target="_blank">31276602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17086804">
<a name="17086804"></a>Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. <i>J Reprod Med</i>. 2006;51(10):767-772.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17086804/pubmed" id="17086804" target="_blank">17086804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15787807">
<a name="15787807"></a>MacDonald A, Burden AD. Noninvasive monitoring for methotrexate hepatotoxicity. <i>Br J Dermatol</i>. 2005;152(3):405-408. doi:10.1111/j.1365-2133.2005.06605.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15787807/pubmed" id="15787807" target="_blank">15787807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9602195">
<a name="9602195"></a>Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn’s disease after 6-mercaptopurine. <i>J Pediatr</i>. 1998;132:830-835.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/9602195/pubmed" id="9602195" target="_blank">9602195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31970405">
<a name="31970405"></a>Mackie SL, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology (Oxford)</i>. 2020;59(3):e1-e23. doi:10.1093/rheumatology/kez672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/31970405/pubmed" id="31970405" target="_blank">31970405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25445718">
<a name="25445718"></a>Magge RS, DeAngelis LM. The double-edged sword: Neurotoxicity of chemotherapy. <i>Blood Rev</i>. 2015;29(2):93-100. doi:10.1016/j.blre.2014.09.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25445718/pubmed" id="25445718" target="_blank">25445718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30948039">
<a name="30948039"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. <i>Am J Obstet Gynecol</i>. 2019;220(4):308-323. doi:10.1016/j.ajog.2019.02.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/30948039/pubmed" id="30948039" target="_blank">30948039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10715299">
<a name="10715299"></a>Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. <i>J Clin Oncol</i>. 2000;18(6):1285-1294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10715299/pubmed" id="10715299" target="_blank">10715299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17665429">
<a name="17665429"></a>Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. <i>Arthritis Rheum</i>. 2007;56(8):2789-2797. doi:10.1002/art.22754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17665429/pubmed" id="17665429" target="_blank">17665429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mandl.1">
<a name="Mandl.1"></a>Mandl LA, Nigrovic PA. Treatment of adult-onset Still's disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16609069">
<a name="16609069"></a>Matloub Y, Lindemulder S, Gaynon PS, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. <i>Blood</i>. 2006;108(4):1165-1173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16609069/pubmed" id="16609069" target="_blank">16609069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10607779">
<a name="10607779"></a>Matzkies FK, Tombach B, Dietrich M, et al. MVAC-therapy for advanced urothelial carcinoma in an anuric renal transplant recipient. <i>Nephrol Dial Transplant.</i> 2000;15(1):110-112. doi:10.1093/ndt/15.1.110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10607779/pubmed" id="10607779" target="_blank">10607779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24004183">
<a name="24004183"></a>May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND. High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. <i>Leuk Lymphoma</i>. 2014;55(6):1345-1349. doi:10.3109/10428194.2013.840780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24004183/pubmed" id="24004183" target="_blank">24004183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34235884">
<a name="34235884"></a>Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. <i>Arthritis Rheumatol</i>. 2021;73(8):1349-1365. doi:10.1002/art.41774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34235884/pubmed" id="34235884" target="_blank">34235884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26892661">
<a name="26892661"></a>Mazori DR, Wright NA, Patel M, et al. Characteristics and treatment of adult-onset linear morphea: a retrospective cohort study of 61 patients at 3 tertiary care centers. <i>J Am Acad Dermatol</i>. 2016;74(3):577-579. doi:10.1016/j.jaad.2015.09.069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26892661/pubmed" id="26892661" target="_blank">26892661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30341597">
<a name="30341597"></a>McGrath ER, Doughty CT, Amato AA. Autoimmune myopathies: updates on evaluation and treatment. <i>Neurotherapeutics</i>. 2018;15(4):976-994. doi:10.1007/s13311-018-00676-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/30341597/pubmed" id="30341597" target="_blank">30341597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19447771">
<a name="19447771"></a>McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?. <i>Rheumatology (Oxford)</i>. 2009;48(8):867-871. doi:10.1093/rheumatology/kep101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19447771/pubmed" id="19447771" target="_blank">19447771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18612102">
<a name="18612102"></a>Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 Trial). <i>Blood</i>. 2008;112(6):2248-2260.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18612102/pubmed" id="18612102" target="_blank">18612102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12181251">
<a name="12181251"></a>Mead GM, Sydes MR, Walewski J, et al. An International Evaluation of CODOX-M and CODOX-M Alternating With IVAC in Adult Burkitt's Lymphoma: Results of United Kingdom Lymphoma Group LY06 Study. <i>Ann Oncol</i>. 2002;13(8):1264-1274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12181251/pubmed" id="12181251" target="_blank">12181251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18094347">
<a name="18094347"></a>Mebazaa A, Kenani N, Denguezli M, et al. Methotrexate-induced papular eruption following treatment of psoriasis. <i>Ann Pharmacother</i>. 2008;42(1):138-141. doi:10.1345/aph.1K271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18094347/pubmed" id="18094347" target="_blank">18094347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32224144">
<a name="32224144"></a>Medina D, Estacio M, Rosales M, Manzi E. Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children. <i>Hematol Oncol Stem Cell Ther</i>. 2020;13(4):208-213. doi:10.1016/j.hemonc.2020.01.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/32224144/pubmed" id="32224144" target="_blank">32224144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34143362">
<a name="34143362"></a>Melani AS, Bigliazzi C, Cimmino FA, Bergantini L, Bargagli E. A comprehensive review of sarcoidosis treatment for pulmonologists. <i>Pulm Ther.</i> 2021;7(2):325-344. doi:10.1007/s41030-021-00160-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34143362/pubmed" id="34143362" target="_blank">34143362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32119894">
<a name="32119894"></a>Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>J Am Acad Dermatol.</i> 2020;82(6):1445-1486. doi:10.1016/j.jaad.2020.02.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/32119894/pubmed" id="32119894" target="_blank">32119894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27371354">
<a name="27371354"></a>Mergenthal MC, Senapati S, Zee J, et al. Medical management of ectopic pregnancy with single-dose and 2-dose methotrexate protocols: human chorionic gonadotropin trends and patient outcomes. <i>Am J Obstet Gynecol</i>. 2016;215(5):590.e1-590.e5. doi:10.1016/j.ajog.2016.06.040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27371354/pubmed" id="27371354" target="_blank">27371354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merkel.1">
<a name="Merkel.1"></a>Merkel PA. Treatment of Takayasu arteritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merkel.2">
<a name="Merkel.2"></a>Merkel PA, Kaplan AA, Falk RJ. Granulomatosis with polyangiitis and microscopic polyangiitis: induction and maintenance therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Methotrexate.1">
<a name="Methotrexate.1"></a>Methotrexate injection [prescribing information]. Durham, NC: Accord Healthcare Inc; March 2022.</div>
</li>
<li>
<div class="reference">
                  Methotrexate injection [prescribing information]. Eatontown, NJ: West Ward Pharmaceuticals; August 2019.</div>
</li>
<li>
<div class="reference">
                  Methotrexate injection [prescribing information]. Lake Forest, IL: Hospira Inc; June 2021.</div>
</li>
<li>
<div class="reference">
                  Methotrexate injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; May 2020.</div>
</li>
<li>
<div class="reference">
                  Methotrexate injection [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; June 2021.</div>
</li>
<li>
<div class="reference">
                  Methotrexate injection [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; July 2019.</div>
</li>
<li>
<div class="reference">
                  Methotrexate tablets [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; May 2020.</div>
</li>
<li>
<div class="reference">
                  Methotrexate tablets [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries; July 2020.</div>
</li>
<li>
<div class="reference">
                  Methotrexate tablets [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; May 2020.</div>
</li>
<li>
<div class="reference">
                  Methotrexate tablets [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; May 2018.</div>
</li>
<li>
<div class="reference">
                  Methotrexate tablets [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Methotrexate.12">
<a name="Methotrexate.12"></a>M-Methotrexate tablets, USP [product monograph]. Brossard, Quebec, Canada: Mantra Pharma Inc; February 2023.</div>
</li>
<li>
<div class="reference">
                  Methotrexate Sodium injection [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA Inc; June 2021.</div>
</li>
<li>
<div class="reference">
                  Methotrexate Sodium tablet [prescribing information]. Pulaski, TN: AvKare; September 2020.</div>
</li>
<li>
<div class="reference">
                  Metoject solution for injection (methotrexate sodium) [product monograph]. Bolton, Ontario, Canada: Medexus Inc; December 2019.</div>
</li>
<li>
<div class="reference">
                  Metoject Subcutaneous (methotrexate sodium) [product monograph]. Bolton, Ontario, Canada: Medexus Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15675136">
<a name="15675136"></a>Metzler C, Hellmich B, Gause A, Gross WL, de Groot K. Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment.<i> Clin Exp Rheumatol.</i> 2004;22(6)(suppl 36):S52-S61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15675136/pubmed" id="15675136" target="_blank">15675136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21220601">
<a name="21220601"></a>Meyers PA, Flombaum C. High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?. <i>J Clin Oncol</i>. 2011;29(7):e180-e181. doi:10.1200/JCO.2010.32.8245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21220601/pubmed" id="21220601" target="_blank">21220601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1370176">
<a name="1370176"></a>Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. <i>J Clin Oncol</i>. 1992;10(1):5-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/1370176/pubmed" id="1370176" target="_blank">1370176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15774791">
<a name="15774791"></a>Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. <i>J Clin Oncol</i>. 2005;23(9):2004-2011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15774791/pubmed" id="15774791" target="_blank">15774791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36705384">
<a name="36705384"></a>Miyata M, Ishiwata S, Kuroda M, Tasaki K, Migita K, Ohira H. Hepatic failure in a patient with rheumatoid arthritis treated with methotrexate: a case report. <i>Medicine (Baltimore)</i>. 2023;102(4):e32711. doi:10.1097/MD.0000000000032711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/36705384/pubmed" id="36705384" target="_blank">36705384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30997053">
<a name="30997053"></a>Montejo C, Navarro-Otano J, Mayà-Casalprim G, Campolo M, Casanova-Mollá J. Acute lumbar polyradiculoneuropathy as early sign of methotrexate intrathecal neurotoxicity: Case report and literature review. <i>Clin Case Rep</i>. 2019;7(4):638-643. doi:10.1002/ccr3.2026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/30997053/pubmed" id="30997053" target="_blank">30997053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, Ajithkumar T. Management of uncommon chemotherapy-induced emergencies. <i>Lancet Oncol</i>. 2011;12(8):806-814. doi:10.1016/S1470-2045(10)70208-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27128679">
<a name="27128679"></a>Mori S, Hidaka M, Kawakita T, et al. Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases. <i>PLoS One</i>. 2016;11(4):e0154744. doi:10.1371/journal.pone.0154744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27128679/pubmed" id="27128679" target="_blank">27128679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24101038">
<a name="24101038"></a>Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. <i>J Clin Oncol</i>. 2013;31(31):3971-3979. doi:10.1200/JCO.2013.50.4910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24101038/pubmed" id="24101038" target="_blank">24101038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18688259">
<a name="18688259"></a>Muñoz-Fernández S, García-Aparicio AM, Hidalgo MV, et al. Methotrexate: an option for preventing the recurrence of acute anterior uveitis. <i>Eye (Lond)</i>. 2009;23(5):1130-1133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18688259/pubmed" id="18688259" target="_blank">18688259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19339090">
<a name="19339090"></a>Murashima M, Adamski J, Milone MC, Shaw L, Tsai DE, Bloom RD. Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case report. <i>Am J Kidney Dis.</i> 2009;53(5):871-874. doi:10.1053/j.ajkd.2009.01.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19339090/pubmed" id="19339090" target="_blank">19339090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26055509">
<a name="26055509"></a>Murata KY, Maeba A, Yamanegi M, Nakanishi I, Ito H. Methotrexate myelopathy after intrathecal chemotherapy: a case report. <i>J Med Case Rep</i>. 2015;9:135. doi:10.1186/s13256-015-0597-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26055509/pubmed" id="26055509" target="_blank">26055509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Murrell.1">
<a name="Murrell.1"></a>Murrell DF, Ramirez-Quizon M. Management and prognosis of bullous pemphigoid. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22432089">
<a name="22432089"></a>Mutsando H, Fahim M, Gill DS, et al. High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease. <i>Am J Blood Res</i>. 2012;2(1):66-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22432089/pubmed" id="22432089" target="_blank">22432089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34473863">
<a name="34473863"></a>Muto R, Kawakita T, Miyoshi H, et al. The first case of methotrexate-associated lymphoproliferative disorder presenting as follicular T-cell lymphoma. <i>Pathol Int</i>. 2021;71(11):765-770. doi:10.1111/pin.13155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34473863/pubmed" id="34473863" target="_blank">34473863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10979948">
<a name="10979948"></a>Nash R, Antin J, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-vs-host disease after marrow transplantation from unrelated donors. <i>Blood</i>. 2000;96(6):2062-2068.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10979948/pubmed" id="10979948" target="_blank">10979948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17559377">
<a name="17559377"></a>Nathan DM, Iser JH, and Gibson PR. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. <i> Gastroenterol</i>, 2008;23(6):954-958.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17559377/pubmed" id="17559377" target="_blank">17559377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27868581">
<a name="27868581"></a>Neuss MN, Gilmore TR, Belderson KM, et al. 2016 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology. <i>J Oncol Pract</i>. 2016;12(12):1262-1271. doi:10.1200/JOP.2016.017905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27868581/pubmed" id="27868581" target="_blank">27868581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10673528">
<a name="10673528"></a>Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. <i>J Clin Oncol</i>. 2000;18(4):854-859. doi:10.1200/JCO.2000.18.4.854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10673528/pubmed" id="10673528" target="_blank">10673528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19077954">
<a name="19077954"></a>Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. <i>J Clin Rheumatol.</i> 1995;1(2):99-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19077954/pubmed" id="19077954" target="_blank">19077954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31295228">
<a name="31295228"></a>Oarbeascoa G, Rodriguez-Macias G, Guzman-de-Villoria JA, et al. Methotrexate-induced subacute neurotoxicity surrounding an ommaya reservoir in a patient with lymphoma. <i>Am J Case Rep</i>. 2019;20:1002-1005. doi:10.12659/AJCR.915632<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/31295228/pubmed" id="31295228" target="_blank">31295228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27098592">
<a name="27098592"></a>Oddis CV. Update on the pharmacological treatment of adult myositis. <i>J Intern Med</i>. 2016;280(1):63-74. doi:10.1111/joim.12511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27098592/pubmed" id="27098592" target="_blank">27098592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12761601">
<a name="12761601"></a>Oka M, Terae S, Kobayashi R, et al. MRI in methotrexate-related leukoencephalopathy: Disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. <i>Neuroradiology</i>. 2003;45(7):493-497. doi:10.1007/s00234-003-0983-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12761601/pubmed" id="12761601" target="_blank">12761601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25568347">
<a name="25568347"></a>Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. <i>Blood</i>. 2015;125(9):1403-1410. doi:10.1182/blood-2014-10-604561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25568347/pubmed" id="25568347" target="_blank">25568347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234524">
<a name="16234524"></a>Ortega JJ, Madero L, Martín G, et al; PETHEMA Group. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. <i>J Clin Oncol</i>. 2005;23(30):7632-7640.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16234524/pubmed" id="16234524" target="_blank">16234524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2940870">
<a name="2940870"></a>Ory SJ, Villanueva AL, Sand PK, Tamura RK. Conservative treatment of ectopic pregnancy with methotrexate. <i>Am J Obstet Gynecol</i>. 1986;154(6):1299-1306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/2940870/pubmed" id="2940870" target="_blank">2940870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34238226">
<a name="34238226"></a>Osaki Y, Kawaratani H, Kachi H, et al. Small intestinal follicular lymphoma induced by methotrexate: a case report. <i>BMC Gastroenterol</i>. 2021;21(1):280. doi:10.1186/s12876-021-01849-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34238226/pubmed" id="34238226" target="_blank">34238226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12810441">
<a name="12810441"></a>Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. <i>Ann Rheum Dis</i>. 2003;62(7):686-687. doi:10.1136/ard.62.7.686<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12810441/pubmed" id="12810441" target="_blank">12810441</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Otrexup (methotrexate injection) [prescribing information]. Ewing, NJ: Antares Pharma Inc; December 2019.</div>
</li>
<li>
<div class="reference">
                  Otrexup PFS (methotrexate injection) [prescribing information]. Ewing, NJ: Antares Pharma Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30805487">
<a name="30805487"></a>Özdemir ZC, Bozkurt Turhan A, Düzenli Kar Y, Bör Ö. The frequency of hepatotoxicity and myelotoxicity in leukemic children with different high doses of methotrexate. <i>Int J Pediatr Adolesc Med</i>. 2016;3(4):162-168. doi:10.1016/j.ijpam.2016.08.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/30805487/pubmed" id="30805487" target="_blank">30805487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19109574">
<a name="19109574"></a>Pagnoux C, Mahr A, Hamidou MA, et al; French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. <i>N Engl J Med</i>. 2008;359(26):2790-2803. doi:10.1056/NEJMoa0802311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19109574/pubmed" id="19109574" target="_blank">19109574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23737767">
<a name="23737767"></a>Patanè M, Ciriaco M, Chimirri S, et al. Interactions among low dose of methotrexate and drugs used in the treatment of rheumatoid arthritis. <i>Adv Pharmacol Sci</i>. 2013;2013:313858. doi:10.1155/2013/313858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23737767/pubmed" id="23737767" target="_blank">23737767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12222551">
<a name="12222551"></a>Patatanian E, Thompson DF. A review of methotrexate-induced accelerated nodulosis. <i>Pharmacotherapy</i>. 2002;22(9):1157-1162. doi:10.1592/phco.22.13.1157.33525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12222551/pubmed" id="12222551" target="_blank">12222551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26508914">
<a name="26508914"></a>Patel N, Singh D, Patel K, Ahmed S, Anand P. Atypical presentation of disseminated zoster in a patient with rheumatoid arthritis. <i>Case Rep Med</i>. 2015;2015:124840. doi:10.1155/2015/124840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26508914/pubmed" id="26508914" target="_blank">26508914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25157445">
<a name="25157445"></a>Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn's disease. <i>Cochrane Database Syst Rev</i>. 2014;(8):CD006884. doi:10.1002/14651858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25157445/pubmed" id="25157445" target="_blank">25157445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24108504">
<a name="24108504"></a>Patil P, Parker RA, Rawcliffe C, et al. Methotrexate-induced nausea and vomiting in adolescent and young adult patients. <i>Clin Rheumatol</i>. 2014;33(3):403-407. doi:10.1007/s10067-013-2389-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24108504/pubmed" id="24108504" target="_blank">24108504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8089289">
<a name="8089289"></a>Paul MA, Jorizzo JL, Fleischer AB Jr, White WL. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. <i>J Am Acad Dermatol</i>. 1994;31(4):620-625. doi:10.1016/s0190-9622(94)70227-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8089289/pubmed" id="8089289" target="_blank">8089289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27942481">
<a name="27942481"></a>Pavlidou E, Pavlou E, Anastasiou A, et al. Posterior reversible encephalopathy syndrome after intrathecal methotrexate infusion: a case report and literature update. <i>Quant Imaging Med Surg</i>. 2016;6(5):605-611. doi:10.21037/qims.2016.10.07<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27942481/pubmed" id="27942481" target="_blank">27942481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi:10.1002/pbc.27646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16365690">
<a name="16365690"></a>Pay S, Türkçapar N, Kalyoncu M, et al; Ankara Rheumatology Study Group. A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis. <i>Clin Rheumatol.</i> 2006;25(5):639-644. doi:10.1007/s10067-005-0138-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16365690/pubmed" id="16365690" target="_blank">16365690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26024041">
<a name="26024041"></a>Pazhayattil GS, Brewster UC, Perazella MA. A case of crystalline nephropathy. <i>Kidney Int</i>. 2015;87(6):1265-1266. doi:10.1038/ki.2014.317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26024041/pubmed" id="26024041" target="_blank">26024041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21146122">
<a name="21146122"></a>Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. <i>Semin Nephrol</i>. 2010;30(6):570-581. doi:10.1016/j.semnephrol.2010.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21146122/pubmed" id="21146122" target="_blank">21146122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17658395">
<a name="17658395"></a>Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. <i>Lancet</i>. 2007;370(9583):240-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17658395/pubmed" id="17658395" target="_blank">17658395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23199900">
<a name="23199900"></a>Pistilli B, Bellettini G, Giovannetti E, et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding? <i>Cancer Treat Rev</i>. 2013;39(3):207-211. doi:10.1016/j.ctrv.2012.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23199900/pubmed" id="23199900" target="_blank">23199900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24821881">
<a name="24821881"></a>Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.<i> J Clin Oncol. </i>2014;32(18):1895-1901. doi:10.1200/JCO.2013.53.2465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24821881/pubmed" id="24821881" target="_blank">24821881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33453378">
<a name="33453378"></a>Po L, Thomas J, Mills K, et al Guideline no. 414: Management of pregnancy of unknown location and tubal and nontubal ectopic pregnancies. <i>J Obstet Gynaecol Can</i>. 2021:S1701-S2163(21)00016-5. doi:10.1016/j.jogc.2021.01.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/33453378/pubmed" id="33453378" target="_blank">33453378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36739322">
<a name="36739322"></a>Polesie S, Gillstedt M, Schmidt SAJ, Egeberg A, Pottegård A, Kristensen K. Use of methotrexate and risk of skin cancer: a nationwide case-control study. <i>Br J Cancer</i>. 2023;128(7):1311-1319. doi:10.1038/s41416-023-02172-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/36739322/pubmed" id="36739322" target="_blank">36739322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14597741">
<a name="14597741"></a>Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al; European Organization for Research and Treatment of Cancer Lymphoma Group. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. <i>J Clin Oncol</i>. 2003;21(24):4483-4488. doi:10.1200/JCO.2003.03.108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/14597741/pubmed" id="14597741" target="_blank">14597741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11407694">
<a name="11407694"></a>Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. <i>Arthritis Rheum</i>. 2001;44(6):1351-1358.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11407694/pubmed" id="11407694" target="_blank">11407694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20705755">
<a name="20705755"></a>Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i>. 2010;116(19):3751-3757. doi:10.1182/blood-2010-02-269621<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/20705755/pubmed" id="20705755" target="_blank">20705755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9146556">
<a name="9146556"></a>Primka EJ 3rd, Camisa C. Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis. <i>J Am Acad Dermatol</i>. 1997;36(5 pt 2):815-818. doi:10.1016/s0190-9622(97)70029-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/9146556/pubmed" id="9146556" target="_blank">9146556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28600132">
<a name="28600132"></a>Prince HM, Kim YH, Horwitz SM, et al; ALCANZA Study Group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet</i>. 2017;390(10094):555-566. doi:10.1016/S0140-6736(17)31266-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28600132/pubmed" id="28600132" target="_blank">28600132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21569069">
<a name="21569069"></a>Pugi A, Benemei S, Vietri M, et al. Anaphylaxis during the first course of high-dose methotrexate: a case report and literature review. <i>J Clin Pharm Ther</i>. 2012;37(2):245-248. doi:10.1111/j.1365-2710.2011.01275.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21569069/pubmed" id="21569069" target="_blank">21569069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28543445">
<a name="28543445"></a>Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. <i>Australas J Dermatol</i>. 2018;59(2):86-100. doi:10.1111/ajd.12641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28543445/pubmed" id="28543445" target="_blank">28543445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32198218">
<a name="32198218"></a>Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. <i>Eur Respir Rev.</i> 2020;29(155):190146. doi:10.1183/16000617.0146-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/32198218/pubmed" id="32198218" target="_blank">32198218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16255046">
<a name="16255046"></a>Ramanan AV, Campbell-Webster N, Ota S, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. <i>Arthritis Rheum</i>. 2005;52(11):3570-3578.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16255046/pubmed" id="16255046" target="_blank">16255046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29641725">
<a name="29641725"></a>Rampon G, Henkin C, Jorge VM, Almeida HL Jr. Methotrexate-induced mucositis with extra-mucosal involvement after accidental overdose. <i>An Bras Dermatol</i>. 2018;93(1):155-156. doi:10.1590/abd1806-4841.20186687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/29641725/pubmed" id="29641725" target="_blank">29641725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21597286">
<a name="21597286"></a>Ranchon F, Vantard N, Gouraud A, et al. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed? <i>Chemotherapy</i>. 2011;57(3):225-229. doi:10.1159/000327372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21597286/pubmed" id="21597286" target="_blank">21597286</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Rasuvo (methotrexate) [prescribing information]. Chicago, IL: Medexus Pharma Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RediTrex.1">
<a name="RediTrex.1"></a>RediTrex (methotrexate) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10552938">
<a name="10552938"></a>Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. <i>Blood</i>. 1999;94(10):3294-3306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10552938/pubmed" id="10552938" target="_blank">10552938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31021516">
<a name="31021516"></a>Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. <i>Arthritis Care Res (Hoboken)</i>. 2019;71(6):717-734. doi:10.1002/acr.23870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/31021516/pubmed" id="31021516" target="_blank">31021516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24339215">
<a name="24339215"></a>Ringold S, Weiss PF, Colbert RA, et al. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2014;66(7):1063-1072. doi:10.1002/acr.22259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24339215/pubmed" id="24339215" target="_blank">24339215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15042678">
<a name="15042678"></a>Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. <i>Cancer</i>. 2004;100(7):1438-1448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15042678/pubmed" id="15042678" target="_blank">15042678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6693915">
<a name="6693915"></a>Robain O, Dulac O, Dommergues JP, et al. Necrotising leukoencephalopathy complicating treatment of childhood leukaemia. <i>J Neurol Neurosurg Psychiatry</i>. 1984;47(1):65-72. doi:10.1136/jnnp.47.1.65<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/6693915/pubmed" id="6693915" target="_blank">6693915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):S119-S133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15569732">
<a name="15569732"></a>Rollins N, Winick N, Bash R, Booth T. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. <i>AJNR Am J Neuroradiol</i>. 2004;25(10):1688-1695.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15569732/pubmed" id="15569732" target="_blank">15569732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16145068">
<a name="16145068"></a>Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. <i>J Clin Oncol</i>. 2005;23(28):7013-7023. doi:10.1200/JCO.2005.01.1825<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16145068/pubmed" id="16145068" target="_blank">16145068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17399848">
<a name="17399848"></a>Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. <i>J Hepatol</i>. 2007;46(6):1111-1118. doi:10.1016/j.jhep.2007.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17399848/pubmed" id="17399848" target="_blank">17399848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10534058">
<a name="10534058"></a>Ross M, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs-host disease: effect on chronic graft-vs-host disease and long-term survival. <i>Biol Blood Marrow Transplant.</i> 1999;5(5):285-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10534058/pubmed" id="10534058" target="_blank">10534058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30852832">
<a name="30852832"></a>Rossi DC, Ribi C, Guex-Crosier Y. Treatment of chronic non-infectious uveitis and scleritis. <i>Swiss Med Wkly.</i> 2019;149:w20025. doi:10.4414/smw.2019.20025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/30852832/pubmed" id="30852832" target="_blank">30852832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23569323">
<a name="23569323"></a>Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). <i>J Clin Oncol.</i> 2013;31(25):3061-3068. doi:10.1200/JCO.2012.46.9957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23569323/pubmed" id="23569323" target="_blank">23569323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9697870">
<a name="9697870"></a>Rubnitz JE, Relling MV, Harrison PL, et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. <i>Leukemia</i>. 1998;12(8):1176-1181. doi:10.1038/sj.leu.2401098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/9697870/pubmed" id="9697870" target="_blank">9697870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22516861">
<a name="22516861"></a>Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55(1):93-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22516861/pubmed" id="22516861" target="_blank">22516861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33280011">
<a name="33280011"></a>Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. <i>Rheumatology (Oxford).</i> 2020;59(suppl 5):v69-v81. doi:10.1093/rheumatology/keaa403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/33280011/pubmed" id="33280011" target="_blank">33280011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26645190">
<a name="26645190"></a>Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. <i>Lancet</i>. 2016;387(10019):671-678.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26645190/pubmed" id="26645190" target="_blank">26645190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23892326">
<a name="23892326"></a>Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN Working Group recommendations for a standardized practice. <i>Bone Marrow Transplant</i>. 2013;49(2):168-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23892326/pubmed" id="23892326" target="_blank">23892326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18512708">
<a name="18512708"></a>Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Arthritis Rheum</i>. 2008;59(6):762-784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18512708/pubmed" id="18512708" target="_blank">18512708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34642767">
<a name="34642767"></a>Sadoghi B, Kränke B, Cerroni L, Weger W. Unusual cutaneous reaction at site of methotrexate injection in two patients with psoriasis and psoriatic arthritis. <i>Acta Derm Venereol</i>. 2021;101(11):adv00593. doi:10.2340/actadv.v101.352<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34642767/pubmed" id="34642767" target="_blank">34642767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33168010">
<a name="33168010"></a>Salari N, Kazeminia M, Shohaimi S, Nankali AA, Mohammadi M. Evaluation of treatment of previous cesarean scar pregnancy with methotrexate: a systematic review and meta-analysis. <i>Reprod Biol Endocrinol</i>. 2020;18(1):108. doi:10.1186/s12958-020-00666-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/33168010/pubmed" id="33168010" target="_blank">33168010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28655345">
<a name="28655345"></a>Salehi M, Miller R, Khaing M. Methotrexate-induced hypersensitivity pneumonitis appearing after 30 years of use: a case report. <i>J Med Case Rep</i>. 2017;11(1):174. doi:10.1186/s13256-017-1333-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28655345/pubmed" id="28655345" target="_blank">28655345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19060002">
<a name="19060002"></a>Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. <i>Ann Rheum Dis</i>. 2009;68(7):1100-1104. doi:10.1136/ard.2008.093690<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19060002/pubmed" id="19060002" target="_blank">19060002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Salvarani.1">
<a name="Salvarani.1"></a>Salvarani C, Muratore F. Treatment of giant cell arteritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26955111">
<a name="26955111"></a>Sancheti K, Podder I, Gharami RC. Toxic epidermal necrolysis like reaction due to low-dose methotrexate in a case of cutaneous lupus erythematosus: a rare occurrence. <i>Indian J Dermatol</i>. 2016;61(1):102-104. doi:10.4103/0019-5154.174052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26955111/pubmed" id="26955111" target="_blank">26955111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20081543">
<a name="20081543"></a>Sandhu BK, Fell JME, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. <i>JPGN</i>. 2010;50:S1-S13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/20081543/pubmed" id="20081543" target="_blank">20081543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14561622">
<a name="14561622"></a>Sandoval C, Kutscher M, Jayabose S, Tenner M. Neurotoxicity of intrathecal methotrexate: MR imaging findings. <i>AJNR Am J Neuroradiol</i>. 2003;24(9):1887-1890.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/14561622/pubmed" id="14561622" target="_blank">14561622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20944174">
<a name="20944174"></a>Santucci R, Levêque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. <i>Anticancer Res</i>. 2010;30(9):3807-3810.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/20944174/pubmed" id="20944174" target="_blank">20944174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14576047">
<a name="14576047"></a>Sanz MA, Martín G, González M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-<i>trans</i>-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA Group. <i>Blood.</i> 2004;103(4):1237-1243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/14576047/pubmed" id="14576047" target="_blank">14576047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12923285">
<a name="12923285"></a>Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. <i>Rheumatology (Oxford)</i>. 2004;43(2):143-147. doi:10.1093/rheumatology/keg466<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12923285/pubmed" id="12923285" target="_blank">12923285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2444463">
<a name="2444463"></a>Sauer MV, Gorrill MJ, Rodi IA, et al. Nonsurgical management of unruptured ectopic pregnancy: an extended clinical trial. <i>Fertil Steril</i>. 1987;48(5):752-755.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/2444463/pubmed" id="2444463" target="_blank">2444463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19467968">
<a name="19467968"></a>Sawada Y, Kawakami C, Nakamura M, Tokura Y, Yoshiki R. Toxic epidermal necrosis-like dermatosis induced by the first course of methotrexate. <i>Eur J Dermatol</i>. 2009;19(4):397-398. doi:10.1684/ejd.2009.0690<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19467968/pubmed" id="19467968" target="_blank">19467968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3479687">
<a name="3479687"></a>Schleuning M, Clemm C. Chromosomal aberrations in a newborn whose mother received cytotoxic treatment during pregnancy. <i>N Engl J Med</i>. 1987;317(26):1666-1667.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/3479687/pubmed" id="3479687" target="_blank">3479687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24470205">
<a name="24470205"></a>Schmajuk G, Miao Y, Yazdany J, Boscardin WJ, Daikh DI, Steinman MA. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. <i>Arthritis Care Res (Hoboken)</i>. 2014;66(8):1159-1166. doi:10.1002/acr.22294<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24470205/pubmed" id="24470205" target="_blank">24470205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19538530">
<a name="19538530"></a>Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. <i>Br J Haematol</i>. 2009;146(5):489-503. doi:10.1111/j.1365-2141.2009.07765.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19538530/pubmed" id="19538530" target="_blank">19538530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7939138">
<a name="7939138"></a>Schnabel A, Reinhold-Keller E, Willmann V, Gross WL. Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. <i>Rheumatol Int</i>. 1994;14(1):33-38. doi:10.1007/BF00302669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/7939138/pubmed" id="7939138" target="_blank">7939138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21514637">
<a name="21514637"></a>Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. <i>J Allergy Clin Immunol.</i> 2011;128(2):353-359. doi:10.1016/j.jaci.2011.03.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21514637/pubmed" id="21514637" target="_blank">21514637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10828010">
<a name="10828010"></a>Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. <i>Blood</i>. 2000;95(11):3310-3322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10828010/pubmed" id="10828010" target="_blank">10828010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20089389">
<a name="20089389"></a>Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. <i>Respir Med</i>. 2010;104(5):717-723. doi:10.1016/j.rmed.2009.12.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/20089389/pubmed" id="20089389" target="_blank">20089389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18055849">
<a name="18055849"></a>Schwartz S, Borner K, Muller K, et al, “Glucarpidase (Carboxypeptidase G2) Intervention in Adult and Elderly Cancer Patients With Renal Dysfunction and Delayed Methotrexate Elimination After High-Dose Methotrexate Therapy,” <i>Oncologist</i>, 2007 12(11):1299-308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18055849/pubmed" id="18055849" target="_blank">18055849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449130">
<a name="16449130"></a>Seeber BE and Barnhart KT, “Suspected Ectopic Pregnancy,” <i>Obstet Gynecol</i>, 2006, 107(2 Pt 1):399-413.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16449130/pubmed" id="16449130" target="_blank">16449130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18039957">
<a name="18039957"></a>Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i>. 2008;111(5):2548-2555.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18039957/pubmed" id="18039957" target="_blank">18039957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9704833">
<a name="9704833"></a>Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Low-dose methotrexate in the treatment of widespread morphea. <i>J Am Acad Dermatol</i>. 1998;39(2, pt 1):220-225. doi:10.1016/s0190-9622(98)70079-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/9704833/pubmed" id="9704833" target="_blank">9704833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33409982">
<a name="33409982"></a>Shafie M, Abbaszadeh M, Sharifi F. Hyperpigmentation, severe alopecia, and six days of instability in a case of severe methotrexate hypersensitivity reaction. <i>Daru</i>. 2021;29(1):205-209. doi:10.1007/s40199-020-00379-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/33409982/pubmed" id="33409982" target="_blank">33409982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17947720">
<a name="17947720"></a>Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. <i>J Clin Oncol</i>. 2007;25(30):4730-4735.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17947720/pubmed" id="17947720" target="_blank">17947720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36443884">
<a name="36443884"></a>Shah S, Haeger-Overstreet K, Flynn B. Methotrexate-induced acute cardiotoxicity requiring veno-arterial extracorporeal membrane oxygenation support: a case report. <i>J Med Case Rep</i>. 2022;16(1):447. doi:10.1186/s13256-022-03644-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/36443884/pubmed" id="36443884" target="_blank">36443884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10576662">
<a name="10576662"></a>Sharma S, Jagdev S, Coleman RE, Hancock BW, Lorigan PC. Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. <i>Br J Cancer</i>. 1999;81(6):1037-1041. doi:10.1038/sj.bjc.6690804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/10576662/pubmed" id="10576662" target="_blank">10576662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35078225">
<a name="35078225"></a>Sherbini AA, Gwinnutt JM, Hyrich KL; RAMS Co-Investigators, Verstappen SMM. Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. <i>Rheumatology (Oxford)</i>. 2022;keab917. doi:10.1093/rheumatology/keab917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/35078225/pubmed" id="35078225" target="_blank">35078225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shiratori.2019">
<a name="Shiratori.2019"></a>Shiratori S, Takahashi S, Miyashita N, et al. GVHD prophylaxis using tacrolimus and mini-dose methotrexate improves engraftment and reduces mortality in cord blood transplantation. Abstracts. <i>Biol Blood Marrow Transplant.</i> 2019;25(suppl):S212-S213.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25046458">
<a name="25046458"></a>Shiver MB, Hall LA, Conner KB, Brown GE, Cheung WL, Wirges ML. Cutaneous erosions: a herald for impending pancytopenia in methotrexate toxicity. <i>Dermatol Online J</i>. 2014;20(7):13030/qt46k975h8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25046458/pubmed" id="25046458" target="_blank">25046458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24813298">
<a name="24813298"></a>Sidbury R, Davis DM, Cohen DE, et al; American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. <i>J Am Acad Dermatol.</i> 2014;71(2):327-349. doi:10.1016/j.jaad.2014.03.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24813298/pubmed" id="24813298" target="_blank">24813298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553975">
<a name="20553975"></a>Simonini G, Cantarini L, Bresci C, Lorusso M, Galeazzi M, Cimaz R. Current therapeutic approaches to autoimmune chronic uveitis in children. <i>Autoimmun Rev</i>. 2010;9(10):674-683.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/20553975/pubmed" id="20553975" target="_blank">20553975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22879466">
<a name="22879466"></a>Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. <i>Rheumatol</i>. 2013;52:825-831.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22879466/pubmed" id="22879466" target="_blank">22879466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2004324">
<a name="2004324"></a>Simmons ED, Somberg KA. Acute tumor lysis syndrome after intrathecal methotrexate administration. <i>Cancer</i>. 1991;67(8):2062-2065. doi:10.1002/1097-0142(19910415)67:8&lt;2062::aid-cncr2820670809&gt;3.0.co;2-u<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/2004324/pubmed" id="2004324" target="_blank">2004324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36810186">
<a name="36810186"></a>Singh D, Hesse N, Skapenko A, Schulze-Koops H. A rare side effect of methotrexate therapy: drug-induced osteopathy with multiple fractures of the lower limb. <i>RMD Open</i>. 2023;9(1):e002982. doi:10.1136/rmdopen-2023-002982<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/36810186/pubmed" id="36810186" target="_blank">36810186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26545940">
<a name="26545940"></a>Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Rheumatol</i>. 2016;68(1):1-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26545940/pubmed" id="26545940" target="_blank">26545940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28264816">
<a name="28264816"></a>Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Ann Rheum Dis</i>. 2017;76(6):960-977. doi:10.1136/annrheumdis-2016-210715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28264816/pubmed" id="28264816" target="_blank">28264816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31972162">
<a name="31972162"></a>Society for Maternal-Fetal Medicine (SMFM). Electronic address: <a class="__cf_email__" data-cfemail="4f3f3a2d3c0f3c22292261203d28" href="/cdn-cgi/l/email-protection">[email protected]</a>, Miller R, Timor-Tritsch IE, Gyamfi-Bannerman C. Society for Maternal-Fetal Medicine (SMFM) consult series #49: cesarean scar pregnancy. <i>Am J Obstet Gynecol</i>. 2020;222(5):B2-B14. doi:10.1016/j.ajog.2020.01.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/31972162/pubmed" id="31972162" target="_blank">31972162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32066146">
<a name="32066146"></a>Solomon DH, Glynn RJ, Karlson EW, et al. Adverse effects of low-dose methotrexate: a randomized trial. <i>Ann Intern Med</i>. 2020;172(6):369-380. doi:10.7326/M19-3369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/32066146/pubmed" id="32066146" target="_blank">32066146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26701971">
<a name="26701971"></a>Song T, Kim MK, Kim ML, Jung YW, Yun BS, Seong SJ. Single-dose versus two-dose administration of methotrexate for the treatment of ectopic pregnancy: a randomized controlled trial. <i>Hum Reprod</i>. 2016;31(2):332-338. doi:10.1093/humrep/dev312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26701971/pubmed" id="26701971" target="_blank">26701971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15330370">
<a name="15330370"></a>Sonis ST. A biological approach to mucositis. <i>J Support Oncol</i>. 2004;2(1):21-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15330370/pubmed" id="15330370" target="_blank">15330370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12560282">
<a name="12560282"></a>Sosin M, Handa S. Low dose methotrexate and bone marrow suppression. <i>BMJ</i>. 2003;326(7383):266-267. doi:10.1136/bmj.326.7383.266<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12560282/pubmed" id="12560282" target="_blank">12560282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21044455">
<a name="21044455"></a>Spies CM, Burmester GR, Buttgereit F. Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica. <i>Clin Exp Rheumatol</i>. 2010;28(5)(suppl 61):S172-S177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21044455/pubmed" id="21044455" target="_blank">21044455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11352955">
<a name="11352955"></a>Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. <i>J Clin Oncol.</i> 2001;19(10):2638-2646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11352955/pubmed" id="11352955" target="_blank">11352955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16330205">
<a name="16330205"></a>Sternberg CN, de Mulder P, Schornagel JH, et al; EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. <i>Eur J Cancer</i>. 2006;42(1):50-54. doi:10.1016/j.ejca.2005.08.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16330205/pubmed" id="16330205" target="_blank">16330205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19289630">
<a name="19289630"></a>Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. <i>J Clin Oncol</i>. 2009;27(11):1864-1871.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19289630/pubmed" id="19289630" target="_blank">19289630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8317518">
<a name="8317518"></a>Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. <i>Am J Obstet Gynecol</i>. 1993;168(6, pt 1):1759-1762; discussion 1762-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8317518/pubmed" id="8317518" target="_blank">8317518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2784113">
<a name="2784113"></a>Stovall TG, Ling FW, Buster JE. Outpatient chemotherapy of unruptured ectopic pregnancy. <i>Fertil Steril</i>. 1989;51(3):435-438.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/2784113/pubmed" id="2784113" target="_blank">2784113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2014091">
<a name="2014091"></a>Stovall TG, Ling FW, Gray LA. Single-dose methotrexate for treatment of ectopic pregnancy. <i>Obstet Gynecol</i>. 1991;77(5):754-757.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/2014091/pubmed" id="2014091" target="_blank">2014091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15520148">
<a name="15520148"></a>Strang A, Pullar T. Methotrexate toxicity induced by acute renal failure. <i>J R Soc Med</i>. 2004;97(11):536-537. doi:10.1258/jrsm.97.11.536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15520148/pubmed" id="15520148" target="_blank">15520148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15229018">
<a name="15229018"></a>Stubblefield PG, Carr-Ellis S, Borgatta L. Methods for induced abortion. <i>Obstet Gynecol</i>. 2004;104(1):174-185. doi:10.1097/01.AOG.0000130842.21897.53<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15229018/pubmed" id="15229018" target="_blank">15229018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19076159">
<a name="19076159"></a>Suzuki K, Doki K, Homma M, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. <i>Br J Clin Pharmacol</i>. 2009;67(1):44-49. doi:10.1111/j.1365-2125.2008.03303.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19076159/pubmed" id="19076159" target="_blank">19076159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19475580">
<a name="19475580"></a>Tanaka T, Walsh W, Verjee Z et al. Methotrexate use in a lactating woman with an ectopic pregnancy. Abstracts of the 49th Annual Meeting of the Teratology Society, 2009, Rio Grande, Puerto Rico. <i>Birth Defects Res A Clin Mol Teratol.</i> 2009; 85(5):494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19475580/pubmed" id="19475580" target="_blank">19475580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.2019">
<a name="Miller.2019"></a>Targoff IN. Initial treatment of dermatomyositis and polymyositis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23615343">
<a name="23615343"></a>Taylor SR, Banker A, Schlaen A, et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. <i>Retina</i>. 2013;33(10):2149-2154. doi:10.1097/IAE.0b013e31828ac07d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23615343/pubmed" id="23615343" target="_blank">23615343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17304378">
<a name="17304378"></a>Teh HS, Fadilah SA, Leong CF. Transverse myelopathy following intrathecal administration of chemotherapy. <i>Singapore Med J</i>. 2007;48(2):e46-e49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17304378/pubmed" id="17304378" target="_blank">17304378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33518561">
<a name="33518561"></a>Teshima K, Kume M, Kondo R, et al. Methotrexate-induced transient encephalopathy in an adolescent and young adult patient with acute lymphoblastic leukemia. <i>Intern Med</i>. 2021;60(13):2115-2118. doi:10.2169/internalmedicine.5937-20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/33518561/pubmed" id="33518561" target="_blank">33518561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24267474">
<a name="24267474"></a>Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. <i>Gastroenterology</i>. 2013;145(6):1459-1463.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/24267474/pubmed" id="24267474" target="_blank">24267474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33268456">
<a name="33268456"></a>Thillai M, Atkins CP, Crawshaw A, et al. BTS clinical statement on pulmonary sarcoidosis. <i>Thorax</i>. 2021;76(1):4-20. doi:10.1136/thoraxjnl-2019-214348<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/33268456/pubmed" id="33268456" target="_blank">33268456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16502413">
<a name="16502413"></a>Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i>. 2006;106(7):1569-1580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16502413/pubmed" id="16502413" target="_blank">16502413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25362724">
<a name="25362724"></a>Thorne JC, Nadarajah T, Moretti M, Ito S. Methotrexate use in a breastfeeding patient with rheumatoid arthritis. <i>J Rheumatol</i>. 2014;41(11):2332. doi:10.3899/jrheum.140263<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25362724/pubmed" id="25362724" target="_blank">25362724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34692291">
<a name="34692291"></a>Tiewsoh I, Dey B, Chhangte M, Lyngdoh M, Sathees V. Methotrexate-induced septicemia with severe pancytopenia and diffuse cutaneous ulcerative lesions. <i>Cureus</i>. 2021;13(9):e18069. doi:10.7759/cureus.18069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/34692291/pubmed" id="34692291" target="_blank">34692291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17163236">
<a name="17163236"></a>Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. <i>Clin Drug Investig</i>. 2006;26(2):55-62. doi:10.2165/00044011-200626020-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17163236/pubmed" id="17163236" target="_blank">17163236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28565788">
<a name="28565788"></a>Tomizawa M, Shinozaki F, Hasegawa R, et al. Immunosuppressive agents are associated with peptic ulcer bleeding. <i>Exp Ther Med</i>. 2017;13(5):1927-1931. doi:10.3892/etm.2017.4214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/28565788/pubmed" id="28565788" target="_blank">28565788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26494588">
<a name="26494588"></a>Toquet S, Nguyen Y, Sabbagh A, Djerada Z, Boulagnon C, Bani-Sadr F. Severe apoptotic enteropathy caused by methotrexate treatment for rheumatoid arthritis. <i>Joint Bone Spine</i>. 2016;83(2):217-219. doi:10.1016/j.jbspin.2015.08.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26494588/pubmed" id="26494588" target="_blank">26494588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8697606">
<a name="8697606"></a>Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. <i>Clin Chem. </i> 1996;42(8, pt 2):1322-1329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8697606/pubmed" id="8697606" target="_blank">8697606</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Trexall (methotrexate) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23601229">
<a name="23601229"></a>Troeltzsch M, von Blohn G, Kriegelstein S, et al. Oral mucositis in patients receiving low-dose methotrexate therapy for rheumatoid arthritis: report of 2 cases and literature review. <i>Oral Pathol Oral Radiol</i>. 2013;115(5):e28-e33. doi:10.1016/j.oooo.2012.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23601229/pubmed" id="23601229" target="_blank">23601229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tulandi.1">
<a name="Tulandi.1"></a>Tulandi T. Ectopic pregnancy: methotrexate therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18042110">
<a name="18042110"></a>Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. <i>Am J Gastroenterol</i>. 2007;102(12):2804-1282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/18042110/pubmed" id="18042110" target="_blank">18042110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21064136">
<a name="21064136"></a>Vagace JM, Caceres-Marzal C, Jimenez M, Casado MS, de Murillo SG, Gervasini G. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. <i>Am J Hematol</i>. 2011;86(1):98-101. doi:10.1002/ajh.21897<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21064136/pubmed" id="21064136" target="_blank">21064136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8624641">
<a name="8624641"></a>van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. <i>Br J Rheumatol</i>. 1996;35(4):364-372. doi:10.1093/rheumatology/35.4.364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8624641/pubmed" id="8624641" target="_blank">8624641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8123573">
<a name="8123573"></a>Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, Van de Kerkhof PC. Methotrexate revisited: effects of long-term treatment in psoriasis. <i>Br J Dermatol</i>. 1994;130(2):204-210. doi:10.1111/j.1365-2133.1994.tb02901.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8123573/pubmed" id="8123573" target="_blank">8123573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11465701">
<a name="11465701"></a>van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. <i>Arthritis Rheum</i>. 2001;44(7):1515-1524. doi:10.1002/1529-0131(200107)44:7&lt;1515::AID-ART273&gt;3.0.CO;2-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11465701/pubmed" id="11465701" target="_blank">11465701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23571545">
<a name="23571545"></a>van Hasselt JG, van Eijkelenburg NK, Huitema AD, Schellens JH, Schouten-van Meeteren AY. Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate. <i>Antimicrob Agents Chemother</i>. 2013;57(6):2878-2881. doi:10.1128/AAC.00068-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23571545/pubmed" id="23571545" target="_blank">23571545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21044430">
<a name="21044430"></a>van Roon EN, van de Laar MA. Methotrexate Bioavailability. <i>Clin Exp Rheumatol. </i>2010;28(suppl 61):27-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/21044430/pubmed" id="21044430" target="_blank">21044430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17519278">
<a name="17519278"></a>Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). <i>Ann Rheum Dis</i>. 2007;66(11):1443-1449. doi:10.1136/ard.2007.071092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/17519278/pubmed" id="17519278" target="_blank">17519278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19006245">
<a name="19006245"></a>Vezmar S, Schüsseler P, Becker A, Bode U, Jaehde U. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. <i>Pediatr Blood Cancer</i>. 2009;52(1):26-32. doi:10.1002/pbc.21827<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19006245/pubmed" id="19006245" target="_blank">19006245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19033291">
<a name="19033291"></a>Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <i>Ann Rheum Dis</i>. 2009a;68(7):1086-1093. doi:10.1136/ard.2008.094474<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19033291/pubmed" id="19033291" target="_blank">19033291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19033290">
<a name="19033290"></a>Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. <i>Ann Rheum Dis.</i> 2009b;68(7):1094-1099. doi:10.1136/ard.2008.092668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19033290/pubmed" id="19033290" target="_blank">19033290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vleugels.1">
<a name="Vleugels.1"></a>Vleugels RA. Cutaneous dermatomyositis in adults: overview and initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11001674">
<a name="11001674"></a>von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. <i>J Clin Oncol.</i> 2000;18(17):3068-3077. doi:10.1200/JCO.2000.18.17.3068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/11001674/pubmed" id="11001674" target="_blank">11001674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16034041">
<a name="16034041"></a>von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. <i>J Clin Oncol</i>. 2005;23(21):4602-4608.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16034041/pubmed" id="16034041" target="_blank">16034041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8609262">
<a name="8609262"></a>Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. <i>J Am Acad Dermatol</i>. 1996;34(3):470-481. doi:10.1016/s0190-9622(96)90442-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8609262/pubmed" id="8609262" target="_blank">8609262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23538719">
<a name="23538719"></a>Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. <i>Chest</i>. 2013;144(3):805-812. doi:10.1378/chest.12-1728<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/23538719/pubmed" id="23538719" target="_blank">23538719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8957036">
<a name="8957036"></a>Wall SM, Johansen MJ, Molony DA, DuBose TD Jr, Jaffe N, Madden T. Effective clearance of methotrexate using high-flux hemodialysis membranes.<i> Am J Kidney Dis.</i> 1996;28(6):846-854. doi:10.1016/s0272-6386(96)90384-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/8957036/pubmed" id="8957036" target="_blank">8957036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3466693">
<a name="3466693"></a>Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma. <i>Cancer Treat Rep</i>. 1986;70(12):1431-1432.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/3466693/pubmed" id="3466693" target="_blank">3466693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9709718">
<a name="9709718"></a>Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. <i>J Pediatr</i>. 1998;133(2):266-268.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/9709718/pubmed" id="9709718" target="_blank">9709718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19412004">
<a name="19412004"></a>Weiss B, Lerner A, Shapiro R, et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. <i>J Pediatr Gastroenterol Nutr</i>. 2009;48:526-530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19412004/pubmed" id="19412004" target="_blank">19412004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16029342">
<a name="16029342"></a>Wenzel J, Brähler S, Bauer R, Bieber T, Tüting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. <i>Br J Dermatol</i>. 2005;153(1):157-162. doi:10.1111/j.1365-2133.2005.06552.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16029342/pubmed" id="16029342" target="_blank">16029342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12161090">
<a name="12161090"></a>WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). <i>Control Clin Trials.</i> 2002;23(4):450-468. doi:10.1016/s0197-2456(02)00209-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/12161090/pubmed" id="12161090" target="_blank">12161090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25421877">
<a name="25421877"></a>Whelan JS, Bielack SS, Marina N, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. <i>Ann Oncol</i>. 2015;26(2):407-414.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25421877/pubmed" id="25421877" target="_blank">25421877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33482862">
<a name="33482862"></a>Whitfield N, Krasniak A, Nguyen H. Concomitant large loculated pleural and pericardial effusions in a patient with rheumatoid arthritis on methotrexate. <i>Perm J</i>. 2020;24:1. doi:10.7812/TPP/19.239<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/33482862/pubmed" id="33482862" target="_blank">33482862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26152702">
<a name="26152702"></a>Wiczer T, Dotson E, Tuten A, Phillips G, Maddocks K. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. <i>J Oncol Pharm Pract</i>. 2016;22(3):430-436. doi:10.1177/1078155215594417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/26152702/pubmed" id="26152702" target="_blank">26152702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16794248">
<a name="16794248"></a>Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. <i>Oncologist</i>. 2006;11(6):694-703. doi:10.1634/theoncologist.11-6-694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/16794248/pubmed" id="16794248" target="_blank">16794248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15139068">
<a name="15139068"></a>Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. <i>Cancer</i>. 2004a;100(10):2222-2232. doi:10.1002/cncr.20255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15139068/pubmed" id="15139068" target="_blank">15139068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9164227">
<a name="9164227"></a>Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. <i>J Clin Oncol.</i> 1997;15(5):2125-2134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/9164227/pubmed" id="9164227" target="_blank">9164227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494606">
<a name="15494606"></a>Widemann BC, Balis FM, Shalabi A, et al. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. <i>J Natl Cancer Inst. </i>2004b;96(20):1557-1559.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/15494606/pubmed" id="15494606" target="_blank">15494606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19019306">
<a name="19019306"></a>Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. <i>Neurotherapeutics.</i> 2008;5(4):548-557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/19019306/pubmed" id="19019306" target="_blank">19019306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2448428">
<a name="2448428"></a>Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. <i>J Clin Oncol</i>. 1988;6(2):329-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/2448428/pubmed" id="2448428" target="_blank">2448428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30138085">
<a name="30138085"></a>Winter SS, Dunsmore KP, Devidas M, et al. Improved survival for children and young adults with t-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. <i>J Clin Oncol</i>. 2018;36(29):2926-2934. doi:10.1200/JCO.2018.77.7250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/30138085/pubmed" id="30138085" target="_blank">30138085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2028435">
<a name="2028435"></a>Wollner A, Mohle-Boetani J, Lambert RE, Perruquet JL, Raffin TA, McGuire JL. <i>Pneumocystis carinii</i> pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. <i>Thorax</i>. 1991;46(3):205-207. doi:10.1136/thx.46.3.205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/2028435/pubmed" id="2028435" target="_blank">2028435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22309341">
<a name="22309341"></a>Wong SM, Chong YT, Thevarajah S, Baba R. Methotrexate toxicity presenting as ulcerated psoriatic plaques. <i>Australas J Dermatol</i>. 2012;53(1):81-83. doi:10.1111/j.1440-0960.2011.00779.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/22309341/pubmed" id="22309341" target="_blank">22309341</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Xatmep (methotrexate) [prescribing information]. Wilmington, MA: Azurity Pharmaceuticals Inc; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25267808">
<a name="25267808"></a>Yamakawa H, Yoshida M, Takagi M, Kuwano K. Late-onset methotrexate-induced pneumonitis with neutrophilia in bronchoalveolar lavage fluid. <i>BMJ Case Rep</i>. 2014;2014:bcr2014206123. doi:10.1136/bcr-2014-206123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25267808/pubmed" id="25267808" target="_blank">25267808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27338776">
<a name="27338776"></a>Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. <i>Ann Rheum Dis</i>. 2016;75(9):1583-1594. doi:10.1136/annrheumdis-2016-209133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/27338776/pubmed" id="27338776" target="_blank">27338776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25401478">
<a name="25401478"></a>Yélamos O, Català A, Vilarrasa E, Roé E, Puig L. Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion. <i>Dermatology</i>. 2014;229(4):306-309. doi:10.1159/000366501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/25401478/pubmed" id="25401478" target="_blank">25401478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30362229">
<a name="30362229"></a>Yeung J, Vaughan E, Chadban S, Saunders J, Thiagarajah N, Brown C. High-dose intravenous methotrexate with high-flux, extended-hours haemodialysis in treatment of primary central nervous system, post-transplant lymphoproliferative disorder and end-stage kidney disease: a case report. <i>Nephrology (Carlton).</i> 2018;23(11):1063-1064. doi:10.1111/nep.13254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/30362229/pubmed" id="30362229" target="_blank">30362229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14576667">
<a name="14576667"></a>Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. <i>J Am Acad Dermatol</i>. 2003;49(5):873-878.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/14576667/pubmed" id="14576667" target="_blank">14576667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30049384">
<a name="30049384"></a>Zhou B, Xia X, Wang P, et al. Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut microbiota. <i>EBioMedicine</i>. 2018;33:122-133. doi:10.1016/j.ebiom.2018.06.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methotrexate-drug-information/abstract-text/30049384/pubmed" id="30049384" target="_blank">30049384</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9630 Version 652.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
